<SEC-DOCUMENT>0001140361-24-028104.txt : 20240530
<SEC-HEADER>0001140361-24-028104.hdr.sgml : 20240530
<ACCEPTANCE-DATETIME>20240530160259
ACCESSION NUMBER:		0001140361-24-028104
CONFORMED SUBMISSION TYPE:	S-3
PUBLIC DOCUMENT COUNT:		9
FILED AS OF DATE:		20240530
DATE AS OF CHANGE:		20240530

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GYRE THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001124105
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				562020050
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-279820
		FILM NUMBER:		241005106

	BUSINESS ADDRESS:	
		STREET 1:		12770 HIGH BLUFF DRIVE, SUITE 150
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
		BUSINESS PHONE:		(619) 949-3681

	MAIL ADDRESS:	
		STREET 1:		12770 HIGH BLUFF DRIVE, SUITE 150
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CATALYST BIOSCIENCES, INC.
		DATE OF NAME CHANGE:	20150820

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TARGACEPT INC
		DATE OF NAME CHANGE:	20000919
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-3
<SEQUENCE>1
<FILENAME>ny20028941x1_s3.htm
<DESCRIPTION>S-3
<TEXT>
<html><head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using Broadridge PROfile 24.3.1.5224
         Copyright 1995 - 2024 Broadridge -->
  </head><body style="color: #000000;" bgcolor="#ffffff">
<!--Begin Page 1-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="ny20028941x1_s3_100-regcov_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 540pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 25pt; text-align: center;">As filed with the Securities and Exchange Commission on May 30, 2024 </div><div class="regno" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 1pt; text-align: right;">Registration No. 333-&#8195;&#8195;&#8195;<font style="font-weight: normal;"> </font></div></div></div><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 2pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-left: auto; margin-right: auto; margin-top: 4pt;"> </div></div></div><div class="block-main" style="width: 540pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 14pt; font-weight: bold; margin-top: 9.5pt; text-align: center;">UNITED STATES <br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 14pt; font-weight: bold; margin-top: 0pt; text-align: center;">SECURITIES AND EXCHANGE COMMISSION <br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 14pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-size: 12pt;">Washington, D.C. 20549 </font></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 16pt; font-weight: bold; margin-top: 3pt; text-align: center;">FORM S-3 <br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 16pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-size: 12pt;">REGISTRATION STATEMENT </font><br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 16pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-size: 12pt;">UNDER </font><br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 16pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-size: 12pt;">THE SECURITIES ACT OF 1933 </font></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 18pt; font-weight: bold; margin-top: 3pt; text-align: center;">GYRE THERAPEUTICS, INC.<font style="font-weight: normal;"> </font><br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 18pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-size: 9.5pt; font-weight: normal;">(Exact name of registrant as specified in its charter) </font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="txttab" style="border-collapse: collapse; width: 540pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 48.89%; text-align: center; vertical-align: top; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; text-align: center;">Delaware</div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.89%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; text-align: center;">56-2020050 </div></td></tr><tr><td style="width: 48.89%; text-align: center; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; text-align: center;">(State or other jurisdiction of <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; text-align: center;">incorporation or organization) </div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.89%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; text-align: center;">(I.R.S. Employer <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; text-align: center;">Identification Number)</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 3pt; text-align: center;">Gyre Therapeutics, Inc. <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; text-align: center;">12770 High Bluff Drive <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; text-align: center;">Suite 150 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; text-align: center;">San Diego, CA 92130 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; text-align: center;">(858) 567-7770<font style="font-weight: normal;"> </font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-weight: normal;">&#8195;</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-weight: normal;">(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices) </font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 3pt; text-align: center;">Han Ying, Ph.D. <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; text-align: center;">Chief Executive Officer <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; text-align: center;">12770 High Bluff Drive <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; text-align: center;">Suite 150 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; text-align: center;">San Diego, CA 92130 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; text-align: center;">(858) 567-7770<font style="font-weight: normal;"> </font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-weight: normal;">&#8195;</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-weight: normal;">(Name, address, including zip code, and telephone number, including area code, of agent for service) </font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 3pt; text-align: center;">Copies to: <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; text-align: center;">Ryan A. Murr <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; text-align: center;">Branden C. Berns <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; text-align: center;">Gibson, Dunn &amp; Crutcher LLP <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; text-align: center;">One Embarcadero Center, Suite 2600 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; text-align: center;">San Francisco, CA 94111 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; text-align: center;">(415) 393-8200<font style="font-weight: normal;"> </font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 3pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Approximate date of commencement of proposed sale to the public: From time to time after this Registration Statement becomes effective.<font style="font-weight: normal;"> </font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 3pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If the only securities being registered on this Form&#160;are being offered pursuant to dividend or interest reinvestment plans, please check the following box. <font style="font-size: 1pt;">&#8201;</font>&#x2610; </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 3pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If any of the securities being registered on this Form&#160;are to be offered on a delayed or continuous basis pursuant to Rule&#160;415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box. &#x2612; </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 3pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If this Form&#160;is filed to register additional securities for an offering pursuant to Rule&#160;462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. <font style="font-size: 1pt;">&#8201;</font>&#x2610; </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 3pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If this Form&#160;is a post-effective amendment filed pursuant to Rule&#160;462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. <font style="font-size: 1pt;">&#8201;</font>&#x2610; </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 3pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If this Form&#160;is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule&#160;462(e) under the Securities Act, check the following box. <font style="font-size: 1pt;">&#8201;</font>&#x2610; </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 3pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If this Form&#160;is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule&#160;413(b) under the Securities Act, check the following box. <font style="font-size: 1pt;">&#8201;</font>&#x2610; </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 3pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="txttab" style="border-collapse: collapse; width: 540pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 23.33%; text-align: left; vertical-align: top; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Large accelerated filer <font style="font-size: 1pt;">&#8201;</font>&#x2610;</div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 23.33%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Accelerated filer <font style="font-size: 1pt;">&#8201;</font>&#x2610;</div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 23.33%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Non-accelerated filer &#x2612;</div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 23.33%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Emerging growth company <font style="font-size: 1pt;">&#8201;</font>&#x2610; </div></td></tr><tr><td style="width: 23.33%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 23.33%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 23.33%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 23.33%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Smaller reporting company &#x2612;</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 3pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;7(a)(2)(B) of the Securities Act. <font style="font-size: 1pt;">&#8201;</font>&#x2610; </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 3pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment that specifically states that this registration statement shall thereafter become effective in accordance with Section&#160;8(a) of the Securities Act of 1933, as amended, or until this registration statement shall become effective on such date as the Commission, acting pursuant to said Section&#160;8(a), may determine.<font style="font-weight: normal;"> </font></div></div><div class="block-frill" style="width: 540pt; margin-top: 12pt; margin-left: 0pt;"><div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 2pt solid #000000; margin-bottom: 1pt; margin-left: auto; margin-right: auto; margin-top: 4pt;"> </div></div></div></div>
<!--End Page 1-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 2-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 456pt;"><a name="ny20028941x1_s3_101-cov_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 456pt; margin-left: 0pt;"><div class="h1" style="color: #FC0014; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><div style="font-family: Arial, Helvetica, sans-serif; text-align: left; margin-bottom: 12pt;">The information in this preliminary prospectus is not complete and may be changed. The Selling Stockholder may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted. </div>SUBJECT TO COMPLETION, DATED MAY 30, 2024<font style="color: #000000;"> </font></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">Prospectus </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 13.25pt; text-align: center;"><img style="height: 45px; width: 175px;" src="logo_gyre.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold; margin-top: 20.5pt; text-align: center;">1,081,332 Shares <br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold; margin-top: 0pt; text-align: center;">COMMON STOCK <br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold; margin-top: 0pt; text-align: center;">Offered by the Selling Stockholder </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">This prospectus relates to the potential resale from time to time by the Selling Stockholder (as defined below) of up to 1,081,332 shares of common stock, par value $0.001 per share (the &#8220;Common Stock&#8221;), of Gyre&#160;Therapeutics, Inc., a Delaware corporation (the &#8220;Company&#8221;), consisting of (i) 540,666 shares of Common Stock issued upon the conversion of the Company&#8217;s Series&#160;X Convertible Preferred Stock, par value $0.001 per share (the &#8220;Convertible Preferred Stock&#8221;), effective January&#160;23, 2024 and (ii) 540,666 shares of Common Stock issuable upon the conversion of Convertible Preferred Stock issuable pursuant to the exercise of a warrant issued to GNI USA, Inc., a Delaware corporation (&#8220;GNI USA&#8221;). The &#8220;Selling Stockholder&#8221; refers to GNI USA and its respective permitted transferees. The shares of Common Stock registered by this prospectus are referred to herein as the &#8220;Resale Shares.&#8221; The Resale Shares (adjusted for the 1 to 15 reverse stock split effected by the Company on October&#160;30, 2023) consist of: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(i)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">540,666 shares of Common Stock issued upon conversion of 811 shares of Convertible Preferred Stock effective January&#160;23, 2024, previously issued to GNI USA pursuant to that certain Securities Purchase Agreement, dated October&#160;27, 2023 (the &#8220;Securities Purchase Agreement&#8221;), by and between the Company and GNI USA; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(ii)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">540,666 shares of Common Stock issuable upon conversion of 811 shares of Convertible Preferred Stock issuable upon the exercise of warrants to purchase shares of Convertible Preferred stock held by GNI USA, previously issued pursuant to the Securities Purchase Agreement (the &#8220;Warrants&#8221;). </div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We are not offering or selling any shares of Common Stock under this prospectus, and we will not receive any proceeds from the sale of the Resale Shares by the Selling Stockholder pursuant to this prospectus. However, upon any cash exercise of the Warrants by the Selling Stockholder, we will receive cash proceeds per share equal to the exercise price of the Warrants. If the Warrants are exercised in a cashless exercise, we will not receive any proceeds from the exercise of the Warrants. Our registration of the securities covered by this prospectus does not mean that the Selling Stockholder will offer or sell any of the Resale Shares. The Selling Stockholder may sell the Resale Shares covered by this prospectus in a number of different ways and at varying prices. We provide more information about how the Selling Stockholder may sell the Resale Shares in the section entitled &#8220;<font style="font-style: italic;">Plan of Distribution</font>.&#8221; </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If any underwriters, dealers or agents are involved in the sale of any of the Resale Shares, their names and any applicable purchase price, fee, commission or discount arrangement between or among them will be set forth, or will be calculable from the information set forth, in an applicable prospectus supplement. See the sections of this prospectus entitled &#8220;<font style="font-style: italic;">About this Prospectus</font>&#8221; and &#8220;<font style="font-style: italic;">Plan of Distribution</font>&#8221; for more information. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our Common Stock is currently listed on The Nasdaq Capital Market (&#8220;Nasdaq&#8221;) under the symbol &#8220;GYRE.&#8221; On May 28, 2024, the last reported sale price of our Common Stock as reported on Nasdaq was $10.15 per share. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Investing in our Common Stock involves risk. See &#8220;Risk Factors&#8221; beginning on page <a href="#tRF">8</a> of this prospectus and in the documents incorporated by reference in this prospectus for a discussion of the factors you should carefully consider before deciding to purchase these securities.<font style="font-weight: normal;"> </font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Securities and Exchange Commission and state securities regulators have not approved or disapproved these securities, or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.<font style="font-weight: normal;"> </font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; text-align: center;">The date of this prospectus is &#8195;&#8195;&#8195;&#8195;&#8195;, 2024. </div></div></div></div>
<!--End Page 2-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 3-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20028941x1_s3_102-toc_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">TABLE OF CONTENTS </div><a name="TOC"><!--Anchor--></a><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.09%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 3.51%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Page </div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tATP">About this Prospectus<font style="padding-left: 0.08pt;"></font></a></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.51%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.73pt; text-align: left;"><a href="#tATP"><font style="padding-left: 9.99pt;">1</font></a></div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tFLS">Cautionary Note&#160;Regarding Forward-Looking Statements<font style="padding-left: 0.68pt;"></font></a></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.51%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.73pt; text-align: left;"><a href="#tFLS"><font style="padding-left: 9.99pt;">2</font></a></div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tWYC">Where You Can Find More Information<font style="padding-left: 1.49pt;"></font></a></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.51%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.73pt; text-align: left;"><a href="#tWYC"><font style="padding-left: 9.99pt;">4</font></a></div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tIIR">Information Incorporated by Reference<font style="padding-left: 0.13pt;"></font></a></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.51%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.73pt; text-align: left;"><a href="#tIIR"><font style="padding-left: 9.99pt;">5</font></a></div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tPS">Prospectus Summary<font style="padding-left: 3.97pt;"></font></a></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.51%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.73pt; text-align: left;"><a href="#tPS"><font style="padding-left: 9.99pt;">6</font></a></div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tTO">The Offering<font style="padding-left: 1.37pt;"></font></a></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.51%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.73pt; text-align: left;"><a href="#tTO"><font style="padding-left: 9.99pt;">7</font></a></div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tRF">Risk Factors<font style="padding-left: 3.41pt;"></font></a></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.51%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.73pt; text-align: left;"><a href="#tRF"><font style="padding-left: 9.99pt;">8</font></a></div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tUOP">Use of Proceeds<font style="padding-left: 2.87pt;"></font></a></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.51%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.73pt; text-align: left;"><a href="#tUOP"><font style="padding-left: 9.99pt;">9</font></a></div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tSS">Selling Stockholder<font style="padding-left: 4.51pt;"></font></a></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.51%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.73pt; text-align: left;"><a href="#tSS"><font style="padding-left: 4.99pt;">10</font></a></div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tPOD">Plan of Distribution<font style="padding-left: 3.41pt;"></font></a></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.51%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.73pt; text-align: left;"><a href="#tPOD"><font style="padding-left: 4.99pt;">12</font></a></div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tDP">Dividend Policy<font style="padding-left: 3.4pt;"></font></a></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.51%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.73pt; text-align: left;"><a href="#tDP"><font style="padding-left: 4.99pt;">14</font></a></div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tLM">Legal Matters<font style="padding-left: 2.86pt;"></font></a></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.51%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.73pt; text-align: left;"><a href="#tLM"><font style="padding-left: 4.99pt;">15</font></a></div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tE">Experts<font style="padding-left: 3.95pt;"></font></a></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.51%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.73pt; text-align: left;"><a href="#tE"><font style="padding-left: 4.99pt;">16</font></a></div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tP2">Part&#160;II Information Not Required In Prospectus<font style="padding-left: 0.69pt;"></font></a></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.51%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.73pt; text-align: left;"><a href="#tP2">II-1 </a></div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tSIG">Signatures<font style="padding-left: 2.29pt;"></font></a></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.51%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.73pt; text-align: left;"><a href="#tSIG">II-7</a></div></td></tr></table></div></div></div>
<!--End Page 3-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 4-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20028941x1_s3_103-about_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tATP"><!--Anchor--></a>ABOUT THIS PROSPECTUS </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">This prospectus is part of the registration statement that we filed with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) using a &#8220;shelf&#8221; registration process. Under this shelf registration process, the Selling Stockholder may, from time to time, sell the shares of our Common Stock through any means described in the section entitled &#8220;<font style="font-style: italic;">Plan of Distribution</font>.&#8221; More specific terms of any securities that the Selling Stockholder offers and sells may be provided in a prospectus supplement that describes, among other things, the specific amounts and prices of the Common Stock being offered and the terms of the offering. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">A prospectus supplement may also add, update or change information included in this prospectus. Any statement contained in this prospectus will be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained in such prospectus supplement modifies or supersedes such statement. Any statement so modified will be deemed to constitute a part of this prospectus only as so modified, and any statement so superseded will be deemed not to constitute a part of this prospectus. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Neither we nor the Selling Stockholder have authorized anyone to provide you with any information other than the information contained or incorporated by reference in this prospectus or any free writing prospectus prepared by or on behalf of us in connection with this offering to which we have referred you. We and the Selling Stockholder take no responsibility for, and can provide no assurances as to the reliability of, any other information that others may give you. The information contained or incorporated by reference in this prospectus or any such free writing prospectus provided in connection with this offering is accurate only as of the date thereof, regardless of the time of delivery of such document or of any sale of our Common Stock. Our business, financial condition and results of operations may have changed since those dates. It is important for you to read and consider all the information contained in this prospectus, including the documents incorporated by reference herein or any free writing prospectus prepared by or on behalf of us in connection with this offering, in making your investment decision. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Selling Stockholder is not offering to sell, or seeking offers to buy, shares of our Common Stock in any jurisdictions where offers and sales are not permitted. The distribution of this prospectus and the offering of the Resale Shares in certain jurisdictions may be restricted by law. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the Resale Shares and the distribution of this prospectus outside the United States. This prospectus does not constitute, and may not be used in connection with, an offer to sell, or a solicitation of an offer to buy, any securities offered by this prospectus by any person in any jurisdiction in which it is unlawful for such person to make such an offer or solicitation. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">This prospectus contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus is a part, and you may obtain copies of those documents as described below under &#8220;<font style="font-style: italic;">Where You Can </font><font style="font-style: italic;">Find More Information</font>.&#8221; </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In this prospectus, unless otherwise indicated or the context otherwise requires, the terms &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Gyre Therapeutics, Inc. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">1<br></div></div></div>
<!--End Page 4-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 5-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20028941x1_s3_104-fls_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tFLS"><!--Anchor--></a>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">This prospectus and the documents incorporated by reference herein contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include information concerning our future results of operations and financial position, strategy and plans, and our expectations for future operations. Forward-looking statements include all statements that are not historical facts and, in some cases, can be identified by terms such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;design,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;possible,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would&#8221; or the negative version of these words and similar expressions. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including those described in &#8220;<font style="font-style: italic;">Risk Factors</font>&#8221; included elsewhere in this prospectus and in the documents that are incorporated by reference herein. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Also, forward-looking statements represent our beliefs and assumptions only as of the date of this prospectus, or, in the case of any document incorporated by reference herein in this prospectus, as of the date of such document. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. You should read this prospectus and the documents incorporated by reference herein completely and with the understanding that our actual future results may be materially different from what we expect. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">These forward-looking statements include, but are not limited to, statements concerning the following: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the ability of our clinical trials to demonstrate safety and efficacy of our product candidates and other positive results; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our ability to develop a pipeline of product candidates to address unmet needs in the treatment of organ fibrosis and other inflammatory diseases; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the timing, progress and results of clinical trials for F351 (Hydronidone) from the Phase 2a trial, F573&#160;from the Phase 2 clinical trial, ETUARY&#174; (Pirfenidone) from the Phase 2/3 clinical trial, and other product candidates we may develop, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the studies or trials will become available and research and development programs; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the timing, scope and likelihood of regulatory filings and approvals, including timing of investigational new drugs and final U.S. Food and Drug Administration approval of F351 for the treatment of liver fibrosis associated with nonalcoholic associated steatohepatitis and chronic hepatitis B, ETUARY for the treatment of dermatomyositis-related interstitial lung disease and sclerosis-related interstitial lung disease, F528 for the treatment of chronic obstructive pulmonary disease, F230 for the treatment of pulmonary arterial hypertension, and any other future product candidates; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the timing, scope or likelihood of foreign regulatory filings and approvals; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our expectations regarding the future pursuit of product development efforts, including whether we will pursue such efforts, estimates regarding the expenses, future revenue, timing of any future revenue, capital requirements and need for additional financing related to such efforts, the timing of and our ability to pursue such efforts and our plans to develop and, if approved, subsequently commercialize any product candidates resulting from such efforts; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our expectations regarding our ability to fund our operating expenses and capital expenditure requirements with our cash and investments; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our ability to develop and advance current product candidates and programs into, and successfully complete, clinical studies; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our manufacturing, commercialization and marketing capabilities and strategy; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">plans relating to commercializing our product candidates, if approved, including the geographic areas of focus and sales strategy; </div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">2<br></div></div></div>
<!--End Page 5-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 6-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20028941x1_s3_104-fls_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the need to hire additional personnel and our ability to attract and retain such personnel; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the size of the market opportunity for our product candidates, including estimates of the number of patients who suffer from the diseases we are targeting; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">expectations regarding the approval and use of our product candidates in combination with other drugs; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">expectations regarding the potential for accelerated approval or other expedited regulatory designation; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our competitive position and the success of competing therapies that are or may become available; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">estimates of the number of patients that we will enroll in our clinical trials; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the beneficial characteristics and the potential safety, efficacy and therapeutic effects of our product candidates; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our ability to obtain and maintain regulatory approval of our product candidates and our expectations regarding particular lines of therapy; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">plans relating to the further development of our product candidates, including additional indications we may pursue; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">existing regulations and regulatory developments in the People&#8217;s Republic of China, the United States, Europe, and other jurisdictions; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our intellectual property position, including the scope of protection we are able to establish and maintain for intellectual property rights covering ETUARY, F351, F573, F528, and F230, and other product candidates we may develop, including the extensions of existing patent terms where available, the validity of intellectual property rights held by third parties and our ability not to infringe, misappropriate or otherwise violate any third-party intellectual property rights; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our continued reliance on third parties to conduct additional clinical trials of our product candidates and for the manufacture of our product candidates for clinical trials; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our relationships with patient advocacy groups, key opinion leaders, regulators, the research community and payors; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our ability to obtain and negotiate favorable terms of, any collaboration, licensing or other arrangements that may be necessary or desirable to develop, manufacture or commercialize our product candidates; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the pricing and reimbursement of ETUARY, F351, F573, F528, and F230, and other product candidates we may develop, if approved; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the rate and degree of market acceptance and clinical utility of F351, and other product candidates the Company may develop; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our financial performance; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the period over which we estimate our existing cash will be sufficient to fund our planned operating expenses and capital expenditure requirements; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">expectations about the continued listing of our Common Stock on Nasdaq; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the impact of laws and regulations; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">expectations regarding the period during which we will qualify as a smaller reporting company under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). </div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">3<br></div></div></div>
<!--End Page 6-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 7-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20028941x1_s3_104-fls_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tWYC"><!--Anchor--></a>WHERE YOU CAN FIND MORE INFORMATION </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We have filed with the SEC this registration statement under the Securities Act of 1933, as amended (the&#160;&#8220;Securities Act&#8221;) covering the Common Stock to be offered and sold by this prospectus and any applicable prospectus supplement. This prospectus does not contain all of the information included in the registration statement, some of which is contained in exhibits to the registration statement. In addition, we are subject to the information and periodic and current reporting requirements of the Exchange Act, and in accordance therewith, we file periodic and current reports, proxy statements and other information with the SEC. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">You may access our annual reports on Form&#160;10-K, quarterly reports on Form&#160;10-Q, current reports on Form&#160;8-K, proxy statements on Schedule 14A and amendments or supplements to those reports and statements, filed with the SEC, free of charge at our website at <font style="font-style: italic;">www.gyretx.com </font>or by means of the SEC&#8217;s website at <font style="font-style: italic;">www.sec.gov</font>. The information found on, or that can be accessed from or that is hyperlinked to, our website or the SEC&#8217;s website is not part of this prospectus and you should not rely on that information when making a decision to invest in our Common Stock. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Any statement made in this prospectus and any prospectus supplement, periodic and current reports, proxy statements and other information filed or furnished with the SEC concerning the contents of any contract, agreement or other document is only a summary of the actual contract, agreement or other document. If we have filed any contract, document, agreement or other document as an exhibit to such filing or furnishing, you should read the exhibit for a more complete understanding of the document or matter involved. Each statement regarding a contract, agreement or other document is qualified in its entirety by reference to the actual document. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Upon written or oral request, we will provide without charge to each person to whom a copy of the prospectus is delivered a copy of the documents incorporated by reference herein (other than exhibits to such documents unless such exhibits are specifically incorporated by reference herein). You may request a copy of these filings, at no cost, by writing or calling us at the contact information set forth below. We have authorized no one to provide you with any information that differs from that contained in this prospectus. Accordingly, we take no responsibility for any other information that others may give you. You should not assume that the information in this prospectus is accurate as of any date other than the date of the front cover of this prospectus. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; text-align: center;">Gyre Therapeutics, Inc. <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Investor Relations <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">12770 High Bluff Drive, Suite 150 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">San Diego, CA 92130 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">(858) 567-7770 </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">4<br></div></div></div>
<!--End Page 7-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 8-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20028941x1_s3_105-info_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tIIR"><!--Anchor--></a>INFORMATION INCORPORATED BY REFERENCE </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The SEC allows us to &#8220;incorporate by reference&#8221; the information we file with them, which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference herein is considered to be part of this prospectus, and information that we file later with the SEC will automatically update and supersede this information. We incorporate by reference the documents listed below (except the information contained in such documents to the extent &#8220;furnished&#8221; and not &#8220;filed&#8221;) and any future filings we make with the SEC under Section&#160;13(a), 13(c), 14 or 15(d) of the Exchange Act (except the information contained in such documents to the extent &#8220;furnished&#8221; and not &#8220;filed&#8221;): </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC on <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001124105/000095017024037242/gyre-20231231.htm">March 27, 2024</a> (including the portions of our Definitive Proxy Statement on Schedule 14A filed on <a href="https://www.sec.gov/Archives/edgar/data/1124105/000114036124022721/ny20022295x2_def14a.htm">April 29, 2024</a> incorporated by reference therein) and our Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC on <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001124105/000156459023004830/cbio-10k_20221231.htm">March 30, 2023</a>; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our Quarterly Reports on Form&#160;10-Q for the quarters ended March&#160;31, 2023, June&#160;30, 2023, September&#160;30, 2023 and March&#160;31, 2024, filed with the SEC on <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001124105/000156459023007276/cbio-10q_20230331.htm">May&#160;15, 2023</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001124105/000095017023042218/cbio-20230630.htm">August&#160;14, 2023</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001124105/000095017023055695/cbio-20230930.htm">October&#160;26, 2023</a> and <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001124105/000095017024058642/gyre-20240331.htm">May&#160;13, 2024</a>, respectively; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Our Current Reports on Form&#160;8-K and Form&#160;8-K/A, as applicable, filed with the SEC on <a href="https://www.sec.gov/Archives/edgar/data/1124105/000114036124002118/ef20018550_8ka.htm">January&#160;12, 2024</a>, <a href="https://www.sec.gov/Archives/edgar/data/1124105/000114036124002903/ef20019132_8ka.htm">January&#160;19, 2024</a>, <a href="https://www.sec.gov/Archives/edgar/data/1124105/000114036124014493/ef20024709_8k.htm">March&#160;21, 2024</a> (excluding Items 7.01 and 9.01), <a href="https://www.sec.gov/Archives/edgar/data/1124105/000114036124015318/ef20025179_8k.htm">March&#160;26, 2024</a> and <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001124105/000114036124024799/ef20028687_8k.htm">May&#160;8, 2024</a> (excluding items 7.01 and 9.01); and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the description of our Common Stock attached as <a href="https://www.sec.gov/Archives/edgar/data/1124105/000095017024037242/gyre-ex4_1.htm">Exhibit&#160;4.1</a> to our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2023, filed with the SEC on March&#160;27, 2024, including any amendment or report filed for the purpose of updating such description. </div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We will provide without charge upon written or oral request a copy of any or all of the documents that are incorporated by reference herein into this prospectus, other than exhibits which are specifically incorporated by reference herein into such documents. Requests should be directed to our Investor Relations department at Gyre Therapeutics, Inc., 12770 High Bluff Drive, Suite 150, San Diego, CA 92130. Our telephone number is (858) 567-7770. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Any statement contained in a document incorporated or deemed to be incorporated by reference herein into this prospectus shall be deemed to be modified or superseded for the purposes of this prospectus to the extent that a statement contained in this prospectus (or in any document incorporated by reference herein therein) or in any other subsequently filed document that is or is deemed to be incorporated by reference herein into this prospectus modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">5<br></div></div></div>
<!--End Page 8-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 9-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 492pt;"><a name="ny20028941x1_s3_106-summary_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;"><div class="page-content" style="margin-left: 12pt;"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tPS"><!--Anchor--></a>PROSPECTUS SUMMARY </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">You should read the following summary together with the entire prospectus and the documents incorporated by reference herein, including our consolidated financial statements and related notes as well as any free writing prospectus prepared by us or on our behalf. You should carefully consider, among other things, the matters discussed in the sections entitled &#8220;Risk Factors&#8221; included in or incorporated by reference in this prospectus.<font style="font-style: normal;"> </font></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Our Company </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We are a financially-sustainable pharmaceutical company with a record of financial success that develops and commercializes small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. Fibrotic diseases represent a large patient population with significant unmet medical needs. Fibrosis involves a complex, multi-stage process with multiple pathways. While there are numerous potential targets for anti-fibrotic therapy, both established and emerging, addressing a single molecular pathway may not be sufficient to prevent, halt, or reverse fibrosis. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our strategy is to use our experience in the successful development and commercialization of ETUARY&#174; (Pirfenidone) to expand into new indications and develop similar drug candidates. Pirfenidone, the first&#160;anti-fibrotic drug approved for idiopathic pulmonary fibrosis (&#8220;IPF&#8221;) in Japan, the EU, the United States, and the People&#8217;s Republic of China (the &#8220;PRC&#8221;), is a small molecule drug that inhibits the synthesis of TGF-&#223;1, TNF-&#945;, and other fibrosis and inflammation modulators. We have obtained approval for ETUARY (pirfenidone) in the PRC for IPF. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Beijing Continent Pharmaceuticals Co., Ltd., a company organized under the laws of the PRC (d/b/a&#160;Gyre&#160;Pharmaceuticals, Inc.) (&#8220;Gyre Pharmaceuticals&#8221;) successfully advanced Pirfenidone from research and development to commercialization in the PRC for the treatment of IPF. ETUARY&#8217;s annual sales have consistently grown each year, reaching $112.1&#160;million in 2023. In addition to IPF, Pirfenidone is undergoing three additional Phase 3 studies for connective tissue disease associated with interstitial lung disease to broaden its indications and market: sclerosis-related interstitial lung disease, dermatomyositis-related interstitial lung disease and pneumoconiosis. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">F351, our lead development candidate, is a structural derivative of ETUARY (Pirfenidone). It is a new oral chemical entity with an anti-fibrotic, TGF-&#223;1-targeting mechanism of action, for which we hold patents in major markets. Studies suggest that F351 and its major metabolites have minimal drug-drug interaction risks. Despite potential efficacy in IPF, we are prioritizing F351 for the treatment of liver fibrosis due to the large potential addressable market and significant unmet need. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Gyre Pharmaceuticals has completed a Phase 2 trial of F351 in the PRC for chronic hepatitis B (&#8220;CHB&#8221;)-associated liver fibrosis. The Phase 2 trial showed that F351 was well-tolerated without notable toxicity and patients treated showed statistically-significant improvement of liver fibrosis, with the best efficacy results achieved at 270&#160;mg/day dosing. Based on these results, a confirmatory Phase 3 trial is ongoing in the PRC. The enrollment of 248 patients for the confirmatory Phase 3 trial has been completed, with last patient out expected in 2024 and clinical results expected by early 2025. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In the United States, we have completed a Phase 1 clinical trial of F351 in healthy volunteers. We are preparing an investigational new drug (an &#8220;IND&#8221;) application and expect to submit it in late 2024. Following results from the PRC Phase 3 trial in CHB-associated liver fibrosis and pending approval of our IND, we expect to initiate a Phase&#160;2a trial to evaluate F351 for the treatment of nonalcoholic associated steatohepatitis-associated liver fibrosis in 2025. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Corporate Information </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We were incorporated in Delaware in 1997 as a wholly-owned subsidiary of R.J. Reynolds Tobacco Company. In August&#160;2000, we became an independent company when we issued and sold stock to venture capital investors. On August&#160;20, 2015, pursuant to the merger agreement between Targacept, Inc. and Catalyst Biosciences, Inc. (&#8220;Private Catalyst&#8221;), we acquired Private Catalyst and on August&#160;20, 2015, we changed our name from Targacept, Inc. to Catalyst Biosciences, Inc. On October&#160;30, 2023, we consummated a business combination pursuant to which we acquired an indirect controlling interest in Gyre Pharmaceuticals (the &#8220;Closing&#8221;). At the Closing, we changed our name from Catalyst Biosciences, Inc. to Gyre Therapeutics, Inc. Our principal executive offices are located at 12770&#160;High Bluff Drive, Suite&#160;150, San Diego, CA 92130, and our telephone number is (858) 567-7770. Our website </div></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">6<br></div></div></div>
<!--End Page 9-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 10-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 492pt;"><a name="ny20028941x1_s3_106-summary_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;"><div class="page-content" style="margin-left: 12pt;"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">address is www.gyretx.com. We do not incorporate the information on, or accessible through, our website into this prospectus, and you should not consider any information on, or accessible through, our website as part of this prospectus. </div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; text-align: center;"><a name="tTO"><!--Anchor--></a>THE OFFERING </div><div class="sum1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; width: 216pt; margin-top: 6pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Common Stock offered by the Selling Stockholder <font style="font-weight: normal; padding-left: 4.69pt;"></font></div><div class="sum2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: -10pt; margin-left: 240pt; text-align: left;">1,081,332 shares of Common Stock. </div><div class="sum1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; width: 216pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">Use of proceeds <font style="font-weight: normal; padding-left: 4.05pt;"></font></div><div class="sum2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: -12pt; margin-left: 240pt; text-align: left;">We will not receive any proceeds from the sale of our Common Stock by the Selling Stockholder pursuant to this prospectus, except for the exercise price paid for the exercise of the Warrants. See &#8220;<font style="font-style: italic;">Use of Proceeds</font>&#8221; and &#8220;<font style="font-style: italic;">Selling Stockholder</font>.&#8221; </div><div class="sum1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; width: 216pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">Plan of distribution <font style="font-weight: normal; padding-left: 5.19pt;"></font></div><div class="sum2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: -12pt; margin-left: 240pt; text-align: left;">The Selling Stockholder may sell all or a portion of the Resale Shares owned by them and offered hereby from time to time directly or through one or more underwriters, broker-dealers or agents. Registration of the Resale Shares covered by this prospectus does not mean, however, that such shares necessarily will be offered or sold. See &#8220;<font style="font-style: italic;">Plan of Distribution</font>.&#8221; </div><div class="sum1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; width: 216pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">Risk factors <font style="font-weight: normal; padding-left: 1.97pt;"></font></div><div class="sum2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: -12pt; margin-left: 240pt; text-align: left;">Investing in our Common Stock involves a high degree of risk. See &#8220;<font style="font-style: italic;">Risk Factors</font>&#8221; and other information included or incorporated into this prospectus for a discussion of the factors you should carefully consider before deciding to invest in our Common Stock. </div><div class="sum1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; width: 216pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">Nasdaq Symbol <font style="font-weight: normal; padding-left: 4.4pt;"></font></div><div class="sum2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: -10pt; margin-left: 240pt; text-align: left;">&#8220;GYRE&#8221; </div></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">7<br></div></div></div>
<!--End Page 10-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 11-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20028941x1_s3_107-risk_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tRF"><!--Anchor--></a>RISK FACTORS </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Investing in our Common Stock involves a high degree of risk. You should carefully consider the risks, uncertainties and other factors described in our most recent Annual Report on Form&#160;10-K, including under the heading &#8220;Risk Factors,&#8221; as supplemented and updated by subsequent Quarterly Reports on Form&#160;10-Q and Current Reports on Form&#160;8-K that we have filed or will file with the SEC, and in other documents which are incorporated by reference into this prospectus in their entirety, together with all of the other information contained in this prospectus or any document incorporated by reference herein and any free writing prospectus that we may authorize for use in connection with this offering. The risks described in this prospectus or any document incorporated by reference herein are not the only risks facing us, but those that we consider to be material. There may be other unknown or unpredictable economic, business, competitive, regulatory or other factors that could have material adverse effects on our future results. Past financial performance may not be a reliable indicator of future performance, and historical trends should not be used to anticipate results or trends in future periods. If any of these risks actually occurs, our business, financial condition, results of operations or cash flow could be adversely affected, which could cause the trading price of our Common Stock to decline, resulting in a loss of all or part of your investment. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">For more information about our SEC filings, please see &#8220;Where You Can Find More Information&#8221; and &#8220;Incorporation of Certain Information by Reference.&#8221; </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">8<br></div></div></div>
<!--End Page 11-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 12-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20028941x1_s3_108-use_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tUOP"><!--Anchor--></a>USE OF PROCEEDS </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We are not selling any securities under this prospectus and we will not receive any proceeds from the sale of the Resale Shares covered hereby. The net proceeds from the sale of the Resale Shares offered by this prospectus will be received by the Selling Stockholder. However, upon any cash exercise of the Warrants by the Selling Stockholder, we will receive cash proceeds per share equal to the exercise price of the Warrants. The Warrants have a per-share exercise price equal to $4,915.00. If the Warrants are exercised in a cashless exercise, we will not receive any proceeds from the exercise of the Warrants. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Subject to limited exceptions, the Selling Stockholder will pay any underwriting discounts and commissions and expenses incurred by the Selling Stockholder for brokerage, accounting, tax or legal services or any other expenses incurred by the Selling Stockholder in disposing of any of the Resale Shares. We will bear the costs, fees and expenses incurred in effecting the registration of the Resale Shares covered by this prospectus, including all registration and filing fees, Nasdaq listing fees and fees and expenses of our counsel and our independent registered public accounting firm. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">9<br></div></div></div>
<!--End Page 12-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 13-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20028941x1_s3_109-stock_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tSS"><!--Anchor--></a>SELLING STOCKHOLDER </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">This prospectus relates to the resale by the Selling Stockholder identified in the table below from time to time of 1,081,332 shares of Common Stock, consisting of (i) 540,666 shares of Common Stock issued upon the conversion of the Company&#8217;s Convertible Preferred Stock effective January 23, 2024 and (ii) 540,666 shares of Common Stock issuable upon the conversion of Convertible Preferred Stock issuable upon the exercise of a warrant issued to GNI USA (collectively, the &#8220;Shares&#8221;). The Selling Stockholder may from time to time offer and sell any or all of the Resale Shares set forth below pursuant to this prospectus and any accompanying prospectus supplement. We do not know how long the Selling Stockholder will hold the Warrants, whether the Selling Stockholder will exercise the Warrants, and upon such exercise, how long the Selling Stockholder will hold the Shares before selling them, and we currently have no agreements, arrangements or understandings with the Selling Stockholder regarding the sale of any of the Shares. When we refer to the &#8220;Selling Stockholder&#8221; in this prospectus, we mean the persons listed in the table below, and the pledgees, donees, transferees, assignees, successors, designees and others who later come to hold any of the Selling Stockholder&#8217;s interest in the Resale Shares other than through a public sale. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Certain Information Concerning the Selling Stockholder </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The table below presents information regarding the Selling Stockholder and the shares of our Common Stock that they may sell or otherwise dispose of from time to time under this prospectus. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In accordance with the Asset Purchase Agreement dated December&#160;26, 2022, by and among the Company, GNI Group Ltd., a company incorporated under the laws of Japan with limited liability (&#8220;GNI Group&#8221;) and GNI Hong Kong Limited, a company incorporated under the laws of Hong Kong with limited liability (&#8220;GNI Hong Kong&#8221;) on December&#160;26, 2022, our board of directors (the &#8220;Board&#8221;) appointed two persons affiliated with GNI USA, Ying Luo, Ph.D. and Thomas Eastling, to our Board. Dr.&#160;Luo serves as the Chairman of the Board and as a Class&#160;I director with a term expiring at our 2025 annual meeting of the stockholders and until such time as his successor is duly elected and qualified, or until his earlier death, resignation or removal. Mr.&#160;Eastling serves as a Class&#160;III director with a term expiring at our 2024 annual meeting of the stockholders and until such time as his successor is duly elected and qualified, or until his earlier death, resignation or removal. On October&#160;30, 2023, Dr.&#160;Luo and Mr.&#160;Eastling were appointed to the Nominating and Corporate Governance Committee of the Board, and Dr.&#160;Luo was appointed the chair of the committee. GNI USA, through entities affiliated with GNI Group, is a wholly-owned subsidiary of GNI Group. Dr.&#160;Luo is a director, representative executive officer, president and chief executive officer and executive committee member of GNI Group. Mr.&#160;Eastling is an outside member of GNI Group and an advisor to the executive committee of GNI Group. In addition, in connection with the Closing, Ruoyu Chen was appointed as the Company&#8217;s Interim Chief Financial Officer and subsequently became the Company&#8217;s Chief Financial Officer. Ms.&#160;Chen has worked as the senior vice president of finance of GNI USA since 2021. Mr.&#160;Eastling and Ms.&#160;Chen are husband and wife. Except as disclosed herein, the Selling Stockholder does not have, and within the past three years has not had, any position, office or other material relationship with us. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">For the Selling Stockholder listed on the table below, we have calculated the maximum estimated number of Resale Shares that could become saleable by such Selling Stockholder pursuant to this prospectus based on: (i)&#160;540,666 shares of Common Stock issued upon conversion of 811 shares of Convertible Preferred Stock effective January&#160;23, 2024, previously issued to GNI USA pursuant to the Securities Purchase Agreement; and (ii)&#160;540,666&#160;shares of Common Stock issuable upon conversion of 811 shares of Convertible Preferred Stock issuable upon the exercise of the Warrants. On an aggregate basis, the total number of the Resale Shares saleable pursuant to this prospectus is 1,081,332 shares. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">For purposes of the table below, we have assumed that the Selling Stockholder will not acquire beneficial ownership of any additional securities during the offering. The following table is prepared based on information provided to us by the Selling Stockholder. In addition, we assume that the Selling Stockholder has not sold, transferred or otherwise disposed of, our Common Stock in transactions exempt from the registration requirements of the Securities Act. Any changed or new information given to us by the Selling Stockholder, including regarding the identity of, and the securities held by, each Selling Stockholder, will be set forth in a prospectus supplement or amendments to the registration statement of which this prospectus is a part, if and when necessary. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">10<br></div></div></div>
<!--End Page 13-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 14-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20028941x1_s3_109-stock_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We have determined beneficial ownership in accordance with the rules of the SEC. Beneficial ownership generally includes voting or investment power over securities. Except in cases where community property laws apply or as indicated in the footnotes to this table, to our knowledge, each Selling Stockholder identified in the table possesses sole voting and investment power over the Resale Shares shown as beneficially owned by the Selling Stockholder. The information is not necessarily indicative of beneficial ownership for any other purpose. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="fintab" style="border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.15%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 29.53%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Beneficial Ownership Prior to the <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Date of this Prospectus</div></td><td class="gutter" style="width: 1.15%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.15%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 24.85%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Beneficial Ownership Assuming <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">the Sale of All Shares registered <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">pursuant to this Prospectus </div></td></tr><tr class="header"><td style="width: 41.03%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name</div></td><td class="gutter" style="width: 1.15%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.15%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 14.34%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of Shares <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Beneficially Owned <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Following <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Conversion<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></div></td><td class="gutter" style="width: 1.15%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.15%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 12.89%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Percent of <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Outstanding <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Common Stock<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup></div></td><td class="gutter" style="width: 1.15%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.15%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.38%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares</div></td><td class="gutter" style="width: 1.15%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.15%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 12.16%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Percent of <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Outstanding <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Common Stock </div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">GNI USA<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(3)</sup><font style="padding-left: 4.66pt;"></font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.34%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.05pt; text-align: left;">73,313,885</div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.89%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.4pt; text-align: left;">85.2%</div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.38%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.81pt; text-align: left;">72,232,553</div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.71pt; text-align: left;">84.0%</div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 13.25pt;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">One share of Convertible Preferred Stock converts into 10,000 shares of Common Stock, such underlying Common Stock then appropriately adjusted to reflect the reverse stock split effected on October&#160;30, 2023. In January&#160;2024, the Selling Stockholder converted 811 shares of Convertible Preferred Stock into 540,666 shares of Common Stock. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(2)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Based upon 86,030,782 shares of Common Stock outstanding as of May&#160;1, 2024 assuming the exercise of the Warrants for 811 shares of Convertible Preferred Stock and subsequent conversion of the Convertible Preferred Stock into 540,666 shares of Common Stock. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(3)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">GNI USA, through entities affiliated with GNI Group, is a wholly-owned subsidiary of GNI Group. By virtue of such relationship, GNI Group may be deemed to have voting and investment power with respect to the shares held by GNI USA. Ying Luo, Ph.D. is a director, representative executive officer, president and chief executive officer and executive committee member of GNI Group and may be deemed to share voting and dispositive power over the shares held of record by GNI USA. The business address for GNI USA is 12730 High Bluff Drive, Suite 250, San Diego, California 92130. The address for GNI Group and Ying Luo, Ph.D. is c/o GNI Group Ltd., Nihonbashi-Honcho YS Bldg. 3rd Floor 2-2-2 Nihonbashi-Honcho, Chuo-ku, 103-0023 Tokyo, Japan. </div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">11<br></div></div></div>
<!--End Page 14-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 15-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20028941x1_s3_110-plan_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tPOD"><!--Anchor--></a>PLAN OF DISTRIBUTION </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Selling Stockholder may sell all or a portion of the Resale Shares covered by this prospectus from time to time. The Selling Stockholder will act independently of us in making decisions with respect to the timing, manner and size of each sale. Such sales may be made directly or through one or more underwriters, broker-dealers or agents. If the Resale Shares are sold through underwriters or broker-dealers, the Selling Stockholder will be responsible for underwriting discounts or commissions or agent&#8217;s commissions. The Resale Shares may be sold on any national securities exchange or quotation service on which the securities may be listed or quoted at the time of sale, in the over-the-counter market or in transactions otherwise than on these exchanges or systems or in the over-the-counter market and in one or more transactions at fixed prices, at prevailing market prices at the time of the sale, at varying prices determined at the time of sale, or at negotiated prices. These sales may be effected in transactions, which may involve crosses or block transactions. The Selling Stockholder may use any one or more of the following methods when selling the Resale Shares: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">on the Nasdaq, in the over-the-counter market or on any other national securities exchange on which our securities are listed or traded; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">in privately negotiated transactions; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">in underwritten offerings; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">in ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">in a block trade in which the broker-dealer will attempt to sell the offered shares as agent but may position and resell a portion of the block as principal to facilitate the transaction; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">through purchases by a broker-dealer as principal and resale by the broker-dealer for its account pursuant to this prospectus; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">through the writing of options (including put or call options), whether the options are listed on an options exchange or otherwise; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">through the distribution of the shares by any Selling Stockholder to its partners, members or stockholders; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">in short sales entered into after the effective date of the registration statement of which this prospectus is a part; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">by pledge to secured debts and other obligations; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">through delayed delivery arrangements; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">an exchange distribution in accordance with the rules of the applicable exchange; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">through delayed delivery arrangements; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">to or through underwriters or agents; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">&#8220;at the market&#8221; or through market makers or into an existing market for the securities; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">through trading plans entered into by a Selling Stockholder pursuant to Rule&#160;10b5-1 under the Exchange Act that are in place at the time of an offering pursuant to this prospectus and any applicable prospectus supplement hereto that provide for periodic sales of securities on the basis of parameters described in such trading plans; or </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a combination of any such methods of sale. </div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Selling Stockholder also may resell all or a portion of the Resale Shares in open market transactions in reliance upon Rule&#160;144 under the Securities Act, as permitted by that rule, or Section&#160;4(a)(1) under the Securities Act, if available, rather than under this prospectus, provided that they meet the criteria and conform to the requirements of those provisions. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Broker-dealers engaged by the Selling Stockholder may arrange for other broker-dealers to participate in sales. If the Selling Stockholder effects such transactions by selling the Resale Shares to or through underwriters, broker-dealers or agents, such underwriters, broker-dealers or agents may receive commissions in the form of discounts, concessions or commissions from the Selling Stockholder or commissions from purchasers of the </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">12<br></div></div></div>
<!--End Page 15-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 16-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20028941x1_s3_110-plan_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Resale Shares for whom they may act as agent or to whom they may sell as principal. Such commissions will be in amounts to be negotiated, but, except as set forth in a supplement to this prospectus, in the case of an agency transaction will not be in excess of a customary brokerage commission in compliance with FINRA Rule&#160;2121; and in the case of a principal transaction a markup or markdown in compliance with FINRA Rule&#160;2121.01. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Selling Stockholder may transfer and donate the Resale Shares in other circumstances in which case the transferees, donees or pledgees will be the selling beneficial owners for purposes of this prospectus. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Any broker-dealer or agents participating in the distribution of the Resale Shares may be deemed to be &#8220;underwriters&#8221; within the meaning of Section&#160;2(11) of the Securities Act in connection with such sales. In such event, any commissions paid, or any discounts or concessions allowed to, any such broker-dealer or agent and any profit on the resale of the Resale Shares purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Selling Stockholder may also sell our securities short and deliver the securities to close out their short positions or loan or pledge the securities to broker-dealers that in turn may sell the securities. The shares may be sold directly or through broker-dealers acting as principal or agent or pursuant to a distribution by one or more underwriters on a firm commitment or best-efforts basis. The Selling Stockholder may also enter into hedging transactions with broker-dealers. In connection with such transactions, broker-dealers of other financial institutions may engage in short sales of our securities in the course of hedging the positions they assume with the Selling Stockholder. The Selling Stockholder may also enter into options or other transactions with broker-dealers or other financial institutions, which require the delivery to such broker-dealer or other financial institution of securities offered by this prospectus, which securities such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction). </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Each Selling Stockholder has informed the Company that it is not a registered broker-dealer and does not have any written or oral agreement or understanding, directly or indirectly, with any person to distribute the Resale Shares. Upon the Company being notified in writing by a Selling Stockholder that any material arrangement has been entered into with a broker-dealer for the Resale Shares through a block trade, special offering, exchange distribution or secondary distribution or a purchase by a broker or dealer, a supplement to this prospectus will be filed, if required, pursuant to Rule&#160;424(b) under the Securities Act, disclosing (i) the name of each such Selling Stockholder and of the participating broker-dealer(s), (ii) the number of Resale Shares involved, (iii) the price at which the Resale Shares were sold, (iv) the commissions paid or discounts or concessions allowed to such broker-dealer(s), where applicable, (v) that such broker-dealer(s) did not conduct any investigation to verify the information set out or incorporated by reference in this prospectus, and (vi) other facts material to the transaction. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Under the securities laws of some U.S. states, shares of our Common Stock may be sold in such states only through registered or licensed brokers or dealers. In addition, in some U.S. states shares of our Common Stock may not be sold unless such shares have been registered or qualified for sale in such state or an exemption from registration or qualification is available and is complied with. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">There can be no assurance that any Selling Stockholder will sell any or all of the Resale Shares registered pursuant to the shelf registration statement, of which this prospectus is a part. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Each Selling Stockholder and any other person participating in such distribution will be subject to applicable provisions of the Exchange Act and the rules and regulations thereunder, including, without limitation, to the extent applicable, Regulation M of the Exchange Act, which may limit the timing of purchases and sales of any of the Resale Shares by the Selling Stockholder and any other participating person. To the extent applicable, Regulation M may also restrict the ability of any person engaged in the distribution of the Resale Shares to engage in market-making activities with respect to the Resale Shares. All of the foregoing may affect the marketability of the Resale Shares and the ability of any person or entity to engage in market-making activities with respect to the Resale Shares. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Selling Stockholder will pay all of the expenses incurred in connection with the registration of the Resale Shares, including, without limitation, SEC filing fees and expenses of compliance with state securities or &#8220;blue sky&#8221; laws, all underwriting discounts and selling commissions, if any, and any legal or other expenses incurred by us or them in connection with the registration and offer and sale of the Resale Shares. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">13<br></div></div></div>
<!--End Page 16-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 17-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20028941x1_s3_110-plan_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tDP"><!--Anchor--></a>DIVIDEND POLICY </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We have no present intention to pay cash dividends on our Common Stock for the foreseeable future. Any determination to pay dividends to holders of our Common Stock will be at the discretion of our Board and will depend on many factors, including our financial condition, results of operations, liquidity, earnings, projected capital and other cash requirements, legal requirements, restrictions in the agreements governing any indebtedness we may enter into, business prospects and other factors that our Board deems relevant. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">14<br></div></div></div>
<!--End Page 17-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 18-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20028941x1_s3_110-plan_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tLM"><!--Anchor--></a>LEGAL MATTERS </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The validity of the issuance of the Resale Shares offered by this prospectus has been passed upon for us by Gibson, Dunn &amp; Crutcher LLP, San Francisco, California. Certain legal matters in connection with the Resale Shares offered hereby will be passed on for any agents, dealers or underwriters by counsel that will be named in the applicable prospectus supplement. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">15<br></div></div></div>
<!--End Page 18-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 19-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20028941x1_s3_110-plan_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tE"><!--Anchor--></a>EXPERTS </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The audited consolidated financial statements of Gyre Therapeutics, Inc. for the years ended December 31, 2023 and December 31, 2022 incorporated by reference in this prospectus and elsewhere in the registration statement have been so incorporated by reference in reliance upon the report of Grant Thornton Zhitong Certified Public Accountants LLP, independent registered public accountants, upon the authority of said firm as experts in accounting and auditing.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The consolidated balance sheets of Catalyst Biosciences, Inc. as of December 31, 2022 and 2021, and the related consolidated statements of operations, comprehensive loss, redeemable convertible preferred stock and stockholders' equity (deficit), and cash flows for each of the years then ended, have been audited by EisnerAmper LLP, independent registered public accounting firm, as stated in their report which is incorporated herein by reference, which report includes an explanatory paragraph about the existence of substantial doubt concerning the Company's ability to continue as a going concern. Such financial statements have been incorporated herein by reference in reliance on the report of such firm given upon their authority as experts in accounting and auditing. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">16<br></div></div></div>
<!--End Page 19-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 20-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 456pt;"><a name="ny20028941x1_s3_300-bcv_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 456pt; margin-left: 0pt;"><div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 2pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-left: auto; margin-right: auto; margin-top: 4pt;"> </div></div></div><div class="page-content"><div class="block-main" style="width: 456pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; text-align: center;"><img style="height: 54px; width: 210px;" src="logo_gyrex1.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold; margin-top: 247.5pt; text-align: center;">1,081,332 Shares <br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold; margin-top: 0pt; text-align: center;">COMMON STOCK<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195; <br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold; margin-top: 0pt; text-align: center;">Offered by the Selling Stockholder </div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 14pt; font-weight: bold; margin-top: 65.5pt; text-align: center;">PROSPECTUS </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 240pt; text-align: center;">The date of this prospectus is &#8195;&#8195;&#8195;&#8195;, 2024</div></div></div><div class="block-frill" style="width: 456pt; margin-top: 12pt; margin-left: 0pt;"><div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 2pt solid #000000; margin-bottom: 1pt; margin-left: auto; margin-right: auto; margin-top: 4pt;"> </div></div></div></div>
<!--End Page 20-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 21-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20028941x1_s3_400-part2_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tP2"><!--Anchor--></a>PART II <br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">INFORMATION NOT REQUIRED IN PROSPECTUS </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 50pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">ITEM 14.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Other Expenses of Issuance and Distributions. </div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following table sets forth the expenses to be borne by Gyre Therapeutics, Inc. in connection with the offerings described in this Registration Statement. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="fintab" style="border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 87.18%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Registration fee&#8201;-&#8201;SEC*<font style="padding-left: 4.42pt;"></font></div></td><td class="gutter" style="width: 2.94%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.94%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<font style="padding-left: 5pt;">&#8203;</font>1,781 </div></td></tr><tr><td style="width: 87.18%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Printing and engraving expenses<font style="padding-left: 2.77pt;"></font></div></td><td class="gutter" style="width: 2.94%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.94%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$10,000 </div></td></tr><tr><td style="width: 87.18%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Legal fees and expenses<font style="padding-left: 1.11pt;"></font></div></td><td class="gutter" style="width: 2.94%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.94%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$35,000 </div></td></tr><tr><td style="width: 87.18%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Accounting fees and expenses<font style="padding-left: 2.22pt;"></font></div></td><td class="gutter" style="width: 2.94%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.94%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$10,000 </div></td></tr><tr><td style="width: 87.18%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total<font style="padding-left: 0.09pt;"></font></div></td><td class="gutter" style="width: 2.94%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.94%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$56,781</div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 8.25pt;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">*<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Excludes registration fee offset pursuant to Rule 457(p) of the Securities Act. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 50pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">ITEM 15.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Indemnification of Directors and Officers. </div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Company is a Delaware corporation. Section 145(a) of the Delaware General Corporation Law (the &#8220;DGCL&#8221;) provides that a Delaware corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, other than an action by or in the right of the corporation, by reason of the fact that such person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys&#8217; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with such action, suit or proceeding if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Section 145(b) of the DGCL provides that a Delaware corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact that such person acted in any of the capacities set forth above, against expenses (including attorneys&#8217; fees) actually and reasonably incurred by such person in connection with the defense or settlement of such action or suit if the person acted in good faith and in a manner the person reasonably believed to be in, or not opposed to, the best interests of the corporation, except that no indemnification shall be made in respect of any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation, unless and only to the extent that the Court of Chancery or the court in which such action or suit was brought shall determine, upon application, that, despite the adjudication of liability but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the court shall deem proper. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Further subsections of DGCL Section 145 provide that: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">to the extent a present or former director or officer of a corporation has been successful on the merits or otherwise in the defense of any action, suit or proceeding referred to in subsections (i) and (ii) of Section&#160;145 or in the defense of any claim, issue or matter therein, such person shall be indemnified against expenses, including attorneys&#8217; fees, actually and reasonably incurred by such person in connection therewith; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(2)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the indemnification and advancement of expenses provided for pursuant to Section 145 shall not be deemed exclusive of any other rights to which those seeking indemnification or advancement of expenses may be entitled under any bylaw, agreement, vote of shareholders or disinterested directors or otherwise; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(3)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the corporation shall have the power to purchase and maintain insurance of behalf of any person who is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against any liability asserted against such person and incurred by such person in any such capacity, or arising out of such person&#8217;s status as such, whether or not the corporation would have the power to indemnify such person against such liability under Section 145. </div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">II-1<br></div></div></div>
<!--End Page 21-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 22-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20028941x1_s3_400-part2_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As used in this Item&#160;14, the term &#8220;proceeding&#8221; means any threatened, pending or completed action, suit or proceeding, whether or not by or in the right of the Company, and whether civil, criminal, administrative, investigative or otherwise. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Section 145 of the DGCL makes provision for the indemnification of officers and directors in terms sufficiently broad to indemnify officers and directors of the Company under certain circumstances from liabilities (including reimbursement for expenses incurred) arising under the Securities Act. The Company&#8217;s Fourth&#160;Amended and Restated Certificate of Incorporation, as amended (the &#8220;Certificate of Incorporation&#8221;) and Amended and Restated Bylaws provide, in effect, that, to the fullest extent and under the circumstances permitted by Section 145 of the DGCL, the Company will indemnify any and all of its officers and directors. The Company has entered into indemnification agreements with its officers and directors. The Company may, in its discretion, similarly indemnify its employees and agents. The Company&#8217;s Certificate of Incorporation also relieves the Company&#8217;s directors from monetary damages to the Company or its shareholders for breach of such director&#8217;s fiduciary duty as a director to the fullest extent permitted by the DGCL. Under Section 102(b)(7) of the DGCL, a corporation may relieve its directors from personal liability to such corporation or its shareholders for monetary damages for any breach of their fiduciary duty as directors except (i) for a breach of the duty of loyalty, (ii) for failure to act in good faith, (iii) for intentional misconduct or knowing violation of law, (iv) for willful or negligent violations of certain provisions in the DGCL imposing certain requirements with respect to stock repurchases, redemptions and dividends or (v) for any transactions from which the director derived an improper personal benefit. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Company has purchased insurance policies that, within the limits and subject to the terms and conditions thereof, cover certain expenses and liabilities that may be incurred by directors and officers in connection with proceedings that may be brought against them as a result of an act or omission committed or suffered while acting as a director or officer of the Company. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The underwriting agreements that we may enter into may provide for the indemnification by the underwriters of us and our officers and directors for certain liabilities, including liabilities arising under the Securities Act, and afford certain rights of contribution with respect thereto. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">II-2<br></div></div></div>
<!--End Page 22-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 23-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20028941x1_s3_400-part2_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 0pt;"><tr><td style="width: 50pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">ITEM 16.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Exhibits. </div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="fintab" style="border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td rowspan="2" style="width: 10.26%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Exhibit No.</div></td><td class="gutter" rowspan="2" style="width: 0.82%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" rowspan="2" style="width: 0.82%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td rowspan="2" style="width: 51.28%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Description</div></td><td class="gutter" rowspan="2" style="width: 0.82%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.82%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="7" style="width: 35.16%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Incorporated by reference <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">herein </div></td></tr><tr class="header"><td class="gutter" style="width: 0.82%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 4.39%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Form</div></td><td class="gutter" style="width: 0.82%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.82%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.33%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">File No.</div></td><td class="gutter" style="width: 0.82%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.82%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 17.15%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Filing Date </div></td></tr><tr><td style="width: 10.26%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000114036122046943/brhc10045912_ex2-1.htm">2.1(a)&#8224;#</a></div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 51.28%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Asset Purchase Agreement, dated December&#160;26, 2022, by and among Catalyst Biosciences, Inc., GNI Group Ltd., and GNI Hong Kong Limited</div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.39%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">8-K</div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.33%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">000-51173</div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 17.15%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">December&#160;27, 2022 </div></td></tr><tr><td style="width: 10.26%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000114036123014819/brhc10050607_ex2-2.htm">2.1(b)</a></div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 51.28%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Agreement and Amendment to Asset Purchase Agreement, dated as of March&#160;29, 2023, by and among Catalyst Biosciences, Inc., GNI Group and GNI Hong Kong.</div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.39%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">8-K</div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.33%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">000-51173</div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">March&#160;30, 2023 </div></td></tr><tr><td style="width: 10.26%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000114036122046943/brhc10045912_ex2-2.htm">2.2(a)#</a></div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 51.28%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Business Combination Agreement, dated December&#160;26, 2022, by and among Catalyst Biosciences, Inc., GNI USA, Inc., GNI Group Ltd., GNI Hong Kong Limited, Shanghai Genomics, Inc., the individuals listed on Annex&#160;A thereto and Continent Pharmaceuticals Inc.</div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.39%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">8-K</div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.33%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">000-51173</div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 17.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">December&#160;27, 2022 </div></td></tr><tr><td style="width: 10.26%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000114036123014819/brhc10050607_ex2-1.htm">2.2(b)</a></div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 51.28%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Amendment to Business Combination Agreement, dated as of March&#160;29, 2023, by and among Catalyst Biosciences, Inc., GNI USA, GNI Group, GNI Hong Kong, Shanghai Genomics, Inc., the Minority Holders and Continent Pharmaceuticals, Inc.</div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.39%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">8-K</div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.33%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">000-51173</div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">March&#160;30, 2023 </div></td></tr><tr><td style="width: 10.26%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000114036123042067/brhc20058284_ex2-1.htm">2.2(c)</a></div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 51.28%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Second Amendment to Business Combination Agreement, dated as of August&#160;30, 2023, by and among Catalyst Biosciences, Inc., GNI USA, GNI Group, GNI Hong Kong, Shanghai Genomics, Inc. and Continent Pharmaceuticals Inc.</div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.39%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">8-K</div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.33%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">000-51173</div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 17.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">August&#160;31, 2023 </div></td></tr><tr><td style="width: 10.26%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000119312506103288/dex41.htm">3.1</a></div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 51.28%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Fourth Amended and Restated Certificate of Incorporation of the Registrant</div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.39%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">S-8</div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.33%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">333-133881</div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">May&#160;8, 2006 </div></td></tr><tr><td style="width: 10.26%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000119312515297752/d24322dex31.htm">3.2</a></div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 51.28%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Certificate of Amendment to the Fourth Amended and Restated Certificate of Incorporation of the Registrant</div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.39%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">8-K</div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.33%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">000-51173</div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 17.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">August&#160;20, 2015 </div></td></tr><tr><td style="width: 10.26%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000119312517037156/d326649dex31.htm">3.3</a></div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 51.28%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Second Certificate of Amendment to the Fourth Amended and Restated Certificate of Incorporation of the Registrant</div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.39%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">8-K</div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.33%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">000-51173</div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">February&#160;10, 2017 </div></td></tr><tr><td style="width: 10.26%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000114036123050292/ny20009756x10_ex3-1.htm">3.4</a></div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 51.28%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Third Certificate of Amendment to the Fourth Amended and Restated Certificate of Incorporation of the Registrant</div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.39%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">8-K</div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.33%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">000-51173</div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 17.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">October&#160;30, 2023 </div></td></tr><tr><td style="width: 10.26%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000114036123050292/ny20009756x10_ex3-3.htm">3.5</a></div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 51.28%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Amended and Restated Bylaws of the Registrant</div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.39%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">8-K</div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.33%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">000-51173</div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">October&#160;30, 2023 </div></td></tr><tr><td style="width: 10.26%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000119312517121994/d375894dex31.htm">3.6(a)</a></div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 51.28%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Certificate of Designation of Preferences, Rights and Limitations of Series&#160;A Convertible Preferred Stock, filed with the Delaware Secretary of State on April&#160;10, 2017.</div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.39%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">8-K</div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.33%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">000-51173</div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 17.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">April&#160;13, 2017 </div></td></tr><tr><td style="width: 10.26%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000095017024037242/gyre-ex3_6b.htm">3.6(b)</a></div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 51.28%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Certificate of Elimination of Series&#160;A Preferred Stock, filed with the Delaware Secretary of State on March&#160;25, 2024.</div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.39%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">10-K</div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.33%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">000-51173</div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">March&#160;27, 2024 </div></td></tr><tr><td style="width: 10.26%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000114036122046943/brhc10045912_ex3-1.htm">3.7(a)</a></div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 51.28%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Certificate of Designation of Preferences, Rights and Limitations of Series&#160;X Convertible Preferred Stock, filed with the Delaware Secretary of State on December&#160;27, 2022.</div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.39%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">8-K</div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.33%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">000-51173</div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 17.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">December&#160;27, 2022 </div></td></tr><tr><td style="width: 10.26%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000114036123050292/ny20009756x10_ex3-2.htm">3.7(b)</a></div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 51.28%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Amendment to Certificate of Designation of Preferences, Rights and Limitations of Series&#160;X Convertible Preferred Stock, filed with the Delaware Secretary of State on October&#160;30, 2023</div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.39%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">8-K</div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.33%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">000-51173</div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">October&#160;30, 2023 </div></td></tr><tr><td style="width: 10.26%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000114036123030517/brhc20054638_ex3-1.htm">3.8(a)</a></div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 51.28%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Certificate of Designation of Preferences, Rights and Limitations of Series&#160;Y Preferred Stock, filed with the Delaware Secretary of State on June&#160;20, 2023, with respect to the Series&#160;Y Preferred Stock</div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.39%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">8-K</div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.33%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">000-51173</div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 17.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">June&#160;20, 2023 </div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">II-3<br></div></div></div>
<!--End Page 23-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 24-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20028941x1_s3_400-part2_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td rowspan="2" style="width: 10.26%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Exhibit No.</div></td><td class="gutter" rowspan="2" style="width: 0.82%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" rowspan="2" style="width: 0.82%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td rowspan="2" style="width: 51.28%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Description</div></td><td class="gutter" rowspan="2" style="width: 0.82%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.82%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="7" style="width: 35.16%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Incorporated by reference <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">herein </div></td></tr><tr class="header"><td class="gutter" style="width: 0.82%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 4.39%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Form</div></td><td class="gutter" style="width: 0.82%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.82%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.33%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">File No.</div></td><td class="gutter" style="width: 0.82%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.82%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 17.15%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Filing Date </div></td></tr><tr><td style="width: 10.26%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000114036123042067/brhc20058284_ex3-1.htm">3.8(b)</a></div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 51.28%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Certificate of Elimination of Series&#160;Y Preferred Stock, filed with the Delaware Secretary of State on August&#160;31, 2023</div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.39%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">8-K</div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.33%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">000-51173</div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 17.15%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">August&#160;31, 2023 </div></td></tr><tr><td style="width: 10.26%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000119312516498295/d117011dex43.htm">4.1</a></div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 51.28%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Warrant to Purchase Stock of Catalyst Biosciences, Inc., issued to Silicon Valley Bank on March&#160;3, 2005</div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.39%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">10-K</div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.33%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">000-51173</div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">March&#160;9, 2016 </div></td></tr><tr><td style="width: 10.26%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000119312516498295/d117011dex45.htm">4.2</a></div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 51.28%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Form&#160;of Warrant to Purchase Stock of Catalyst Biosciences, Inc., issued to purchasers of convertible promissory notes</div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.39%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">10-K</div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.33%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">000-51173</div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 17.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">March&#160;9, 2016 </div></td></tr><tr><td style="width: 10.26%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000114036123050292/ny20009756x10_ex4-1.htm">4.3</a></div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 51.28%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Form&#160;of Warrant to Purchase Series&#160;X Convertible Preferred Stock</div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.39%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">8-K</div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.33%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">000-51173</div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">October&#160;30, 2023 </div></td></tr><tr><td style="width: 10.26%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="ny20028941x1_ex5-1.htm">5.1*</a></div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 51.28%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Opinion and Consent of Gibson, Dunn &amp; Crutcher LLP</div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.39%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.33%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 17.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 10.26%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/1124105/000114036123050292/ny20009756x10_ex10-1.htm">10.1</a></div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 51.28%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Securities Purchase Agreement by and among the Company and GNI USA, dated October&#160;27, 2023</div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.39%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">8-K</div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.33%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">000-51173</div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">October&#160;30, 2023 </div></td></tr><tr><td style="width: 10.26%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="ny20028941x1_ex23-1.htm">23.1*</a></div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 51.28%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consent of Grant Thornton Zhitong Certified Public Accountants LLP, Independent Registered Public Accounting Firm.</div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.39%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.33%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 17.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 10.26%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="ny20028941x1_ex23-2.htm">23.2*</a></div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 51.28%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consent of EisnerAmper LLP</div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.39%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.33%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 10.26%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="ny20028941x1_ex5-1.htm">23.3*</a></div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 51.28%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consent of Gibson, Dunn &amp; Crutcher LLP (contained in Exhibit&#160;5.1)</div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.39%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.33%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 17.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 10.26%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tPOA">24.1*</a></div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 51.28%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Power of Attorney (contained in the signature page hereto)</div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.39%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.33%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 10.26%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="ny20028941x1_ex99-1.htm">99.1*</a></div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 51.28%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Unaudited pro forma condensed combined statement of operations of Catalyst Biosciences, Inc. for the year ended December 31, 2023.</div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.39%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.33%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 17.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 10.26%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="ny20028941x1_ex107.htm">107*</a></div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 51.28%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Filing Fee Table</div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.39%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.33%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 11.5pt;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">*<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Filed herewith. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">&#8224;<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">The annexes, schedules, and certain exhibits to this Exhibit&#160;have been omitted pursuant to Item&#160;601(a)(5). </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">#<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Pursuant to Item&#160;601(b)(10) of Regulation S-K, certain confidential portions of this exhibit were omitted by means of marking such portions with an asterisk because the identified confidential portions (i) the Company customarily and actually treats that information as private or confidential and (ii) the information was not material. </div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We maintain insurance policies that indemnify our directors and officers against various liabilities arising under the Securities Act and the Exchange Act, that might be incurred by any director or officer in his capacity as such. </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 50pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">ITEM 17.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Undertakings. </div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The undersigned registrant hereby undertakes: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">(1)&#8195;To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement: </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(i)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">to include any prospectus required by Section 10(a)(3) of the Securities Act; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(ii)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">to reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration Fee&#8221; table in the effective registration statement; and </div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">II-4<br></div></div></div>
<!--End Page 24-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 25-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20028941x1_s3_400-part2_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(iii)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">to include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement; </div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">provided, however, that paragraphs (a)(1)(i), (a)(1)(ii) and (a)(1)(iii) of this section do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section&#160;15(d) of the Exchange Act that are incorporated by reference in the registration statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the registration statement. </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(2)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial<font style="font-style: italic;"> bona fide</font> offering thereof. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(3)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(4)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">That, for the purpose of determining liability under the Securities Act to any purchaser: </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(i)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(ii)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule&#160;415(a)(1)(i), (vii), or (x) for the purpose of providing the information required by Section&#160;10(a) of the Securities Act shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial<font style="font-style: italic;"> bona fide</font> offering thereof.<font style="font-style: italic;"> </font><font style="font-style: italic;">Provided, however,</font> that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(5)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">That, for the purpose of determining liability of the registrant under the Securities Act to any purchaser in the initial distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser: </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(i)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(ii)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(iii)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(iv)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser. </div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">II-5<br></div></div></div>
<!--End Page 25-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 26-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20028941x1_s3_400-part2_pg6"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(6)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant&#8217;s annual report pursuant to section 13(a) or section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan&#8217;s annual report pursuant to section 15(d) of the Exchange Act) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial <font style="font-style: italic;">bona fide</font> offering thereof. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(7)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(8)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">That, for purposes of determining any liability under the Securities Act, (i) the information omitted from the form of prospectus filed as part of the registration statement in reliance upon Rule&#160;430A and contained in the form of prospectus filed by the registrant pursuant to Rule&#160;424(b)(l) or (4) or 497(h) under the Securities Act shall be deemed to be a part of the registration statement as of the time it was declared effective; and (ii) each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(9)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">To file an application for the purpose of determining the eligibility of the trustee to act under subsection (a)&#160;of Section 310 of the Trust Indenture Act in accordance with the rules and regulations prescribed by the Commission under Section 305(b)(2) of the Trust Indenture Act. </div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">II-6<br></div></div></div>
<!--End Page 26-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 27-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20028941x1_s3_401-sig_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tSIG"><!--Anchor--></a>SIGNATURES </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Diego, State of California, on the 30th day of May, 2024. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="txttab" style="border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 6pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 2pt;">&#8203;</td><td colspan="4" style="width: 51.28%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Gyre Therapeutics, Inc.<font style="font-weight: normal;"> </font></div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 2pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 3.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 3.25pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 2pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">By:</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 3.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 2pt; padding-bottom: 3.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 2pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">/s/ Han Ying </div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Han Ying, Ph.D. <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="font-style: italic;">Chief Executive Officer</font></div></td></tr></table><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 7pt; text-align: center;"><a name="tPOA"><!--Anchor--></a>POWER OF ATTORNEY </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">KNOW ALL PERSONS BY THESE PRESENTS<font style="font-weight: normal;">, that each person whose signature appears below constitutes </font><font style="font-weight: normal;">and appoints Han Ying, Ph.D. and Ruoyu Chen, and each of them, as true and lawful attorneys-in-fact and agents, </font><font style="font-weight: normal;">with full powers of substitution and resubstitution, for them and in their name, place and stead, in any and all </font><font style="font-weight: normal;">capacities, to sign any and all amendments (including post-effective amendments) to this registration statement (or any </font><font style="font-weight: normal;">registration statement for the same offering that is to be effective upon filing pursuant to Rule&#160;462(b) under the </font><font style="font-weight: normal;">Securities Act of 1933), and to file the same, with all exhibits thereto, and other documents in connection therewith, </font><font style="font-weight: normal;">with the SEC, and generally to do all such things in their names and behalf in their capacities as officers and directors </font><font style="font-weight: normal;">to enable the Gyre Therapeutics, Inc. to comply with the provisions of the Securities Act of 1933 and all requirements </font><font style="font-weight: normal;">of the SEC, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and </font><font style="font-weight: normal;">perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents </font><font style="font-weight: normal;">and purposes as he or she might or could do in person, ratifying and confirming all that said attorneys-in-fact and </font><font style="font-weight: normal;">agents, or any of them, or their or his substitutes or substitute, may lawfully do or cause to be done by virtue hereof. </font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed below by the following persons in the capacities and on the dates indicated. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 2pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="txttab" style="border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 23.08%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Signature</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 56.41%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Title</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 15.38%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Date </div></td></tr><tr><td style="width: 23.08%; text-align: left; vertical-align: top; padding-top: 3.25pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3.25pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3.25pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 23.08%; text-align: center; vertical-align: top; border-bottom: 1pt solid #000000; padding-top: 2pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">/s/ Han Ying, Ph.D.</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 2pt; padding-bottom: 3.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 3.25pt;">&#8203;</td><td rowspan="2" style="width: 56.41%; text-align: center; vertical-align: top; padding-top: 2pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Chief Executive Officer, Director<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">(<font style="font-style: italic;">Principal Executive Officer</font>) </div></td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 3.25pt;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 3.25pt;">&#8203;</td><td rowspan="2" style="width: 15.38%; text-align: left; vertical-align: top; padding-top: 2pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">May&#160;30, 2024 </div></td></tr><tr><td style="width: 23.08%; text-align: center; vertical-align: top; padding-top: 3.25pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Han Ying, Ph.D. </div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 2pt;">&#8203;</td></tr><tr><td style="width: 23.08%; text-align: center; vertical-align: top; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 56.41%; text-align: center; vertical-align: top; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: top; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 23.08%; text-align: center; vertical-align: top; border-bottom: 1pt solid #000000; padding-top: 2pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">/s/ Ruoyu Chen</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 2pt; padding-bottom: 3.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 3.25pt;">&#8203;</td><td rowspan="2" style="width: 56.41%; text-align: center; vertical-align: top; padding-top: 2pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Chief Financial Officer <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">(<font style="font-style: italic;">Principal Financial and Accounting Officer</font>) </div></td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 3.25pt;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 3.25pt;">&#8203;</td><td rowspan="2" style="width: 15.38%; text-align: left; vertical-align: top; padding-top: 2pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">May&#160;30, 2024 </div></td></tr><tr><td style="width: 23.08%; text-align: center; vertical-align: top; padding-top: 3.25pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Ruoyu Chen</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 2pt;">&#8203;</td></tr><tr><td style="width: 23.08%; text-align: center; vertical-align: top; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 56.41%; text-align: center; vertical-align: top; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: top; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 23.08%; text-align: center; vertical-align: top; border-bottom: 1pt solid #000000; padding-top: 2pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">/s/ Ying Luo, Ph.D.</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 2pt; padding-bottom: 3.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 3.25pt;">&#8203;</td><td rowspan="2" style="width: 56.41%; text-align: center; vertical-align: top; padding-top: 2pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Chairman of the Board of Directors</div></td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 3.25pt;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 3.25pt;">&#8203;</td><td rowspan="2" style="width: 15.38%; text-align: left; vertical-align: top; padding-top: 2pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">May&#160;30, 2024 </div></td></tr><tr><td style="width: 23.08%; text-align: center; vertical-align: top; padding-top: 3.25pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Ying Luo, Ph.D.</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 2pt;">&#8203;</td></tr><tr><td style="width: 23.08%; text-align: center; vertical-align: top; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 56.41%; text-align: center; vertical-align: top; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: top; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 23.08%; text-align: center; vertical-align: top; border-bottom: 1pt solid #000000; padding-top: 2pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">/s/ Songjiang Ma</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 2pt; padding-bottom: 3.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 3.25pt;">&#8203;</td><td rowspan="2" style="width: 56.41%; text-align: center; vertical-align: top; padding-top: 2pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Director</div></td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 3.25pt;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 3.25pt;">&#8203;</td><td rowspan="2" style="width: 15.38%; text-align: left; vertical-align: top; padding-top: 2pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">May&#160;30, 2024 </div></td></tr><tr><td style="width: 23.08%; text-align: center; vertical-align: top; padding-top: 3.25pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Songjiang Ma</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 2pt;">&#8203;</td></tr><tr><td style="width: 23.08%; text-align: center; vertical-align: top; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 56.41%; text-align: center; vertical-align: top; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: top; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 23.08%; text-align: center; vertical-align: top; border-bottom: 1pt solid #000000; padding-top: 2pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">/s/ Gordon G. Carmichael</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 2pt; padding-bottom: 3.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 3.25pt;">&#8203;</td><td rowspan="2" style="width: 56.41%; text-align: center; vertical-align: top; padding-top: 2pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Director</div></td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 3.25pt;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 3.25pt;">&#8203;</td><td rowspan="2" style="width: 15.38%; text-align: left; vertical-align: top; padding-top: 2pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">May&#160;30, 2024 </div></td></tr><tr><td style="width: 23.08%; text-align: center; vertical-align: top; padding-top: 3.25pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Gordon G. Carmichael </div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 2pt;">&#8203;</td></tr><tr><td style="width: 23.08%; text-align: center; vertical-align: top; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 56.41%; text-align: center; vertical-align: top; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: top; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 23.08%; text-align: center; vertical-align: top; border-bottom: 1pt solid #000000; padding-top: 2pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">/s/ Thomas Eastling</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 2pt; padding-bottom: 3.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 3.25pt;">&#8203;</td><td rowspan="2" style="width: 56.41%; text-align: center; vertical-align: top; padding-top: 2pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Director</div></td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 3.25pt;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 3.25pt;">&#8203;</td><td rowspan="2" style="width: 15.38%; text-align: left; vertical-align: top; padding-top: 2pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">May&#160;30, 2024 </div></td></tr><tr><td style="width: 23.08%; text-align: center; vertical-align: top; padding-top: 3.25pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Thomas Eastling </div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 2pt;">&#8203;</td></tr><tr><td style="width: 23.08%; text-align: center; vertical-align: top; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 56.41%; text-align: center; vertical-align: top; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: top; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 23.08%; text-align: center; vertical-align: top; border-bottom: 1pt solid #000000; padding-top: 2pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">/s/ Rodney L. Nussbaum</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 2pt; padding-bottom: 3.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 3.25pt;">&#8203;</td><td rowspan="2" style="width: 56.41%; text-align: center; vertical-align: top; padding-top: 2pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Director</div></td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 3.25pt;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 3.25pt;">&#8203;</td><td rowspan="2" style="width: 15.38%; text-align: left; vertical-align: top; padding-top: 2pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">May&#160;30, 2024 </div></td></tr><tr><td style="width: 23.08%; text-align: center; vertical-align: top; padding-top: 3.25pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Rodney L. Nussbaum </div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 2pt;">&#8203;</td></tr><tr><td style="width: 23.08%; text-align: center; vertical-align: top; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 56.41%; text-align: center; vertical-align: top; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: top; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 23.08%; text-align: center; vertical-align: top; border-bottom: 1pt solid #000000; padding-top: 2pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">/s/ Renate Parry, Ph.D.</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 2pt; padding-bottom: 3.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 3.25pt;">&#8203;</td><td rowspan="2" style="width: 56.41%; text-align: center; vertical-align: top; padding-top: 2pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Director</div></td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 3.25pt;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 3.25pt;">&#8203;</td><td rowspan="2" style="width: 15.38%; text-align: left; vertical-align: top; padding-top: 2pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">May&#160;30, 2024 </div></td></tr><tr><td style="width: 23.08%; text-align: center; vertical-align: top; padding-top: 3.25pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Renate Parry, Ph.D.</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 2pt;">&#8203;</td></tr><tr><td style="width: 23.08%; text-align: center; vertical-align: top; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 56.41%; text-align: center; vertical-align: top; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: top; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 23.08%; text-align: center; vertical-align: top; border-bottom: 1pt solid #000000; padding-top: 2pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">/s/ Nassim Usman, Ph.D.</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 2pt; padding-bottom: 3.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 3.25pt;">&#8203;</td><td rowspan="2" style="width: 56.41%; text-align: center; vertical-align: top; padding-top: 2pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Director</div></td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 3.25pt;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 3.25pt;">&#8203;</td><td rowspan="2" style="width: 15.38%; text-align: left; vertical-align: top; padding-top: 2pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">May&#160;30, 2024 </div></td></tr><tr><td style="width: 23.08%; text-align: center; vertical-align: top; padding-top: 3.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Nassim Usman, Ph.D.</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 3pt;">&#8203;</td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">II-7<br></div></div></div>
<!--End Page 27-->
</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>ny20028941x1_ex5-1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using Broadridge PROfile 24.3.1.5224
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div>
    <div style="text-align: right;"><font style="font-weight: bold;"> </font>
      <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"><font style="font-weight: bold;">Exhibit 5.1</font><br>
    </div>
    <div> <br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zf0871c903edd404baae0b6d0e58e8b11" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 47.72%; vertical-align: top;">
            <div><img src="ny20028941x1_ex5-1img01.jpg" height="16" width="170"></div>
          </td>
          <td style="width: 52.28%; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif; font-size: 8pt;">Gibson, Dunn &amp; Crutcher LLP</div>
          </td>
        </tr>
        <tr>
          <td style="width: 47.72%; vertical-align: top;">&#160;</td>
          <td style="width: 52.28%; vertical-align: top; font-size: 8pt;">
            <div style="font-family: 'Times New Roman',Times,serif;">One Embarcadero Center</div>
            <div style="font-family: 'Times New Roman',Times,serif;">San Francisco, CA&#160; 94111-3715</div>
            <div style="font-family: 'Times New Roman',Times,serif;">Tel 415.393.8200</div>
            <div style="font-family: 'Times New Roman',Times,serif;">gibsondunn.com</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div>May 30, 2024</div>
    <div><br>
    </div>
    <div>Gyre Therapeutics, Inc.</div>
    <div>12770 High Bluff Drive, Suite 150</div>
    <div>San Diego, California 92130</div>
    <div style="text-indent: -18pt; margin-left: 18pt;"><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z0a643d46d574458db5cb344688477f56" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">Re:</td>
          <td style="width: auto; vertical-align: top;">
            <div>Gyre Therapeutics, Inc.</div>
            <div>Registration Statement on Form S-3 </div>
          </td>
        </tr>

    </table>
    <div style="text-indent: -18pt; margin-left: 18pt;"><br>
    </div>
    <div>Ladies and Gentlemen:</div>
    <div><br>
    </div>
    <div style="text-align: justify;">We have acted as counsel to Gyre Therapeutics, Inc., a Delaware corporation (the &#8220;<u>Company</u>&#8221;), in connection with the preparation and filing with the Securities and Exchange Commission (the &#8220;<u>Commission</u>&#8221;) of
      a Registration Statement on Form S-3 (the &#8220;<u>Registration Statement</u>&#8221;) pursuant to the Securities Act of 1933, as amended (the &#8220;<u>Securities Act</u>&#8221;), relating to the resale from time to time by the selling stockholder named therein of up to
      1,081,332 shares of the Company&#8217;s common stock, par value $0.001 per share (the &#8220;<u>Shares</u>&#8221;).</div>
    <div><br>
    </div>
    <div style="text-align: justify;">In arriving at the opinion expressed below, we have examined originals, or copies certified or otherwise identified to our satisfaction as being true and complete copies of the originals, of the specimen common stock
      certificates and such other documents, corporate records, certificates of officers of the Company and of public officials and other instruments as we have deemed necessary or advisable to enable us to render these opinions.&#160; In our examination, we
      have assumed the genuineness of all signatures, the legal capacity and competency of all natural persons, the authenticity of all documents submitted to us as originals and the conformity to original documents of all documents submitted to us as
      copies.</div>
    <div><br>
    </div>
    <div style="text-align: justify;">Based on the foregoing, and subject to the assumptions, exceptions, qualifications and limitations set forth herein, we are of the opinion that the Shares, when issued against payment therefor as set forth in the
      Registration Statement, will be validly issued, fully paid and non-assessable.</div>
    <div><br>
    </div>
    <div style="text-align: justify;">We consent to the filing of this opinion as an exhibit to the Registration Statement, and we further consent to the use of our name under the caption &#8220;Legal Matters&#8221; in the Registration Statement and the prospectus
      that forms a part thereof.&#160; In giving these consents, we do not thereby admit that we are within the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission.</div>
    <div><br>
    </div>
    <div>Very truly yours,</div>
    <div><br>
    </div>
    <div><u>/s/ Gibson, Dunn &amp; Crutcher LLP</u></div>
    <div><br>
    </div>
    <div>Gibson, Dunn &amp; Crutcher LLP</div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div style="font-size: 8pt; text-align: center;">Abu Dhabi <font style="font-family: 'Wingdings 2',serif;">&#8211;</font> Beijing <font style="font-family: 'Wingdings 2',serif;">&#8211;</font> Brussels <font style="font-family: 'Wingdings 2',serif;">&#8211;</font>
      Century City <font style="font-family: 'Wingdings 2',serif;">&#8211;</font> Dallas <font style="font-family: 'Wingdings 2',serif;">&#8211;</font> Denver <font style="font-family: 'Wingdings 2',serif;">&#8211;</font> Dubai <font style="font-family: 'Wingdings 2',serif;">&#8211;</font> Frankfurt <font style="font-family: 'Wingdings 2',serif;">&#8211;</font> Hong Kong <font style="font-family: 'Wingdings 2',serif;">&#8211;</font> Houston <font style="font-family: 'Wingdings 2',serif;">&#8211;</font> London <font style="font-family: 'Wingdings 2',serif;">&#8211;</font> Los Angeles<font style="font-family: 'Times New Roman',Times,serif;"><br>
      </font>Munich <font style="font-family: 'Wingdings 2',serif;">&#8211;</font> New York <font style="font-family: 'Wingdings 2',serif;">&#8211;</font> Orange County <font style="font-family: 'Wingdings 2',serif;">&#8211;</font> Palo Alto <font style="font-family: 'Wingdings 2',serif;">&#8211;</font> Paris <font style="font-family: 'Wingdings 2',serif;">&#8211;</font> Riyadh <font style="font-family: 'Wingdings 2',serif;">&#8211;</font> San Francisco <font style="font-family: 'Wingdings 2',serif;">&#8211;</font> Singapore <font style="font-family: 'Wingdings 2',serif;">&#8211;</font> Washington, D.C.
      <hr style="height: 2px; color: #000000; background-color: #000000; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>ny20028941x1_ex23-1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using Broadridge PROfile 24.3.1.5224
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div>
    <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">
    <div style="text-align: right;"><font style="font-weight: bold;">Exhibit 23.1<br>
      </font></div>
    <div style="text-align: right;"><font style="font-weight: bold;"><br>
      </font></div>
    <div><br>
      <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</div>
      <div><br>
      </div>
      <div><br>
      </div>
      <div><br>
      </div>
      <div style="text-align: justify;">We have issued our report dated March 27, 2024, with respect to the consolidated financial statements included in the Annual Report of Gyre Therapeutics, Inc. on Form 10-K for the year ended December 31, 2023, which
        is incorporated by reference in this Registration Statement. We consent to the incorporation by reference of the said report in this Registration Statement, and the use of our name as it appears under the caption &#8220;Experts&#8221;.</div>
      <div><br>
      </div>
      <div style="text-align: justify;">/s/ Grant Thornton Zhitong Certified Public Accountants LLP</div>
      <div><br>
      </div>
      <div style="text-align: justify;">Beijing, China</div>
      <div style="text-align: justify;">May 30, 2024<br>
      </div>
      <div><br>
      </div>
      <div>
        <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>4
<FILENAME>ny20028941x1_ex23-2.htm
<DESCRIPTION>EXHIBIT 23.2
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using Broadridge PROfile 24.3.1.5224
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div>
    <div style="text-align: right; font-family: 'Times New Roman',Times,serif; font-weight: bold;">
      <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">Exhibit 23.2<br>
    </div>
    <div style="text-align: justify; font-weight: bold;"> <br>
    </div>
    <div style="text-align: justify; font-weight: bold;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</div>
    <div><br>
    </div>
    <div style="text-align: justify;">We consent to the incorporation by reference in this Registration Statement of Gyre Therapeutics, Inc. on Form S-3 to be filed on or about May 30, 2024 of our report dated March 30, 2023, on our audits of the financial
      statements of Catalyst Biosciences, Inc. (the &#8220;Company&#8221;) as of December 31, 2022 and 2021 and for each of the years then ended, which report was included in the Annual Report on Form 10-K filed<font style="font-style: italic;">&#160;</font>March 30, 2023.
      Our report includes an explanatory paragraph about the existence of substantial doubt concerning the Company&#8217;s ability to continue as a going concern. We also consent to the reference to our firm under the caption &#8220;Experts&#8221; in this Registration
      Statement.</div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify;">EISNERAMPER LLP</div>
    <div style="text-align: justify;">Philadelphia, Pennsylvania</div>
    <div>May 30, 2024</div>
    <div><br>
    </div>
    <div>
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>5
<FILENAME>ny20028941x1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using Broadridge PROfile 24.3.1.5224
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div style="font-weight: bold; text-align: right;">
    <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">EXHIBIT 99.1</div>
  <div style="font-weight: bold; text-align: right;"> <br>
  </div>
  <div style="font-weight: bold; text-align: center;"> UNAUDITED PRO FORMA CONDENSED FINANCIAL INFORMATION</div>
  <div><br>
  </div>
  <div style="text-align: justify;">On October 30, 2023, Gyre Therapeutics, Inc. (the &#8220;Company&#8221; or &#8220;Gyre&#8221;, previously known as Catalyst Biosciences, Inc. or &#8220;Catalyst&#8221;) consummated the transactions (the &#8220;Contributions&#8221;) contemplated by the Business
    Combination Agreement as described in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2023 (the &#8220;Annual Report&#8221;), which were accounted for as a reverse asset acquisition and a purchase of noncontrolling interest in accordance
    with United States generally accepted accounting principles (&#8220;GAAP&#8221;). Continent Pharmaceuticals Inc. (&#8220;CPI&#8221;) was treated as the accounting acquirer of the reverse asset acquisition and is presented as the predecessor for post-acquisition financial
    reporting purposes.</div>
  <div><br>
  </div>
  <div style="text-align: justify;">Pursuant to Article 11 of Regulation S-X, the Company prepared the following unaudited pro forma condensed combined financial information and the accompanying notes, reflecting the combined financial results of
    operations of Catalyst and CPI for the year ended December 31, 2023, assuming that the Contributions took place as of January 1, 2023.</div>
  <div><br>
  </div>
  <div style="text-align: justify;">The unaudited pro forma condensed combined financial information, including the notes thereto, should be read in conjunction with the following historical financial statements and the accompanying notes:</div>
  <div style="text-align: justify;"> <br>
  </div>
  <div style="text-align: justify;">
    <table id="z094020d706cd4238b470fbc604de00f3" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 5%;">
            <div>&#160;</div>
          </td>
          <td style="vertical-align: top; width: 5%; text-align: center;">&#8226;</td>
          <td style="width: 90%;">
            <div>
              <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">the historical unaudited condensed financial statements of Catalyst as of and for the nine months ended September 30, 2023, included in Catalyst&#8217;s Quarterly Report
                on Form 10-Q (the &#8220;10-Q&#8221;) filed with the SEC on October 26, 2023 and incorporated by reference; and</div>
            </div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%;">
            <div>&#160;</div>
          </td>
          <td style="vertical-align: top; width: 5%; text-align: center;">
            <div>&#160;</div>
          </td>
          <td style="width: 90%;">
            <div>&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%;">
            <div>&#160;</div>
          </td>
          <td style="vertical-align: middle; width: 5%; text-align: center;">&#8226;</td>
          <td style="width: 90%;">
            <div style="text-align: left;">the Annual Report filed with the SEC on March 27, 2024 and incorporated by reference.</div>
          </td>
        </tr>

    </table>
  </div>
  <div style="text-align: justify;"> <br>
  </div>
  <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div class="BRPFPageBreak" style="page-break-after: always;">
      <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
  </div>
  <div style="text-align: center;"> <font style="font-weight: bold;">Unaudited Pro Forma Condensed Combined Statement of Operations</font></div>
  <div style="text-align: center;"><font style="font-weight: bold;">For the Year Ended December 31, 2023</font> </div>
  <div style="text-align: center; font-style: italic;"> <font style="font-weight: bold;">(in thousands, except per share data)</font></div>
  <div> </div>
  <br>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zad5fdb2802374f068ea3c67f530cacfa" border="0" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 40%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
        <td style="width: 1.33%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
        <td style="width: 1.33%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
        <td style="vertical-align: bottom; width: 15%; text-align: center; border-bottom: 2px solid rgb(0, 0, 0);">
          <div style="color: #000000; font-weight: bold;">Gyre</div>
          <div style="color: #000000; font-weight: bold;">Consolidated</div>
        </td>
        <td style="vertical-align: bottom; width: 1.33%; text-align: center; padding-bottom: 2px;">&#160;</td>
        <td style="vertical-align: bottom; width: 1.33%; text-align: center; padding-bottom: 2px;">&#160;</td>
        <td style="vertical-align: bottom; width: 15%; text-align: center; border-bottom: 2px solid rgb(0, 0, 0);"> <font style="font-weight: bold;">Catalyst</font>
          <div style="color: #000000; font-weight: bold;">Prior to the</div>
          <div style="color: #000000; font-weight: bold;">Contributions</div>
        </td>
        <td style="vertical-align: bottom; width: 1%; text-align: center; padding-bottom: 2px;">&#160;</td>
        <td style="vertical-align: bottom; width: 1%; text-align: center; padding-bottom: 2px;"><br>
        </td>
        <td style="vertical-align: bottom; width: 1%; text-align: center; border-bottom: 2px solid rgb(0, 0, 0);">
          <div style="color: #000000; font-weight: bold;">Transaction Accounting Adjustments</div>
        </td>
        <td colspan="1" style="vertical-align: bottom; width: 1%; text-align: center; padding-bottom: 2px;">&#160;</td>
        <td style="vertical-align: bottom; width: 1.33%; text-align: center; padding-bottom: 2px;">&#160;</td>
        <td style="vertical-align: bottom; width: 1%; text-align: center; padding-bottom: 2px;">&#160;</td>
        <td style="vertical-align: bottom; width: 15%; text-align: center; border-bottom: 2px solid rgb(0, 0, 0);">
          <div style="color: #000000; font-weight: bold;">Pro Forma </div>
          <div style="color: #000000; font-weight: bold;">Combined</div>
        </td>
      </tr>
      <tr>
        <td style="width: 40%; vertical-align: top; background-color: rgb(204, 238, 255);">
          <div style="color: #000000;">Revenues</div>
        </td>
        <td style="vertical-align: bottom; width: 1.33%; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td style="vertical-align: bottom; width: 1.33%; background-color: rgb(204, 238, 255);">
          <div style="text-align: right; color: #000000;">$</div>
        </td>
        <td style="vertical-align: bottom; width: 15%; background-color: rgb(204, 238, 255);">
          <div style="text-align: right; color: #000000;">113,450</div>
        </td>
        <td style="vertical-align: bottom; width: 1.33%; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td style="vertical-align: bottom; width: 1.33%; background-color: rgb(204, 238, 255);">
          <div style="text-align: right; color: #000000;">$</div>
        </td>
        <td style="vertical-align: bottom; width: 15%; background-color: rgb(204, 238, 255);">
          <div style="text-align: right; color: #000000;">&#8212;</div>
        </td>
        <td style="vertical-align: bottom; width: 1%; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">
          <div style="text-align: right; color: #000000;">$</div>
        </td>
        <td style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">
          <div style="text-align: right; color: #000000;">&#8212;</div>
        </td>
        <td style="vertical-align: bottom; width: 1%; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td colspan="1" style="vertical-align: bottom; width: 1%; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td style="vertical-align: bottom; width: 1.33%; background-color: rgb(204, 238, 255);">
          <div style="text-align: right; color: #000000;">$</div>
        </td>
        <td style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">
          <div style="text-align: right; color: #000000;">113,450</div>
        </td>
      </tr>
      <tr>
        <td style="width: 40%; vertical-align: top;">
          <div style="color: #000000;">Operating expenses (income):</div>
        </td>
        <td style="vertical-align: bottom; width: 1.33%; text-align: right;">&#160;</td>
        <td style="vertical-align: bottom; width: 1.33%; text-align: right;">&#160;</td>
        <td style="vertical-align: bottom; width: 15%; text-align: right;">&#160;</td>
        <td style="vertical-align: bottom; width: 1.33%; text-align: right;">&#160;</td>
        <td style="vertical-align: bottom; width: 1.33%; text-align: right;">&#160;</td>
        <td style="width: 15%; vertical-align: bottom; text-align: right;">&#160;</td>
        <td style="vertical-align: bottom; width: 1%; text-align: right;">&#160;</td>
        <td style="vertical-align: bottom; width: 1%; text-align: right;">&#160;</td>
        <td style="vertical-align: bottom; width: 1%; text-align: right;">&#160;</td>
        <td style="vertical-align: bottom; width: 1%; text-align: right;">&#160;</td>
        <td colspan="1" style="vertical-align: bottom; width: 1%; text-align: right;">&#160;</td>
        <td style="vertical-align: bottom; width: 1.33%; text-align: right;">&#160;</td>
        <td style="vertical-align: bottom; width: 1%; text-align: right;">&#160;</td>
      </tr>
      <tr>
        <td style="width: 40%; vertical-align: top; background-color: rgb(204, 238, 255);">
          <div style="color: #000000;">&#160;&#160;&#160;&#160; Cost of revenues</div>
        </td>
        <td style="vertical-align: bottom; width: 1.33%; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td style="vertical-align: bottom; width: 1.33%; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td style="vertical-align: bottom; width: 15%; background-color: rgb(204, 238, 255);">
          <div style="text-align: right; color: #000000;">4,636</div>
        </td>
        <td style="vertical-align: bottom; width: 1.33%; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td style="vertical-align: bottom; width: 1.33%; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td style="vertical-align: bottom; width: 15%; background-color: rgb(204, 238, 255);">
          <div style="text-align: right; color: #000000;">&#8212;</div>
        </td>
        <td style="vertical-align: bottom; width: 1%; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td style="vertical-align: bottom; width: 1%; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">
          <div style="text-align: right; color: #000000;">&#8212;</div>
        </td>
        <td style="vertical-align: bottom; width: 1%; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td colspan="1" style="vertical-align: bottom; width: 1%; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td style="vertical-align: bottom; width: 1.33%; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">
          <div style="text-align: right; color: #000000;">4,636</div>
        </td>
      </tr>
      <tr>
        <td style="width: 40%; vertical-align: top;">
          <div style="color: #000000;">&#160;&#160;&#160;&#160; Selling and marketing expenses</div>
        </td>
        <td style="vertical-align: bottom; width: 1.33%; text-align: right;">&#160;</td>
        <td style="vertical-align: bottom; width: 1.33%; text-align: right;">&#160;</td>
        <td style="width: 15%; vertical-align: bottom;">
          <div style="text-align: right; color: #000000;">61,159</div>
        </td>
        <td style="vertical-align: bottom; width: 1.33%; text-align: right;">&#160;</td>
        <td style="vertical-align: bottom; width: 1.33%; text-align: right;">&#160;</td>
        <td style="width: 15%; vertical-align: bottom;">
          <div style="text-align: right; color: #000000;">&#8212;</div>
        </td>
        <td style="vertical-align: bottom; width: 1%; text-align: right;">&#160;</td>
        <td style="vertical-align: bottom; width: 1%; text-align: right;">&#160;</td>
        <td style="width: 1%; vertical-align: bottom;">
          <div style="text-align: right; color: #000000;">&#8212;</div>
        </td>
        <td style="vertical-align: bottom; width: 1%; text-align: right;">&#160;</td>
        <td colspan="1" style="vertical-align: bottom; width: 1%; text-align: right;">&#160;</td>
        <td style="vertical-align: bottom; width: 1.33%; text-align: right;">&#160;</td>
        <td style="width: 1%; vertical-align: bottom;">
          <div style="text-align: right; color: #000000;">61,159</div>
        </td>
      </tr>
      <tr>
        <td style="width: 40%; vertical-align: top; background-color: rgb(204, 238, 255);">
          <div style="color: #000000;">&#160;&#160;&#160;&#160; Research and development</div>
        </td>
        <td style="vertical-align: bottom; width: 1.33%; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td style="vertical-align: bottom; width: 1.33%; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td style="vertical-align: bottom; width: 15%; background-color: rgb(204, 238, 255);">
          <div style="text-align: right; color: #000000;">13,780</div>
        </td>
        <td style="vertical-align: bottom; width: 1.33%; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td style="vertical-align: bottom; width: 1.33%; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td style="vertical-align: bottom; width: 15%; background-color: rgb(204, 238, 255);">
          <div style="text-align: right; color: #000000;">1,321</div>
        </td>
        <td style="vertical-align: bottom; width: 1%; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td style="vertical-align: bottom; width: 1%; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">
          <div style="text-align: right; color: #000000;">&#8212;</div>
        </td>
        <td style="vertical-align: bottom; width: 1%; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td colspan="1" style="vertical-align: bottom; width: 1%; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td style="vertical-align: bottom; width: 1.33%; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">
          <div style="text-align: right; color: #000000;">15,101</div>
        </td>
      </tr>
      <tr>
        <td style="width: 40%; vertical-align: top;">
          <div style="color: #000000;">&#160;&#160;&#160;&#160; General and administrative</div>
        </td>
        <td style="vertical-align: bottom; width: 1.33%; text-align: right;">&#160;</td>
        <td style="vertical-align: bottom; width: 1.33%; text-align: right;">&#160;</td>
        <td style="width: 15%; vertical-align: bottom;">
          <div style="text-align: right; color: #000000;">14,662</div>
        </td>
        <td style="vertical-align: bottom; width: 1.33%; text-align: right;">&#160;</td>
        <td style="vertical-align: bottom; width: 1.33%; text-align: right;">&#160;</td>
        <td style="width: 15%; vertical-align: bottom;">
          <div style="text-align: right; color: #000000;">8,603</div>
        </td>
        <td style="vertical-align: bottom; width: 1%; text-align: right;">&#160;</td>
        <td style="vertical-align: bottom; width: 1%; text-align: right;">&#160;</td>
        <td style="width: 1%; vertical-align: bottom;">
          <div style="text-align: right; color: #000000;">&#8212;</div>
        </td>
        <td style="vertical-align: bottom; width: 1%; text-align: right;">&#160;</td>
        <td colspan="1" style="vertical-align: bottom; width: 1%; text-align: right;">&#160;</td>
        <td style="vertical-align: bottom; width: 1.33%; text-align: right;">&#160;</td>
        <td style="width: 1%; vertical-align: bottom;">
          <div style="text-align: right; color: #000000;">23,265</div>
        </td>
      </tr>
      <tr>
        <td style="width: 40%; vertical-align: middle; background-color: rgb(204, 238, 255);">
          <div style="color: #000000;">&#160;&#160;&#160;&#160; Acquired in-process research and development</div>
        </td>
        <td style="vertical-align: bottom; width: 1.33%; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td style="vertical-align: bottom; width: 1.33%; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td style="vertical-align: bottom; width: 15%; background-color: rgb(204, 238, 255);">
          <div style="text-align: right; color: #000000;">83,104</div>
        </td>
        <td style="vertical-align: bottom; width: 1.33%; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td style="vertical-align: bottom; width: 1.33%; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td style="vertical-align: bottom; width: 15%; text-align: right; background-color: rgb(204, 238, 255);">&#8212;</td>
        <td style="vertical-align: bottom; width: 1%; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td style="vertical-align: bottom; width: 1%; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">
          <div style="text-align: right; color: #000000;">&#8212;</div>
        </td>
        <td style="vertical-align: bottom; width: 1%; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td colspan="1" style="vertical-align: bottom; width: 1%; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td style="vertical-align: bottom; width: 1.33%; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">
          <div style="text-align: right; color: #000000;">83,104</div>
        </td>
      </tr>
      <tr>
        <td style="width: 40%; vertical-align: middle;">
          <div style="color: #000000;">&#160;&#160;&#160;&#160; Divestiture losses</div>
        </td>
        <td style="vertical-align: bottom; width: 1.33%; text-align: right;">&#160;</td>
        <td style="vertical-align: bottom; width: 1.33%; text-align: right;">&#160;</td>
        <td style="width: 15%; vertical-align: bottom;">
          <div style="text-align: right; color: #000000;">2,711</div>
        </td>
        <td style="vertical-align: bottom; width: 1.33%; text-align: right;">&#160;</td>
        <td style="vertical-align: bottom; width: 1.33%; text-align: right;">&#160;</td>
        <td style="width: 15%; vertical-align: bottom; text-align: right;">&#8212;</td>
        <td style="vertical-align: bottom; width: 1%; text-align: right;">&#160;</td>
        <td style="vertical-align: bottom; width: 1%; text-align: right;">&#160;</td>
        <td style="width: 1%; vertical-align: bottom;">
          <div style="text-align: right; color: #000000;">&#8212;</div>
        </td>
        <td style="vertical-align: bottom; width: 1%; text-align: right;">&#160;</td>
        <td colspan="1" style="vertical-align: bottom; width: 1%; text-align: right;">&#160;</td>
        <td style="vertical-align: bottom; width: 1.33%; text-align: right;">&#160;</td>
        <td style="width: 1%; vertical-align: bottom;">
          <div style="text-align: right; color: #000000;">2,711</div>
        </td>
      </tr>
      <tr>
        <td style="width: 40%; vertical-align: middle; background-color: rgb(204, 238, 255);">
          <div style="color: #000000;">&#160;&#160;&#160;&#160; GNI cost-sharing reimbursement</div>
        </td>
        <td style="vertical-align: bottom; width: 1.33%; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td style="vertical-align: bottom; width: 1.33%; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td style="vertical-align: bottom; width: 15%; background-color: rgb(204, 238, 255);">
          <div style="text-align: right; color: #000000;">&#8212;</div>
        </td>
        <td style="vertical-align: bottom; width: 1.33%; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td style="vertical-align: bottom; width: 1.33%; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td style="vertical-align: bottom; width: 15%; background-color: rgb(204, 238, 255);">
          <div style="text-align: right; color: #000000;">(1,200)</div>
        </td>
        <td style="vertical-align: bottom; width: 1%; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td style="vertical-align: bottom; width: 1%; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">
          <div style="text-align: right; color: #000000;">&#8212;</div>
        </td>
        <td style="vertical-align: bottom; width: 1%; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td colspan="1" style="vertical-align: bottom; width: 1%; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td style="vertical-align: bottom; width: 1.33%; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">
          <div style="text-align: right; color: #000000;">(1,200)</div>
        </td>
      </tr>
      <tr>
        <td style="width: 40%; vertical-align: middle; padding-bottom: 2px;">
          <div style="color: #000000;">&#160;&#160;&#160;&#160; Loss (gain) on disposal of assets, net</div>
        </td>
        <td style="vertical-align: bottom; width: 1.33%; padding: 0px 0px 2px; text-align: right;">&#160;</td>
        <td style="vertical-align: bottom; width: 1.33%; padding: 0px 0px 2px; text-align: right;">&#160;</td>
        <td style="border-bottom: 1px solid; vertical-align: bottom; width: 15%;">
          <div style="text-align: right; color: #000000;">628</div>
        </td>
        <td style="border-bottom: 1px none; vertical-align: bottom; width: 1.33%; padding: 0px 0px 2px; text-align: right;">&#160;</td>
        <td style="border-bottom: 1px none; vertical-align: bottom; width: 1.33%; padding: 0px 0px 2px; text-align: right;">&#160;</td>
        <td style="border-bottom: 1px solid; vertical-align: bottom; width: 15%;">
          <div style="text-align: right; color: #000000;">(4,736)</div>
        </td>
        <td style="border-bottom: 1px none; vertical-align: bottom; width: 1%; padding: 0px 0px 2px; text-align: right;">&#160;</td>
        <td style="border-bottom: 1px none; vertical-align: bottom; width: 1%; padding: 0px 0px 2px; text-align: right;">&#160;</td>
        <td style="border-bottom: 1px solid; vertical-align: bottom; width: 1%;">
          <div style="text-align: right; color: #000000;">&#8212;</div>
        </td>
        <td style="border-bottom: 1px none; vertical-align: bottom; width: 1%; padding: 0px 0px 2px; text-align: right;">&#160;</td>
        <td colspan="1" style="border-bottom: 1px none; vertical-align: bottom; width: 1%; padding: 0px 0px 2px; text-align: right;">&#160;</td>
        <td style="border-bottom: 1px none; vertical-align: bottom; width: 1.33%; padding: 0px 0px 2px; text-align: right;">&#160;</td>
        <td style="border-bottom: 1px solid; vertical-align: bottom; width: 1%;">
          <div style="text-align: right; color: #000000;">(4,108)</div>
        </td>
      </tr>
      <tr>
        <td style="width: 40%; vertical-align: middle; background-color: rgb(204, 238, 255); padding-bottom: 2px;">
          <div style="color: #000000;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Total operating expenses</div>
        </td>
        <td style="vertical-align: bottom; width: 1.33%; padding: 0px 0px 2px; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td style="vertical-align: bottom; width: 1.33%; padding: 0px 0px 2px; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td style="border-bottom: 1px solid; vertical-align: bottom; width: 15%; background-color: rgb(204, 238, 255);">
          <div style="text-align: right; color: #000000;">180,680</div>
        </td>
        <td style="border-bottom: 1px none; vertical-align: bottom; width: 1.33%; padding: 0px 0px 2px; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td style="border-bottom: 1px none; vertical-align: bottom; width: 1.33%; padding: 0px 0px 2px; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td style="border-bottom: 1px solid; vertical-align: bottom; width: 15%; background-color: rgb(204, 238, 255);">
          <div style="text-align: right; color: #000000;">3,988</div>
        </td>
        <td style="border-bottom: 1px none; vertical-align: bottom; width: 1%; padding: 0px 0px 2px; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td style="border-bottom: 1px none; vertical-align: bottom; width: 1%; padding: 0px 0px 2px; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td style="border-bottom: 1px solid; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">
          <div style="text-align: right; color: #000000;">&#8212;</div>
        </td>
        <td style="border-bottom: 1px none; vertical-align: bottom; width: 1%; padding: 0px 0px 2px; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td colspan="1" style="border-bottom: 1px none; vertical-align: bottom; width: 1%; padding: 0px 0px 2px; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td style="border-bottom: 1px none; vertical-align: bottom; width: 1.33%; padding: 0px 0px 2px; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td style="border-bottom: 1px solid; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">
          <div style="text-align: right; color: #000000;">184,668</div>
        </td>
      </tr>
      <tr>
        <td style="width: 40%; vertical-align: top;">
          <div style="color: #000000;">Loss from operations</div>
        </td>
        <td style="vertical-align: bottom; width: 1.33%; text-align: right;">&#160;</td>
        <td style="vertical-align: bottom; width: 1.33%; text-align: right;">&#160;</td>
        <td style="border-bottom: 1px none; vertical-align: bottom; width: 15%;">
          <div style="text-align: right; color: #000000;">(67,230)</div>
        </td>
        <td style="border-bottom: 1px none; vertical-align: bottom; width: 1.33%; text-align: right;">&#160;</td>
        <td style="border-bottom: 1px none; vertical-align: bottom; width: 1.33%; text-align: right;">&#160;</td>
        <td style="border-bottom: 1px none; vertical-align: bottom; width: 15%;">
          <div style="text-align: right; color: #000000;">(3,988)</div>
        </td>
        <td style="border-bottom: 1px none; vertical-align: bottom; width: 1%; text-align: right;">&#160;</td>
        <td style="border-bottom: 1px none; vertical-align: bottom; width: 1%; text-align: right;">&#160;</td>
        <td style="border-bottom: 1px none; vertical-align: bottom; width: 1%;">
          <div style="text-align: right; color: #000000;">&#8212;</div>
        </td>
        <td style="border-bottom: 1px none; vertical-align: bottom; width: 1%; text-align: right;">&#160;</td>
        <td colspan="1" style="border-bottom: 1px none; vertical-align: bottom; width: 1%; text-align: right;">&#160;</td>
        <td style="border-bottom: 1px none; vertical-align: bottom; width: 1.33%; text-align: right;">&#160;</td>
        <td style="border-bottom: 1px none; vertical-align: bottom; width: 1%;">
          <div style="text-align: right; color: #000000;">(71,218)</div>
        </td>
      </tr>
      <tr>
        <td style="width: 40%; vertical-align: top; background-color: rgb(204, 238, 255);">
          <div style="color: #000000;">Interest and other income (expense), net</div>
        </td>
        <td style="vertical-align: bottom; width: 1.33%; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td style="vertical-align: bottom; width: 1.33%; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td style="border-bottom: 1px none; vertical-align: bottom; width: 15%; background-color: rgb(204, 238, 255);">
          <div style="text-align: right; color: #000000;">(474)</div>
        </td>
        <td style="border-bottom: 1px none; vertical-align: bottom; width: 1.33%; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td style="border-bottom: 1px none; vertical-align: bottom; width: 1.33%; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td style="border-bottom: 1px none; vertical-align: bottom; width: 15%; background-color: rgb(204, 238, 255);">
          <div style="text-align: right; color: #000000;">216</div>
        </td>
        <td style="border-bottom: 1px none; vertical-align: bottom; width: 1%; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td style="border-bottom: 1px none; vertical-align: bottom; width: 1%; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td style="border-bottom: 1px none; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">
          <div style="text-align: right; color: #000000;">&#8212;</div>
        </td>
        <td style="border-bottom: 1px none; vertical-align: bottom; width: 1%; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td colspan="1" style="border-bottom: 1px none; vertical-align: bottom; width: 1%; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td style="border-bottom: 1px none; vertical-align: bottom; width: 1.33%; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td style="border-bottom: 1px none; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">
          <div style="text-align: right; color: #000000;">(258)</div>
        </td>
      </tr>
      <tr>
        <td style="width: 40%; vertical-align: top; padding-bottom: 2px;">
          <div style="color: #000000;">Change in fair value of warrant liability</div>
        </td>
        <td style="vertical-align: bottom; width: 1.33%; padding: 0px 0px 2px; text-align: right;">&#160;</td>
        <td style="vertical-align: bottom; width: 1.33%; padding: 0px 0px 2px; text-align: right;">&#160;</td>
        <td style="border-bottom: 1px solid; vertical-align: bottom; width: 15%;">
          <div style="text-align: right; color: #000000;">(9,261)</div>
        </td>
        <td style="border-bottom: 1px none; vertical-align: bottom; width: 1.33%; padding: 0px 0px 2px; text-align: right;">&#160;</td>
        <td style="border-bottom: 1px none; vertical-align: bottom; width: 1.33%; padding: 0px 0px 2px; text-align: right;">&#160;</td>
        <td style="border-bottom: 1px solid; vertical-align: bottom; width: 15%;">
          <div style="text-align: right; color: #000000;">&#8212;</div>
        </td>
        <td style="border-bottom: 1px none; vertical-align: bottom; width: 1%; padding: 0px 0px 2px; text-align: right;">&#160;</td>
        <td style="border-bottom: 1px none; vertical-align: bottom; width: 1%; padding: 0px 0px 2px; text-align: right;">&#160;</td>
        <td style="border-bottom: 1px solid; vertical-align: bottom; width: 1%;">
          <div style="text-align: right; color: #000000;">&#8212;</div>
        </td>
        <td style="border-bottom: 1px none; vertical-align: bottom; width: 1%; padding: 0px 0px 2px; text-align: right;">&#160;</td>
        <td colspan="1" style="border-bottom: 1px none; vertical-align: bottom; width: 1%; padding: 0px 0px 2px; text-align: right;">&#160;</td>
        <td style="border-bottom: 1px none; vertical-align: bottom; width: 1.33%; padding: 0px 0px 2px; text-align: right;">&#160;</td>
        <td style="border-bottom: 1px solid; vertical-align: bottom; width: 1%;">
          <div style="text-align: right; color: #000000;">(9,261)</div>
        </td>
      </tr>
      <tr>
        <td style="width: 40%; vertical-align: top; background-color: rgb(204, 238, 255);">
          <div style="color: #000000;">Loss before income taxes</div>
        </td>
        <td style="vertical-align: bottom; width: 1.33%; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td style="vertical-align: bottom; width: 1.33%; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td style="border-bottom: 1px none; vertical-align: bottom; width: 15%; background-color: rgb(204, 238, 255);">
          <div style="text-align: right; color: #000000;">(76,965)</div>
        </td>
        <td style="border-bottom: 1px none; vertical-align: bottom; width: 1.33%; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td style="border-bottom: 1px none; vertical-align: bottom; width: 1.33%; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td style="border-bottom: 1px none; vertical-align: bottom; width: 15%; background-color: rgb(204, 238, 255);">
          <div style="text-align: right; color: #000000;">(3,772)</div>
        </td>
        <td style="border-bottom: 1px none; vertical-align: bottom; width: 1%; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td style="border-bottom: 1px none; vertical-align: bottom; width: 1%; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td style="border-bottom: 1px none; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">
          <div style="text-align: right; color: #000000;">&#8212;</div>
        </td>
        <td style="border-bottom: 1px none; vertical-align: bottom; width: 1%; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td colspan="1" style="border-bottom: 1px none; vertical-align: bottom; width: 1%; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td style="border-bottom: 1px none; vertical-align: bottom; width: 1.33%; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td style="border-bottom: 1px none; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">
          <div style="text-align: right; color: #000000;">(80,737)</div>
        </td>
      </tr>
      <tr>
        <td style="width: 40%; vertical-align: top; padding-bottom: 2px;">
          <div style="color: #000000;">Provision for income taxes</div>
        </td>
        <td style="vertical-align: bottom; width: 1.33%; padding: 0px 0px 2px; text-align: right;">&#160;</td>
        <td style="vertical-align: bottom; width: 1.33%; padding: 0px 0px 2px; text-align: right;">&#160;</td>
        <td style="border-bottom: 1px solid; vertical-align: bottom; width: 15%;">
          <div style="text-align: right; color: #000000;">(8,515)</div>
        </td>
        <td style="border-bottom: 1px none; vertical-align: bottom; width: 1.33%; padding: 0px 0px 2px; text-align: right;">&#160;</td>
        <td style="border-bottom: 1px none; vertical-align: bottom; width: 1.33%; padding: 0px 0px 2px; text-align: right;">&#160;</td>
        <td style="border-bottom: 1px solid; vertical-align: bottom; width: 15%;">
          <div style="text-align: right; color: #000000;">(16)</div>
        </td>
        <td style="border-bottom: 1px none; vertical-align: bottom; width: 1%; padding: 0px 0px 2px; text-align: right;">&#160;</td>
        <td style="border-bottom: 1px none; vertical-align: bottom; width: 1%; padding: 0px 0px 2px; text-align: right;">&#160;</td>
        <td style="border-bottom: 1px solid; vertical-align: bottom; width: 1%;">
          <div style="text-align: right; color: #000000;">&#8212;</div>
        </td>
        <td style="border-bottom: 1px none; vertical-align: bottom; width: 1%; padding: 0px 0px 2px; text-align: right;">&#160;</td>
        <td colspan="1" style="border-bottom: 1px none; vertical-align: bottom; width: 1%; padding: 0px 0px 2px; text-align: right;">&#160;</td>
        <td style="border-bottom: 1px none; vertical-align: bottom; width: 1.33%; padding: 0px 0px 2px; text-align: right;">&#160;</td>
        <td style="border-bottom: 1px solid; vertical-align: bottom; width: 1%;">
          <div style="text-align: right; color: #000000;">(8,531)</div>
        </td>
      </tr>
      <tr>
        <td style="width: 40%; vertical-align: top; background-color: rgb(204, 238, 255);">
          <div style="color: #000000;">Net loss from operations</div>
        </td>
        <td style="vertical-align: bottom; width: 1.33%; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td style="vertical-align: bottom; width: 1.33%; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td style="border-bottom: 1px none; vertical-align: bottom; width: 15%; background-color: rgb(204, 238, 255);">
          <div style="text-align: right; color: #000000;">(85,480)</div>
        </td>
        <td style="border-bottom: 1px none; vertical-align: bottom; width: 1.33%; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td style="border-bottom: 1px none; vertical-align: bottom; width: 1.33%; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td style="border-bottom: 1px none; vertical-align: bottom; width: 15%; background-color: rgb(204, 238, 255);">
          <div style="text-align: right; color: #000000;">(3,788)</div>
        </td>
        <td style="border-bottom: 1px none; vertical-align: bottom; width: 1%; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td style="border-bottom: 1px none; vertical-align: bottom; width: 1%; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td style="border-bottom: 1px none; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">
          <div style="text-align: right; color: #000000;">&#8212;</div>
        </td>
        <td style="border-bottom: 1px none; vertical-align: bottom; width: 1%; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td colspan="1" style="border-bottom: 1px none; vertical-align: bottom; width: 1%; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td style="border-bottom: 1px none; vertical-align: bottom; width: 1.33%; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td style="border-bottom: 1px none; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">
          <div style="text-align: right; color: #000000;">(89,268)</div>
        </td>
      </tr>
      <tr>
        <td style="border-bottom: 1px none; vertical-align: middle; width: 40%;">
          <div style="color: #000000;">Net income attributable to noncontrolling interest</div>
        </td>
        <td style="border-bottom: 1px none; vertical-align: bottom; width: 1.33%; text-align: right;">&#160;</td>
        <td style="border-bottom: 1px solid; vertical-align: bottom; width: 1.33%; text-align: right;">&#160;</td>
        <td style="border-bottom: 1px solid; vertical-align: bottom; width: 15%;">
          <div style="text-align: right; color: #000000;">7,453</div>
        </td>
        <td style="border-bottom: 1px none; vertical-align: bottom; width: 1.33%; text-align: right;">&#160;</td>
        <td style="border-bottom: 1px solid; vertical-align: bottom; width: 1.33%; text-align: right;">&#160;</td>
        <td style="border-bottom: 1px solid; vertical-align: bottom; width: 15%;">
          <div style="text-align: right; color: #000000;">&#8212;</div>
        </td>
        <td style="vertical-align: bottom; width: 1%; text-align: right;">&#160;</td>
        <td style="border-bottom: 1px solid; vertical-align: bottom; width: 1%; text-align: right;">&#160;</td>
        <td style="border-bottom: 1px solid; vertical-align: bottom; width: 1%;">
          <div style="text-align: right; color: #000000;">&#8212;</div>
        </td>
        <td style="vertical-align: bottom; width: 1%; text-align: right;">&#160;</td>
        <td colspan="1" style="vertical-align: bottom; width: 1%; text-align: right;">&#160;</td>
        <td style="border-bottom: 1px solid; vertical-align: bottom; width: 1.33%; text-align: right;">&#160;</td>
        <td style="border-bottom: 1px solid; vertical-align: bottom; width: 1%;">
          <div style="text-align: right; color: #000000;">7,453</div>
        </td>
      </tr>
      <tr>
        <td style="width: 40%; vertical-align: top; background-color: rgb(204, 238, 255); padding-bottom: 4px;">
          <div style="color: #000000;">Net loss attributable to common stockholders</div>
        </td>
        <td style="vertical-align: bottom; width: 1.33%; padding: 0px 0px 4px; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td style="border-bottom: 4px double; vertical-align: bottom; width: 1.33%; background-color: rgb(204, 238, 255);">
          <div style="text-align: right; color: #000000;">$</div>
        </td>
        <td style="border-bottom: 4px double; vertical-align: bottom; width: 15%; background-color: rgb(204, 238, 255);">
          <div style="text-align: right; color: #000000;">(92,933)</div>
        </td>
        <td style="vertical-align: bottom; width: 1.33%; padding: 0px 0px 4px; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td style="border-bottom: 4px double; vertical-align: bottom; width: 1.33%; background-color: rgb(204, 238, 255);">
          <div style="text-align: right; color: #000000;">$</div>
        </td>
        <td style="border-bottom: 4px double; vertical-align: bottom; width: 15%; background-color: rgb(204, 238, 255);">
          <div style="text-align: right; color: #000000;">(3,788)</div>
        </td>
        <td style="vertical-align: bottom; width: 1%; padding: 0px 0px 4px; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td style="background-color: #CCEEFF; border-bottom: 4px double; vertical-align: bottom; width: 1%; padding: 0px 0px 4px;">
          <div style="text-align: right; color: #000000;">$</div>
        </td>
        <td style="background-color: #CCEEFF; border-bottom: 4px double; vertical-align: bottom; width: 1%; padding: 0px 0px 4px;">
          <div style="text-align: right; color: #000000;">&#8212;</div>
        </td>
        <td style="vertical-align: bottom; width: 1%; padding: 0px 0px 4px; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td colspan="1" style="vertical-align: bottom; width: 1%; padding: 0px 0px 4px; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td style="border-bottom: 4px double; vertical-align: bottom; width: 1.33%; background-color: rgb(204, 238, 255);">
          <div style="text-align: right; color: #000000;">$</div>
        </td>
        <td style="border-bottom: 4px double; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">
          <div style="text-align: right; color: #000000;">(96,721)</div>
        </td>
      </tr>
      <tr>
        <td style="width: 40%; vertical-align: top;">
          <div style="color: #000000;">Net loss per share attributable to common stockholders:</div>
        </td>
        <td style="vertical-align: bottom; width: 1.33%; text-align: right;">&#160;</td>
        <td style="vertical-align: bottom; width: 1.33%; text-align: right;">&#160;</td>
        <td style="vertical-align: bottom; width: 15%; text-align: right;">&#160;</td>
        <td style="vertical-align: bottom; width: 1.33%; text-align: right;">&#160;</td>
        <td style="vertical-align: bottom; width: 1.33%; text-align: right;">&#160;</td>
        <td style="vertical-align: bottom; width: 15%; text-align: right;">&#160;</td>
        <td style="vertical-align: bottom; width: 1%; text-align: right;">&#160;</td>
        <td style="vertical-align: bottom; width: 1%; text-align: right;">&#160;</td>
        <td style="vertical-align: bottom; width: 1%; text-align: right;">&#160;</td>
        <td style="vertical-align: bottom; width: 1%; text-align: right;">&#160;</td>
        <td colspan="1" style="vertical-align: bottom; width: 1%; text-align: right;">&#160;</td>
        <td style="vertical-align: bottom; width: 1.33%; text-align: right;">&#160;</td>
        <td style="vertical-align: bottom; width: 1%; text-align: right;">&#160;</td>
      </tr>
      <tr>
        <td style="width: 40%; vertical-align: top; background-color: rgb(204, 238, 255); padding-bottom: 4px;">
          <div style="color: #000000;">Basic and diluted</div>
        </td>
        <td style="vertical-align: bottom; width: 1.33%; padding: 0px 0px 4px; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td style="border-bottom: 4px double; vertical-align: bottom; width: 1.33%; background-color: rgb(204, 238, 255);">
          <div style="text-align: right; color: #000000;">$</div>
        </td>
        <td style="border-bottom: 4px double; vertical-align: bottom; width: 15%; background-color: rgb(204, 238, 255);">
          <div style="text-align: right; color: #000000;">(1.41)</div>
        </td>
        <td style="vertical-align: bottom; width: 1.33%; padding: 0px 0px 4px; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td style="vertical-align: bottom; width: 1.33%; padding: 0px 0px 4px; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td style="vertical-align: bottom; width: 15%; padding: 0px 0px 4px; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td style="vertical-align: bottom; width: 1%; padding: 0px 0px 4px; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td style="vertical-align: bottom; width: 1%; padding: 0px 0px 4px; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td style="vertical-align: bottom; width: 1%; padding: 0px 0px 4px; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td style="vertical-align: bottom; width: 1%; padding: 0px 0px 4px; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td colspan="1" style="vertical-align: bottom; width: 1%; padding: 0px 0px 4px; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td style="border-bottom: 4px double; vertical-align: bottom; width: 1.33%; background-color: rgb(204, 238, 255);">
          <div style="text-align: right; color: #000000;">$</div>
        </td>
        <td style="border-bottom: 4px double; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">
          <div style="text-align: right; color: #000000;">(1.26)</div>
        </td>
      </tr>
      <tr>
        <td style="width: 40%; vertical-align: top;">
          <div style="color: #000000;">Weighted average shares used in calculating net </div>
          <div style="color: #000000;">loss per share attributable to common stockholders:</div>
        </td>
        <td style="vertical-align: bottom; width: 1.33%; text-align: right;">&#160;</td>
        <td style="vertical-align: bottom; width: 1.33%; text-align: right;">&#160;</td>
        <td style="vertical-align: bottom; width: 15%; text-align: right;">&#160;</td>
        <td style="vertical-align: bottom; width: 1.33%; text-align: right;">&#160;</td>
        <td style="vertical-align: bottom; width: 1.33%; text-align: right;">&#160;</td>
        <td style="vertical-align: bottom; width: 15%; text-align: right;">&#160;</td>
        <td style="vertical-align: bottom; width: 1%; text-align: right;">&#160;</td>
        <td style="vertical-align: bottom; width: 1%; text-align: right;">&#160;</td>
        <td style="vertical-align: bottom; width: 1%; text-align: right;">&#160;</td>
        <td style="vertical-align: bottom; width: 1%; text-align: right;">&#160;</td>
        <td colspan="1" style="vertical-align: bottom; width: 1%; text-align: right;">&#160;</td>
        <td style="vertical-align: bottom; width: 1.33%; text-align: right;">&#160;</td>
        <td style="vertical-align: bottom; width: 1%; text-align: right;">&#160;</td>
      </tr>
      <tr>
        <td style="width: 40%; vertical-align: top; background-color: rgb(204, 238, 255); padding-bottom: 4px;">
          <div style="color: #000000;">Basic and diluted</div>
        </td>
        <td style="vertical-align: bottom; width: 1.33%; padding: 0px 0px 4px; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td style="border-bottom: 4px double; vertical-align: bottom; width: 1.33%; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td style="border-bottom: 4px double; vertical-align: bottom; width: 15%; background-color: rgb(204, 238, 255);">
          <div style="text-align: right; color: #000000;">65,832</div>
        </td>
        <td style="vertical-align: bottom; width: 1.33%; padding: 0px 0px 4px; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td style="vertical-align: bottom; width: 1.33%; padding: 0px 0px 4px; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td style="vertical-align: bottom; width: 15%; padding: 0px 0px 4px; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td style="vertical-align: bottom; width: 1%; padding: 0px 0px 4px; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td style="vertical-align: bottom; width: 1%; padding: 0px 0px 4px; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td style="border-bottom: 4px double; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">
          <div style="text-align: right; color: #000000;">10,752</div>
        </td>
        <td style="vertical-align: bottom; width: 1%; padding: 0px 0px 4px; text-align: right; background-color: rgb(204, 238, 255);">&#160;</td>
        <td colspan="1" style="vertical-align: bottom; width: 1%; padding: 0px 0px 4px; text-align: right; background-color: rgb(204, 238, 255);"><font style="font-weight: bold;">A</font> <br>
        </td>
        <td style="vertical-align: bottom; width: 1.33%; padding-top: 0px; padding-right: 0px; padding-left: 0px; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);">
          <div style="text-align: right; color: #000000; font-weight: bold;"><br>
          </div>
        </td>
        <td style="border-bottom: 4px double rgb(0, 0, 0); vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">
          <div style="text-align: right; color: #000000;">76,584</div>
        </td>
      </tr>

  </table>
  <div> <br>
  </div>
  <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div class="BRPFPageBreak" style="page-break-after: always;">
      <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
  </div>
  <div style="text-align: center;"> <font style="font-weight: bold;">NOTES TO UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS</font></div>
  <div> <br>
  </div>
  <div>
    <table id="zccecb0c2cd954025b78c1fc5052ed51c" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 5%;">
            <div>&#160;</div>
          </td>
          <td style="width: 5%;">
            <div>&#160;<font style="font-weight: bold;">1.</font></div>
          </td>
          <td style="width: 90%;">
            <div>&#160;<font style="font-weight: bold; color: #000000;">Basis of Pro Forma Presentation</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div> <br>
  </div>
  <div style="text-align: justify;">The unaudited pro forma condensed combined financial information was prepared in accordance with U.S. GAAP and pursuant to Article 11 of Regulation S-X. The unaudited pro forma condensed combined statement of operations
    for the year ended December 31, 2023, gives effect to the Contributions as if they had been consummated on January 1, 2023, and has aggregated: </div>
  <div> <br>
  </div>
  <div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 5%;">
            <div>&#160;</div>
          </td>
          <td style="width: 5%;">a)<br>
          </td>
          <td style="width: 90%;"><font style="color: #000000;">Catalyst&#8217;s operations for the nine months ended September 30, 2023 from the 10-Q, and</font></td>
        </tr>

    </table>
  </div>
  <div> <br>
  </div>
  <div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 5%;">
            <div style="text-align: justify;">&#160;</div>
          </td>
          <td style="vertical-align: top; width: 5%; text-align: justify;">b)<br>
          </td>
          <td style="width: 90%; text-align: justify;"><font style="font-family: 'Times New Roman',Times,serif; color: rgb(0, 0, 0);">the Company&#8217;s consolidated operations from the Annual Report, which includes CPI&#8217;s operations for the year ended December
              2023, and Gyre&#8217;s operations post-merger from October 30, 2023 to December 31, 2023.</font></td>
        </tr>

    </table>
  </div>
  <div> <br>
  </div>
  <div style="text-align: justify;">The Company determined that there were no significant transactions within Catalyst from October 1 to October 30, 2023. The acquired assets and assumed liabilities upon closing of the Contributions were mainly in-process
    research and development (&#8220;IPR&amp;D&#8221;), in addition to the working capital. Therefore, no pro forma adjustments, other than weighted average shares outstanding and loss per share, were deemed necessary. </div>
  <div style="text-align: justify;"> <br>
  </div>
  <div style="text-align: justify;">
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 5%;">
            <div>&#160;</div>
          </td>
          <td style="width: 5%;">
            <div>&#160;<font style="font-weight: bold;">2.</font></div>
          </td>
          <td style="width: 90%;">
            <div><font style="font-weight: bold; color: #000000;">Proforma Adjustments<br>
              </font></div>
          </td>
        </tr>

    </table>
  </div>
  <div> <br>
  </div>
  <div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">(A) The weighted average shares outstanding for the period has been calculated as if the Contributions occurred on January 1, 2023, including:</div>
  </div>
  <div> <br>
  </div>
  <div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 5%;">
            <div style="text-align: justify;">&#160;</div>
          </td>
          <td style="width: 5%; text-align: justify;">(1)<br>
          </td>
          <td style="width: 90%; text-align: justify;"><font style="font-family: 'Times New Roman',Times,serif; color: rgb(0, 0, 0);">the weighted average shares outstanding for common stock deemed issued to Catalyst upon closing of the Contributions, for
              the period from October 1 to October 30, 2023, adjusted for the 1-for-15 reverse stock split completed on October 30, 2023 (the &#8220;Reverse Stock Split&#8221;);</font></td>
        </tr>

    </table>
  </div>
  <div> <br>
  </div>
  <div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 5%;">
            <div style="text-align: justify;">&#160;</div>
          </td>
          <td style="width: 5%; text-align: justify;">(2)<br>
          </td>
          <td style="width: 90%; text-align: justify;"><font style="font-family: 'Times New Roman',Times,serif; color: rgb(0, 0, 0);">the weighted average shares outstanding for common stock issued to certain minority shareholders upon the closing of the
              Contributions, for the period from October 1 to October 30, 2023, as adjusted for the Reverse Stock Split.</font></td>
        </tr>

    </table>
    <div> <br>
    </div>
    <div> The Company&#8217;s Series A Convertible Preferred Stock, stock options and warrants are determined to be anti-dilutive and, therefore, were excluded from the diluted loss per share attributable to common stock calculation because including them would
      have been anti-dilutive.</div>
    <div> <br>
    </div>
    <div>
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>6
<FILENAME>ny20028941x1_ex107.htm
<DESCRIPTION>FILING FEES TABLE
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using Broadridge PROfile 24.3.1.5224
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div>
    <div style="text-align: right; font-weight: bold;">
      <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">Exhibit 107</div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">Calculation of Filing Fee Tables</div>
    <div style="text-align: center; font-weight: bold;">Form S-3</div>
    <div style="text-align: center;">(Form Type)</div>
    <div style="text-align: center; font-weight: bold;">Gyre Therapeutics, Inc.</div>
    <div style="text-align: center;">(Exact Name of Registrant as Specified in its Charter)</div>
    <div style="text-align: center;"><u>Table 1: Newly Registered and Carry Forward Securities</u></div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zc37c2fbea1f1474fb79bcc0d23545437" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 7.34%; vertical-align: middle; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid;">&#160;</td>
          <td style="width: 4.77%; vertical-align: middle; border-right: #000000 2px solid; border-top: #000000 2px solid;">&#160;</td>
          <td style="width: 17.26%; vertical-align: middle; border-right: #000000 2px solid; border-top: #000000 2px solid;">&#160;</td>
          <td style="width: 6.54%; vertical-align: middle; border-right: #000000 2px solid; border-top: #000000 2px solid;">&#160;</td>
          <td style="width: 7.08%; vertical-align: middle; border-right: #000000 2px solid; border-top: #000000 2px solid;">&#160;</td>
          <td style="width: 5.93%; vertical-align: middle; border-right: #000000 2px solid; border-top: #000000 2px solid;">&#160;</td>
          <td style="width: 10.44%; vertical-align: middle; border-right: #000000 2px solid; border-top: #000000 2px solid;">&#160;</td>
          <td style="width: 6.63%; vertical-align: middle; border-right: #000000 2px solid; border-top: #000000 2px solid;">&#160;</td>
          <td style="width: 7.32%; vertical-align: middle; border-right: #000000 2px solid; border-top: #000000 2px solid;">&#160;</td>
          <td style="width: 4.85%; vertical-align: middle; border-right: #000000 2px solid; border-top: #000000 2px solid;">&#160;</td>
          <td style="width: 4.85%; vertical-align: middle; border-right: #000000 2px solid; border-top: #000000 2px solid;">&#160;</td>
          <td style="width: 5.23%; vertical-align: middle; border-right: #000000 2px solid; border-top: #000000 2px solid;">&#160;</td>
          <td style="width: 11.76%; vertical-align: middle; border-right: #000000 2px solid; border-top: #000000 2px solid;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 7.34%; vertical-align: bottom; border-left: #000000 2px solid; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
          <td style="width: 4.77%; vertical-align: bottom; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">Security</div>
            <div style="text-align: center;">Type</div>
          </td>
          <td style="width: 17.26%; vertical-align: bottom; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">Security</div>
            <div style="text-align: center;">Class</div>
            <div style="text-align: center;">Title</div>
          </td>
          <td style="width: 6.54%; vertical-align: bottom; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">Fee</div>
            <div style="text-align: center;">Calculation</div>
            <div style="text-align: center;">or Carry</div>
            <div style="text-align: center;">Forward</div>
            <div style="text-align: center;">Rule</div>
          </td>
          <td style="width: 7.08%; vertical-align: bottom; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">Amount</div>
            <div style="text-align: center;">Registered</div>
          </td>
          <td style="width: 5.93%; vertical-align: bottom; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">Proposed</div>
            <div style="text-align: center;">Maximum</div>
            <div style="text-align: center;">Offering</div>
            <div style="text-align: center;">Price Per</div>
            <div style="text-align: center;">Unit</div>
          </td>
          <td style="width: 10.44%; vertical-align: bottom; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">Maximum</div>
            <div style="text-align: center;">Aggregate</div>
            <div style="text-align: center;">Offering</div>
            <div style="text-align: center;">Price</div>
          </td>
          <td style="width: 6.63%; vertical-align: bottom; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">Fee</div>
            <div style="text-align: center;">Rate</div>
          </td>
          <td style="width: 7.32%; vertical-align: bottom; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">Amount of</div>
            <div style="text-align: center;">Registration</div>
            <div style="text-align: center;">Fee</div>
          </td>
          <td style="width: 4.85%; vertical-align: bottom; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">Carry</div>
            <div style="text-align: center;">Forward</div>
            <div style="text-align: center;">Form</div>
            <div style="text-align: center;">Type</div>
          </td>
          <td style="width: 4.85%; vertical-align: bottom; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">Carry</div>
            <div style="text-align: center;">Forward</div>
            <div style="text-align: center;">File</div>
            <div style="text-align: center;">Number</div>
          </td>
          <td style="width: 5.23%; vertical-align: bottom; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">Carry</div>
            <div style="text-align: center;">Forward</div>
            <div style="text-align: center;">Initial</div>
            <div style="text-align: center;">Effective</div>
            <div style="text-align: center;">Date</div>
          </td>
          <td style="width: 11.76%; vertical-align: bottom; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">Filing Fee</div>
            <div style="text-align: center;">Previously</div>
            <div style="text-align: center;">Paid In</div>
            <div style="text-align: center;">Connection</div>
            <div style="text-align: center;">with Unsold</div>
            <div style="text-align: center;">Securities to</div>
            <div style="text-align: center;">be Carried</div>
            <div style="text-align: center;">Forward</div>
          </td>
        </tr>
        <tr>
          <td colspan="13" style="width: 100%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">Newly Registered Securities</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7.34%; vertical-align: bottom; border-left: #000000 2px solid; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">Fees to Be</div>
            <div style="text-align: center;">Paid</div>
          </td>
          <td style="width: 4.77%; vertical-align: bottom; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">Equity</div>
          </td>
          <td style="width: 17.26%; vertical-align: bottom; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">Common Stock, par value $0.001 per share</div>
          </td>
          <td style="width: 6.54%; vertical-align: bottom; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">Other</div>
          </td>
          <td style="width: 7.08%; vertical-align: bottom; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">1,081,332 (1)</div>
          </td>
          <td style="width: 5.93%; vertical-align: bottom; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">$11.16(2)</div>
          </td>
          <td style="width: 10.44%; vertical-align: bottom; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">$12,067,665.12(2)</div>
          </td>
          <td style="width: 6.63%; vertical-align: bottom; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">$147.60 per</div>
            <div style="text-align: center;">$1,000,000</div>
          </td>
          <td style="width: 7.32%; vertical-align: bottom; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">$1,781.19</div>
          </td>
          <td style="width: 4.85%; vertical-align: bottom; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
          <td style="width: 4.85%; vertical-align: bottom; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
          <td style="width: 5.23%; vertical-align: bottom; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
          <td style="width: 11.76%; vertical-align: bottom; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 7.34%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">Fees</div>
            <div style="text-align: center;">Previously</div>
            <div style="text-align: center;">Paid</div>
          </td>
          <td style="width: 4.77%; vertical-align: top; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">&#8212;</div>
          </td>
          <td style="width: 17.26%; vertical-align: top; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">&#8212;</div>
          </td>
          <td style="width: 6.54%; vertical-align: top; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">&#8212;</div>
          </td>
          <td style="width: 7.08%; vertical-align: top; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">&#8212;</div>
          </td>
          <td style="width: 5.93%; vertical-align: top; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">&#8212;</div>
          </td>
          <td style="width: 10.44%; vertical-align: top; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">&#8212;</div>
          </td>
          <td style="width: 6.63%; vertical-align: top; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">&#8212;</div>
          </td>
          <td style="width: 7.32%; vertical-align: top; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">&#8212;</div>
          </td>
          <td style="width: 4.85%; vertical-align: top; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
          <td style="width: 4.85%; vertical-align: top; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
          <td style="width: 5.23%; vertical-align: top; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
          <td style="width: 11.76%; vertical-align: top; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
        </tr>
        <tr>
          <td colspan="13" style="width: 100%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">Carry Forward Securities</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7.34%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">Carry</div>
            <div style="text-align: center;">Forward</div>
            <div style="text-align: center;">Securities</div>
          </td>
          <td style="width: 4.77%; vertical-align: bottom; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">&#8212;</div>
          </td>
          <td style="width: 17.26%; vertical-align: bottom; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">&#8212;</div>
          </td>
          <td style="width: 6.54%; vertical-align: bottom; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">&#8212;</div>
          </td>
          <td style="width: 7.08%; vertical-align: bottom; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">&#8212;</div>
          </td>
          <td style="width: 5.93%; vertical-align: bottom; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">&#8212;</div>
          </td>
          <td style="width: 10.44%; vertical-align: bottom; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">&#8212;</div>
          </td>
          <td style="width: 6.63%; vertical-align: bottom; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">&#8212;</div>
          </td>
          <td style="width: 7.32%; vertical-align: bottom; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">&#8212;</div>
          </td>
          <td style="width: 4.85%; vertical-align: bottom; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">&#8212;</div>
          </td>
          <td style="width: 4.85%; vertical-align: bottom; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">&#8212;</div>
          </td>
          <td style="width: 5.23%; vertical-align: bottom; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">&#8212;</div>
          </td>
          <td style="width: 11.76%; vertical-align: bottom; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">&#8212;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7.34%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
          <td colspan="4" style="width: 35.65%; vertical-align: bottom; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">Total Offering Amounts</div>
          </td>
          <td style="width: 5.93%; vertical-align: bottom; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
          <td style="width: 10.44%; vertical-align: bottom; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">$12,067,665.12(2)</div>
          </td>
          <td style="width: 6.63%; vertical-align: bottom; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">&#8212;</div>
          </td>
          <td style="width: 7.32%; vertical-align: bottom; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">$1,781.19</div>
          </td>
          <td style="width: 4.85%; vertical-align: bottom; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
          <td style="width: 4.85%; vertical-align: bottom; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
          <td style="width: 5.23%; vertical-align: bottom; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
          <td style="width: 11.76%; vertical-align: bottom; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 7.34%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
          <td colspan="4" style="width: 35.65%; vertical-align: bottom; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">Total Fees Previously Paid</div>
          </td>
          <td style="width: 5.93%; vertical-align: bottom; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
          <td style="width: 10.44%; vertical-align: bottom; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
          <td style="width: 6.63%; vertical-align: bottom; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
          <td style="width: 7.32%; vertical-align: bottom; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">&#8212;</div>
          </td>
          <td style="width: 4.85%; vertical-align: bottom; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
          <td style="width: 4.85%; vertical-align: bottom; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
          <td style="width: 5.23%; vertical-align: bottom; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
          <td style="width: 11.76%; vertical-align: bottom; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 7.34%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
          <td colspan="4" style="width: 35.65%; vertical-align: bottom; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">Total Fee Offsets</div>
          </td>
          <td style="width: 5.93%; vertical-align: bottom; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
          <td style="width: 10.44%; vertical-align: bottom; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
          <td style="width: 6.63%; vertical-align: bottom; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
          <td style="width: 7.32%; vertical-align: bottom; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">$1,027.06(3)</div>
          </td>
          <td style="width: 4.85%; vertical-align: bottom; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
          <td style="width: 4.85%; vertical-align: bottom; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
          <td style="width: 5.23%; vertical-align: bottom; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
          <td style="width: 11.76%; vertical-align: bottom; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 7.34%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
          <td colspan="4" style="width: 35.65%; vertical-align: bottom; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">Net Fee Due</div>
          </td>
          <td style="width: 5.93%; vertical-align: bottom; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
          <td style="width: 10.44%; vertical-align: bottom; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
          <td style="width: 6.63%; vertical-align: bottom; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
          <td style="width: 7.32%; vertical-align: bottom; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">$754.13(3)</div>
          </td>
          <td style="width: 4.85%; vertical-align: bottom; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
          <td style="width: 4.85%; vertical-align: bottom; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
          <td style="width: 5.23%; vertical-align: bottom; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
          <td style="width: 11.76%; vertical-align: bottom; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
        </tr>

    </table>
    <div style="text-align: center;"><u>Table 2: Fee Offset Claims and Sources</u></div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z70d0a66447234366bd8f6b5d8e44361a" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 4.52%; vertical-align: middle; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid;">&#160;</td>
          <td style="width: 8.34%; vertical-align: middle; border-right: #000000 2px solid; border-top: #000000 2px solid;">&#160;</td>
          <td style="width: 4.36%; vertical-align: middle; border-right: #000000 2px solid; border-top: #000000 2px solid;">&#160;</td>
          <td style="width: 4.96%; vertical-align: middle; border-right: #000000 2px solid; border-top: #000000 2px solid;">&#160;</td>
          <td style="width: 6.57%; vertical-align: middle; border-right: #000000 2px solid; border-top: #000000 2px solid;">&#160;</td>
          <td style="width: 6.54%; vertical-align: top; border-top: #000000 2px solid;">&#160;</td>
          <td style="width: 7.67%; vertical-align: middle; border-right: #000000 2px solid; border-top: #000000 2px solid;">&#160;</td>
          <td style="width: 8.74%; vertical-align: middle; border-right: #000000 2px solid; border-top: #000000 2px solid;">&#160;</td>
          <td style="width: 8.72%; vertical-align: middle; border-right: #000000 2px solid; border-top: #000000 2px solid;">&#160;</td>
          <td style="width: 9.93%; vertical-align: middle; border-right: #000000 2px solid; border-top: #000000 2px solid;">&#160;</td>
          <td style="width: 11.81%; vertical-align: middle; border-right: #000000 2px solid; border-top: #000000 2px solid;">&#160;</td>
          <td style="width: 17.83%; vertical-align: middle; border-right: #000000 2px solid; border-top: #000000 2px solid;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 4.52%; vertical-align: bottom; border-left: #000000 2px solid; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
          <td style="width: 8.34%; vertical-align: bottom; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">Registrant or Filer Name</div>
          </td>
          <td style="width: 4.36%; vertical-align: bottom; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">Form or Filing Type</div>
          </td>
          <td style="width: 4.96%; vertical-align: bottom; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">File Number</div>
          </td>
          <td style="width: 6.57%; vertical-align: bottom; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">Initial Filing Date</div>
          </td>
          <td style="width: 6.54%; vertical-align: bottom; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">Filing Date</div>
          </td>
          <td style="width: 7.67%; vertical-align: bottom; border-left: #000000 2px solid; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">Fee Offset Claimed</div>
          </td>
          <td style="width: 8.74%; vertical-align: bottom; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">Security Type Associated with Fee Offset Claimed</div>
          </td>
          <td style="width: 8.72%; vertical-align: bottom; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">Security Title Associated with Fee Offset Claimed</div>
          </td>
          <td style="width: 9.93%; vertical-align: bottom; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">Unsold Securities Associated with Fee Offset Claimed</div>
          </td>
          <td style="width: 11.81%; vertical-align: bottom; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">Unsold Aggregate Offering Amount Associated with Fee Offset Claimed</div>
          </td>
          <td style="width: 17.83%; vertical-align: bottom; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">Fee Paid with Fee Offset Source</div>
          </td>
        </tr>
        <tr>
          <td style="width: 4.52%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
          <td colspan="11" style="width: 95.48%; vertical-align: middle; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">Rule 457(p)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 4.52%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">Fees Offset Claims</div>
          </td>
          <td style="width: 8.34%; vertical-align: bottom; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">Gyre Therapeutics, Inc.</div>
          </td>
          <td style="width: 4.36%; vertical-align: bottom; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">S-3</div>
          </td>
          <td style="width: 4.96%; vertical-align: bottom; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">333-275466</div>
          </td>
          <td style="width: 6.57%; vertical-align: bottom; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">November 13, 2023</div>
          </td>
          <td style="width: 6.54%; vertical-align: bottom; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
          <td style="width: 7.67%; vertical-align: bottom; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">$1,027.06(3)</div>
          </td>
          <td style="width: 8.74%; vertical-align: bottom; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">Equity</div>
          </td>
          <td style="width: 8.72%; vertical-align: bottom; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">Common Stock, par value $0.001 per share</div>
          </td>
          <td style="width: 9.93%; vertical-align: bottom; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">1,081,333(3)</div>
          </td>
          <td style="width: 11.81%; vertical-align: bottom; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">$6,958,377.86</div>
          </td>
          <td style="width: 17.83%; vertical-align: bottom; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 4.52%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">Fees Offset Sources</div>
          </td>
          <td style="width: 8.34%; vertical-align: bottom; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">Gyre Therapeutics, Inc.</div>
          </td>
          <td style="width: 4.36%; vertical-align: bottom; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">S-3</div>
          </td>
          <td style="width: 4.96%; vertical-align: bottom; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">333-275466</div>
          </td>
          <td style="width: 6.57%; vertical-align: bottom; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
          <td style="width: 6.54%; vertical-align: bottom; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">November 13, 2023</div>
          </td>
          <td style="width: 7.67%; vertical-align: bottom; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
          <td style="width: 8.74%; vertical-align: bottom; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
          <td style="width: 8.72%; vertical-align: bottom; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
          <td style="width: 9.93%; vertical-align: bottom; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
          <td style="width: 11.81%; vertical-align: bottom; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
          <td style="width: 17.83%; vertical-align: bottom; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center;">$1,027.06</div>
          </td>
        </tr>

    </table>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 4.02%; vertical-align: top;">
            <div style="text-align: justify;">(1)</div>
          </td>
          <td style="width: 95.83%; vertical-align: top;">
            <div style="text-align: justify;">The shares of common stock will be offered for resale by GNI USA, Inc. (the &#8220;Selling Stockholder&#8221;) pursuant to the prospectus contained in the registration statement to which this exhibit is attached. The
              registration statement registers the resale of an aggregate of 1,081,332 shares of the registrant&#8217;s common stock, consisting of (i) 540,666 shares of the registrant&#8217;s common stock issued upon the conversion of the registrant&#8217;s Series X
              Convertible Preferred Stock, par value $0.001 per share (&#8220;Convertible Preferred Stock&#8221;) effective January 23, 2024, held by the Selling Stockholder and (ii) 540,666 shares of the registrant&#8217;s common stock issuable upon the conversion of
              Convertible Preferred Stock pursuant to the exercise of warrants issued to the Selling Stockholder. Pursuant to Rule 416 under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), the shares of common stock being registered
              hereunder include such indeterminate number of shares of common stock as may be issuable upon stock splits, stock dividends, or other distribution, recapitalization or similar events.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 4.02%; vertical-align: top;">
            <div style="text-align: justify;">(2)</div>
          </td>
          <td style="width: 95.83%; vertical-align: top;">
            <div style="text-align: justify;">This estimate is made pursuant to Rule 457(c) of the Securities Act solely for purposes of calculating the registration fee. The proposed maximum offering price per share and maximum aggregate offering price
              are based upon the average of the high and low sales prices of the registrant&#8217;s common stock on May 28, 2024, as reported on The Nasdaq Capital Market.</div>
          </td>
        </tr>

    </table>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="ze51d45515e1f46579a5715c106b249f5" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 4%; vertical-align: top;">
            <div style="text-align: justify;">(3)</div>
          </td>
          <td style="width: 96%; vertical-align: top;">
            <div style="text-align: justify;">The Registrant previously paid $1,027.06 in registration fees with respect to the registration statement on Form S-3 filed on November 13, 2023 (No. 333-275466) (the &#8220;Withdrawn Registration Statement&#8221;). The
              Registrant filed a Form RW to withdraw the Withdrawn Registration Statement on November 29, 2023.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div>
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>logo_gyre.jpg
<TEXT>
begin 644 logo_gyre.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
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M.S=SHI8G#XI*=&K&HG9Z=-$]G=Z)^I<(##!Z4B@@8)&  ![ ?A30IQU(Y/\
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MU%2PM51=.$90;O%4ES1A)Q?OQYEK%2\E^K1(8'<VT'(.>AP<;3[''Y5^,?\
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M-;_#NVU;7C#%L^T>(]:T>UO]>EF+*&+?VG-<GD @GH*_CW_X);?"S4OV_?\
M@J9XN^-'C2"75_#'AOQ;X@^)NJS3@S1V]]<7^HZKX3A1G#@11:I9J(T^8A4
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MLO'GBZ\NM>U;P[K%CI<4<OBB>6*X6^NK"&V=7CD#+MF.Y26!VC-?WV@<QAD
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MQI^,/[?/[2D?C3Q5<7&A_![X0NVNV6C1.\%I?CR[F!7O9(U#O+%]L69HGG9
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M&Z2UOH]ON,0J[P]>.&E"&+E0K1PLZJ<H0JRA:$IQCK)1E9R2NVM%N?G=9_\
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M-935X9PV%ABG.ERU,93Q4JDJ,8\_M>;D:ES2IJ%VTI-Z'YR?\%9= M/&FF?
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MW[S^ZT5;R7IU(@');<P:)LX &"!SP<\G\!_,T*H"GDG&1UP<'/?GM].GTJ;
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D0 *6FTKM]6DVWJWHK7=M;*R7D@CJETMLDK)72;LG?=[^K/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>logo_gyrex1.jpg
<TEXT>
begin 644 logo_gyrex1.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
M     0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&
M$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W
M.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2
MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KB
MX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /[[S"JG.26[#\?;_/'U
MJ.1RH)49D7[J\Y.3CH/4?ETZU,S$,-W!XP.W7V]_>HW&"9,98>IXZ>G3\^.<
M]J3NY1E\W?2Z36FFZT?XA'2+@GOUTNFTM>WGKMO<826B42(1(P).0?E.[@$>
MIX..#Z^\;RF-552';/"MDX], 8/M^M1W,[Q6XE4@  EV/15'.2>V #R#[@^O
MY(_MS?\ !1BP^!-K/X+^'DECXB\=3[[>ZMXOL\K:5$5<?:;A)C$=L<R*C>7*
M&.[Y<G /T?#'">><99K2RC(<-[:M5ESRDVXX>@FTI5,15Y)QHTH_SO\ PV;M
M?Y/B[C3A[@7)\1G'$.+^K8>A#]VH<D\5BI15XT<'0G4A+$UY*[C1IWE)7<=M
M/T[\1_$WP)X561O$/BO1]':,9:._NT@ *C)R&'7 )[9QSDYKYL\1?MY?L[:#
M++:/\0/#5Z\#%9$M-4MG*,.Q!<8R"3CTS@U_(3\1?C3\3/C%J]]K/Q \9:XU
MU<74\D5GH6J:GI-I#&TDFR)[>*\E1RB,(VVD*67(7D5U7P+_ &<OC/\ M"Z\
MNB?#>PEEL(G/]HZOJ5N]P(U54<N9IYX9)V\EV;(8YV_*<X%?U-0^C'D6393/
M,>+>+9Y?4I0A/$SIK"TL%3EHW&GB,4H.;=^6"48N3:C'5I'\7UOIBY_Q#G2R
MK@/@66>4:E2<<)*C+$XG,9TU://7PF$]K"C!-/VDY5$J:NY.T9']8WA_]OG]
MG35G2.;XA^&M+#G:K7VJ6L0()R#PQX]^![5]$^$/C9\+O'05O"?CCPYK[N!\
MNF7\=RV<XQ\GOVX].3S7\X.I?L8_LN?LMZ)'XS_;&^+6GVAMD$W]DZ?J^K:7
M=321@/) +2RDO6SLW8+1!>.^!7S]=_\ !:+]AC]G34+E?@+\,/&OBU[9A#%?
MGQI%]DG\DE!(EOJ6D!E#_>Y&XYR23DC\]S'PMX2S.A)<$RXVSJO:<:6._LC"
MT\EG4@XK3'2K1<H\U_>A3:72^J7[YPKQKXL5_8XGBO(N"LKP-2I2C6P]+.\R
MKYU0A.TY*K@OJ$,/2JQCR^[/%22NTVK+F_L+24NQ8A5C()!R<DXXZ\'WY'UX
MJ6,H,$$$8X/7KTZ?4XK^4SX:?\'.?PAUO5H=/\<?"+Q#X8L&(5]1E\0:5<11
MC@9:*VTL/C!)XY(!]*_=;]F+]O\ _9H_:KTZWN/A9\1M#U75);:&XN=$,[07
MMDTI5/L[+<Q6IE>-W"$PJ0QY''3\MSKPZXVX=HSKYKD.-I8:"O/%T*<L1AX0
MO92KU:490I-Z74W&U[>O[1A<]RK%-1CC*5*I*48PIXFI3HU*DVK\M",IWJ];
M*%W9/1[GV^ RN3D;3CJ>WM_7'M^,H(/0U4>3>J&-@5(!##N, G!_+'8]O>:(
MYR3@'H/<?GZU\3:U^9M[;[>6WGO?YGL;K9KUO?Y_IZDU,V*&W=SGT_'MFGU#
MO'F$$_=.#[9Z?G_GC%$HQ:7,D[.Z]5M;S[!?=+MKZ77ZV&$['9^#U^@&.I/H
M,9/Y>]>%?&7]I'X+_ ?29-;^*7Q'\+>#K..-V!U_45LTD**'982RG<^U@<>A
M' R*^#/^"J?_  4E\,?L(_"NZ.EW=EJ/Q7\26DT/A'PZYAED5I5N(8M5N8IH
MWBDM(+J(1R0M)&[G # 9-?PQPR?MH_\ !4CXX7RZ7<>*/''B35YXS?Z3IUU>
M0>&M"T^::>."0Z7)?+ID2JS-"Y@PSE5W# 6OV?P]\(\3Q1E]7/\ /\='(^':
M-I?6IR5*M7I\W+*I1J8FDL*J<'>//*H^:5XI+1KY/.^)%@ZRPF I2KXRUO>3
M=.+LG&/[N3FY/MR:::/1']K>O?\ !=K]AS1]0EL_^$[MM16WE>-;FQO;.2VG
M"-M+Q,64L"1QGD\5[A\%O^"M?[%WQQU&'1]"^+WA/1M9O66*TTS6]6MH;NZE
MD*A(X8XPV]V9@H /4=>#7\Q'A/\ X-D/VD]8T2*]\1?%CPAHVHS6PG&FS^']
M<DGMY7CWF)Y8;AHV:-R%?!VDC@D'-?$'[4O_  1C_;,_9!TV;QQ;VE]XQ\.:
M,KW,OBGP9#=Z6^GPP R>?A[S[<2H0.#$A(R,<XK[W"^''@WF]6669=QEB%CD
MN2C4K8K!4Z56JULG4ING.TK*U/WIR=H)W4CQIYYQ'A8NK4P$VHU(^TYL/5<9
MP<DN:'+)35XO7F:45K*70_T?='U2PU/3X;^PNH;JTGC6XANXFWP31RJ&5XV&
M R,&#+CL1ZFM/82Q8LO(.P#@'(SR.O!(/'8_2OYN?^#?BU_;+E^$NKZI\<M5
MU"X^%TTD]OX0M?$]O=7>O_:8+VW-TYU:^O;BX:S-H8!;0M$BQ8<H1EEK^BK4
MO$FBZ-*L>J:MIUGYP+0QW-U!;R%!A7<>:ZDA>"2.>F*_ >*>'7PWQ!CLAIXW
M#YE+!RY56PLN=R3M:,XQNHU()VJ13DHRNKWT/N,%BXXO"4L;*/U=3BFXRO&*
M[J+DTTD_AN[V-Z/C[Q ( ! Z9[@9[ ]*>4&<\G)YY'&>_2LK3]5TO4XQ-I]]
M;WL!P%EMIHYT)/('F1LRY(]3DUH"1UR7PJ@X0GN/7KZ8_7BOF$IQO&:E":=N
M62::M;5II-=M;+J=J<)6<&I)VUBTU)^33].OD1NKHR^6NY2?G./N\CKSZ9]Q
MWJ5ADASPP' QU'X].<]?Y8K(U+Q)H6D/Y=_K&FV,A4MY=U>6\,AP.3LED5L
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MD5Q?$?*=0ED$TGEDM*S-&N_>01FOTC(/I$Y?FL89;QKD]&-/%?NIXC#T:53
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M'?\ !O\ ?&O5OB;^Q+X8TO7+LWFH^%]4UK3OM&]I)!90W_D6<<A<@XCMXE1
M /E&.@K]ZMK#[I  Z#_/Z=OIBOY*XQR7_5OB/-\E7O1R[%UJ5*=U)2I0G:GJ
ME%.\.5W5DWJM+'WN3XOZ_@J-=N\FW"HM5[\'RS5I6:2E%[VMT1:)&.>AI::,
M%1QGCO[<4ZOGH\S2;MJD_.]E?RM>YZ.GXN_]=^X44450!1110 4444 %%%%
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M67XWVM]W_!-5>[3E>W2UOQ"BBBD4%%%% !1110 4444 %%%% !1110 4444
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M>G;![YHK.W]77]?UY,UN_P"2?_@+*:2&!MLG+LP*GK@'@C(Z$\?YSCR+X]^
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M/_@JIX)LM%TJS;X5_%1EM[&UA,__  CR["8X$1C%_I 8H<97@'!%>.?M)?\
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MN-IZ5]9?\$PO >@^'OV8/"NK:?8VD6H>(XH];U*]BC GO;J]MHFE>X(X:1F
M9NAR 2,U^C2*8VV]64<OGD C  ]<#CGT'U&7$_&T^%L\Q7#O"66Y/@\HR*K/
M+_K-;+,/B,;G-2A.TZ^85:JE&O[63<5'E@E3M"UE<7!W /\ KAD&"XJXSS3.
M\9G?$M&CFE3"8?-\70RS)%6IQ]GALHH1M+#JBDFJCG4G*IS5&US<J_(?]E;5
M/VR_A5\7+GX1_%X6_BOP%;6EW_9OBN.Y5IW-L+981/%;6AB5W::=B&N23L!
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M2^JL6];^?;0HQH1(^]BZX8;&' R>.I/;VYZ]J_GG^,DOD_\ !4/X<\D\Z,0
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M_9^_X*"^,O#>H^%?%_Q'\+:MH>JV;V6J0)X1U",W4+8,BJ9=<E50S*I&Z-N
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M[=O@V^\>?LV?$#P_H2B2ZDT#49[>VA3S/.Q;NJPP^6P7+DX7G;UX/2OB*/\
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M0,C(QR7[87[+US^T/JOPOOX-7ETQ/ _B)M:=((X6,KA($V-YC [#L)[X..H
MS]FZ':_8=)L])D)N/L]K%;-(Z JXCC"'<I!7GTQC''>NG,N)\%1X3\,\+@\7
M"MFV18G/<1BL(Z4U[/GS.EBL-SU&N5J5*#NHRNT_YMN7*.$,<^./%C&YC@W#
M*.*<-PSA\#B_;PG&O'"Y-5P6*7U92YH.C5J*-Y1BJC7-?6Y^,_\ P2^_:%L-
M"\,3_L[_ !!F_L?Q]X,OI;5=/O'6T5].A:.TMWB1P5==ZN/EE/0CL<?M*;RQ
M:(3&^M$&S?YOGQ;-I7>"QW<@+C_#M7YS?M1_\$[? WQKUD^.?"VNZA\.?B#$
MN^W\1>'U,4SW +,K2Q":&"1=\C/MD5E)'() KY)_X8O_ &SBH\,W/[0?B&30
MD3[,+A;;2A<RVI'EJQ=3E66(!L[LEB<D\5[&=8/@CCG,:G$M+B.APQC\UKO%
M9QE&+P..Q5/"XB7*JU?!XBC%4ZM&I)N<:'+3<4^6[U9X'#^-\0?#K*X\)U.$
M<1QAEF3T(X/(<\P>:9;@:V/P\(_N*&-P=9NIA:\%:$\1SU(5)7J>XGRK]5!^
MTY\)G^)J_!^/Q+9W/C)K>XNULX)&E+1VCPI(<)"T:X:=!M,H)SD# )J>3X^_
M#!OB%-\+=3UNP@\4_9XIXM*O9,&6.XE>*+ DC$1!:-QM,G0<@=:^8_V7/^"?
MO@KX#ZD/'&M:[JOC?X@7JL;S7]8>1[D-.(UE52)Y$V'RHF(4 93M74?M&_L(
M?#[XY:NOC)=5U7POX]LXD-CXCTF:YBG01!Q#&8X[F*&18FF=L.,$GYAP*^4J
MX#@".>RRR.?8YY0J,:57/HY?75L4FW/$4\#[3V[H.:24%)347=<R5W]I1S/Q
M'EPW#-J_#> 6=?6*M=<,/,\*^;!225/!O-/9RP_UB$/?G5=-PFXN/NMZ?2GB
M[X;?"[QII5[9ZSX6\+ZA'?6[I+<36.E2[5,;!7#202$=<[@20>1ZU^'?P[\'
MZ5\#/^"A>G^"O@WK$G_"-:[9ZI=>+]'TZ2X?3[/48[S3K:,.D/DVD16R8%0L
M;@KG!ZBO9+O]B[]L"RN%T'2OVC/$,?ALN+=KJ2PTIKHVA.PQ;&;?GRCL#AL]
M6P3C/VE^R[^Q/X3_ &?;B_\ %5YJ=]XR\>ZR9+C4_$FKCS+J266&*&94 DEB
MC606\3[8PBAA\H'0?9X',,AX0RG/*<.*UQ53S'!SP.!R3ZMF-&A5E67LUF%6
MMBHR6'E@$U6C0<%*O)<BE&+E)?!9CEO$O&^<<.3GP7+@^>78V&8X[B&..RVM
MB,*L.XU/[,I8?".G4Q4,SM+#U*ZFXT(.4W"3<4?=ZOY(V;2^#G=D#.?K]**=
M$I,:E\(Q )'U'UHK\,=%W_B+I]AOMU3UW_%=]/Z(56-E>#_\"?EW^?\ 6UFB
MBBK*"H9L84E0<-D>Q]?\_P!:FI" 1@TG%R7*I.+>G,MUKNKA>VMD]5H]M7;4
MBC+L,.  /3/(SD YY!QZ5-_D4@&!BEHBG%6YG+SEO_3_ *[M;VE:U^WIMZ=;
M=&121^9_$5X[8^O.?2DB4A"N6QGAC]X\\GIC![=>_/2ICR"/6D P,4:WWTMM
MY][CZ6[??]^_KW%HHHI@%%%% !1110 Q^@XS\P[9QZ9_/M41[_*-Y).>P^IZ
M@G/Y_C4Y&1BFE 23SS]/\*FUY7:7NO1];V7]?=YW?3UNONLR!QM+, V54G'9
MCCL>XX]O?D5';LTBEVBV2$$<J1Q[C.<CG\<8S5QE##!SWZ>] 4 Y&::=^:+2
MT<;-73M9M[6Z_A^$VU3N]+Z:6=[6;[VU\BEY)W[F"@#D*N<Y^I]?J/UX5D\Q
M@& "XZ'AO? !X]C[=JNE02#SQ3&B5CDEOP(_PI**E%0?PRM==[VU]=$/:7,D
MKK;^M_GTZ%62)-BJ#A<@@CT/X'ICH*='L)V$[MH&/4]B,=...OX=>+!B4@ D
MX'3D>_M[TQ;=%;<"V>>I&.?^ T^5-*Z3Y%>/2S?*FUVNE;T$[\T6G9S;4WU:
M5GIIOJ]Q2F%8AL]<9Q@>P_/@?XU7@;<&,FY<DC!^[R>0#P0>IQ^A[V]@QCGM
MZ=L^WO33"I7;EL?49[^WO0K<M[)3;34M=M--^RUT';WE%R?*UJM%=OELW]^M
MB (%4JAW*<\G'?.X].^<5*B;0!QM (]B#P?QYXSCO4BQJB; 3CWQGKGT _2E
MVC '.!_]?_&E>36LFW*7/KYI:>BZ?=MLDDGHK<J4%UT5G?79_/;[R%8P Q!5
MB,[,GA0.GI@CD>WKUJ$Q D[2N0<CV8_>SC@#/IUYZ5;6-5+$$_-USC].*01*
MN<%N?4C_  HDKRA!I.$FG-/K91DMM[-=02=G*]II>ZULDVD_F[_@B)HMP/!#
M+R<#Y68<CZ]?J?6D$9"@N!A/F&.N>??C&?\ ]>*LE0V,YXI3R"/6FYRU3LDE
M=)7Z)=?G]X*$4EUOH_DT^MU^'^929 %9POS-CDY&>>GID#BG*ID!\Q5/(:,#
MJ,8&6]#GG(/3G)JP4!7:<X_#/\J54"],],<__JI)*2O**<FM7=ZK1VZ:7^?F
M/5/1NR5DM-+7MTWL_3RW*ZJ7/SC!0DC /.,COWQ^M)&'4,JYSG(W<9YZ?7\?
M7M5D( Q89RW7T_#B@H#Z]2?S_"E"3TNH[N]NT;6U>KT>O_ &TM?-+;36R;>G
M_#;:$)#2)^\ 5AR,="?Q_#C_ !IVT;<DGG@D=OK^/]/K4I (P:3:,$<X/_UO
M\*JU[WV?3^M1*]DGTZ]]M_N_KI7&68!> .H/'4\]/3'MR?>G,I9AAG7Y^=G<
M<\/G@KZ_AP:E$:AMP)S^&/Y4X#&?<YH5T]-K6_K^M>H678HQJ^]Y&C"N6*$@
M8W(A)0$GD^H/2G&(<D+M+'+9&"?R[8XYZ?GFX5#8SGBE/((]:<KNRB^17NTN
MNV]_-7V)2:M)OFDK)-ZV^RK77;R]"I&=D4FT#(S@<\\>G!_#TQ3XB6B.>#GO
MQW'/.,5((E QDXY[CO\ A2A H*@G!]<9ZY]*$HWD[6:LH]E'W;Q]'H].W0<N
M:Z2D[-7E?K\+7W+[^NQ3=%=V3 )8'/0\\^ASUQ_+VJ6.%855ER"% P.X&>.Q
M(/7&?_K2"% V[+9Y[C'/X?UJ0J" .>*B2Y+RCK*44FW_ "Z-*^M[/75;[W"_
M/NE[CLN^G7U?9=ONRHY)&>3S(F4,=HR"!P<9YY]#]/7FKJ1K"@V L2RY YQG
M@CMQZ]\>U3L@8*#GY>F,?KQ3@H7.,\^M1&4G*7,D^7EY7=W]]*]]/\_GT:24
M8K71N_X;=OZO?0KM$IX<^;D_<?E5SQQZ8]#U]J4[5DV[^2H 4G & 0..P/';
MIQSVE* DGGGZ?X5&]NCR"4EMPQP",<=.JD_K71&*D[-M6UNMWJM'?I_6Q,I.
M*NDG?37SZKS5M/ZM'%N0MYGEHN<($)((.>N<\^V?3TJ0J) <D!0QP >#Z9],
M]#CKSZ8IS0JXP2V/8C_ TJQJJA03@8ZXSQGV]ZEQC*,XM)Q:5UT>JW_K\!+F
MYHN^MD[O>RMI^.G_  Q3D0L T@/7 4#C"G Q^'7VS5B&,)N"[@"P//3@= >X
MR3Q4KH'ZD_ACW]0?6G 8&*;2:BW=N-XQZ**LKI)/KI]W3J]VU9)-MR2^TU9J
?_:U]+>:ZB85LY7H2/F4<X[C/;THIU%(?*NR^Y'__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>ny20028941x1_ex5-1img01.jpg
<TEXT>
begin 644 ny20028941x1_ex5-1img01.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "D!GT# 2(  A$! Q$!_\0
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MU;XD>'_'.GVGVK[1X6\4_#KP-::#JGVBSN+6+[?<>"=#\'>)X_L4\T>HVO\
M9GB/3M]Y:6Z7OVO3VN[&Z\.^/7[$'[3/[-]M>ZS\2?AKJ \&VFH:C9+\0/#%
MS:>*O!DEM9:K8:/9ZMJ&I:-+<7?A+3_$-WJVF+X;C\=Z=X5U75Y+T6<&F#4K
M34;&S^3J_2(</^&G'& CCZ.2\&<3X"M]9IT\PP^ RC,8PJ5E%8J-'&T:52IA
ML5?D]LZ56EB:52,')PJPBX_GT\]\0^#<;+ U<VXMX=QM+ZO4G@:^-S7 2E3I
M.3PSJX.K4IT\1AK<_LE4I5,/4IRFHJ5.<D_W4\$_\%QO']AI5Q#\1_@#X/\
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M.I3E)1C&,Z4I2E)VC&,51;<FVDDE=O1'ZY_\/L/VJ?\ H0/V?O\ PE?B-_\
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M]UJ&C^&[.&\T9+G0;CQ+I&IV^IQ_/W_#]3_JUO\ \S=_^**M#]J?_@CYX_\
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M?QY_9NKV&D7WV3PM;V7A7Q1X<U7[5HGQ,MKF/97X^?%/_@I]^V7\4?[=L_\
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MVG3?'_C/^V?&\'D_\6S\"Q6OB7QXGF_V'/\ \36P^W6.D>$]VD>(++Q!8_\
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MGTG4YM"^'FM:'+J&FRNUG>R:-K.K:4]S#(VG:G?VAANI=#_AR?\ M4_]#_\
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MG[_PE?B-_P#/6K\?**_1?^(*>%7_ $0^2?\ @JM_\N/@?^(O>)G_ $66<?\
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M_P#/6H_X?8?M4_\ 0@?L_?\ A*_$;_YZU?CY17[+_P 04\*O^B'R3_P56_\
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M?\*S^./Q!\(^3]N_MO\ X3KP[X<^(O\ :'F?8_[-_LK_ (1]_A=_8_V39?\
MV[[7_;G]H?:;/R/[,^PS?VA^5G[07_!-[]J7]G;2G\2Z[X4T_P"('@VTT]M0
MUGQA\*;K4_%6E>'(X+;6M0U$^(]-O-&T3Q9H^GZ/I6B3:IJ_BBZ\-KX,T^VO
M=.MY_$@U*X:PB_JGA>7T7N+:]+!Y9EG#F'S"M)0IY?FV%QV58F=24ZD*=*C/
M&RI83%5:JI\\:6#Q.(J*,Z<9QA4FH'\T\1Q^D?PO1J8K,<QX@KX&DG*>.RS$
MX/,\/"$8PE4J5882-3%8:G3<^253%8>A3;A4E"4Z<7,^D?\ A]A^U3_T('[/
MW_A*_$;_ .>M1_P^P_:I_P"A _9^_P#"5^(W_P ]:OQ\HK]6_P"(*>%7_1#Y
M)_X*K?\ RX_,O^(O>)G_ $66<?\ @VE_\I/V#_X?8?M4_P#0@?L_?^$K\1O_
M )ZU>P_ #_@LA\5/%GQF^'GA;XV>&_@]X:^&/B7Q!#X?\3>(_#.C^(]&U'0/
M[9@N-.T;6[G5_%OQ0N?#^E>']*\07.E7WBW4M0MY_L/A6#6;JUAEO8K9&_!N
MBN7'>!GA;C,%C,)3X0RO!5,5A<1AZ>,PU.K'$X2=>E.E'$X>4JKC&O0E)5:3
M::52$6TUH=.#\9O$G"XS"8JIQ5F6+IX;$T*\\)B)TY8?%0HU8U)8>O&-)-T:
MT8NG52:;A*233/\ 0(HK\K/^"6O[8]S^T-\+KGX7_$#6-0U3XQ_"33[4:CKN
MOZQI5YJOQ$\&7VH7T&C>)(85^R:W>ZAX5B&F^%?&>H7UGJ<DUS/X7\0ZQXGU
M/7O&EY:V'ZIU_F;Q=PMFO!?$6:<-9S3C#'97B'2E4IMRH8JA.*JX7&X:32<L
M/C,-.EB://&%6$*BIUZ=*O"I2A_HAPMQ)EO%V0Y;Q#E,Y3P>8T%54)JU;#5H
MMT\3@\1%72Q&$Q$*F'J\KE3E*FYT9U*,Z=211117SA[X4444 %%%% 'P[_P4
M!_:G\5?LC_ W3OB)X)\-^'_$GB?Q!\0= \"Z8GBE]2?0=*_M#2/$?B.]U2_T
M[2;K3=0UC.G^%KO2K6QM]:T7R+S5+?5I;RZ@TR32-3_%S_A]A^U3_P!"!^S]
M_P"$K\1O_GK5_1)\=O@3\-_VC?AOK7PN^*.B_P!J^']5VW5E>VK16VO>%]>M
MHIX],\4^%M3D@N?[*\0:5]IG6WN&@N;.]L[F_P!%UJQU7P_JNK:3?_F;JW_!
M$O\ 9LFTK4X="^)?QQTW7)=/O8]&U'5M7\!:UI5AJLEM(NG7NIZ-9_#_ $"[
MU;3[6[,,][IEKKNBW-_;)):P:MILLJWD/](>%'$G@9EW#CP/B%P[+%9\LSQ$
MY9C4R_%9A2JX*M&BJ#4L/B.>C'#\LXU*$,.KV]K#VM2M-+\ \3>'_&;,,_6,
MX$SY8;)'E]""P%/'8? U:>+I2JNO>->AR595^:$H5I5WO[*?LX4H-_!O_#[#
M]JG_ *$#]G[_ ,)7XC?_ #UJ/^'V'[5/_0@?L_?^$K\1O_GK5Y=^U'_P2U^/
M?[.VE:WXX\.W.G_&/X6:!I\^K:SXH\-VK:-XG\.:58VVCG4=3\3^ [R^O[N'
M3X;N_P!2D%[X4UCQE;:?X>T'4/$_BN3PM8JT47YFU_5_#?A_X$<89='-N&N'
MN&,WP$I<DJN%C7]I0J\JG[#&86K4IXK!8GDE&;PV,HT*ZISA-TU&<6_YCX@X
MY\:N%<?++.(<]XCRK&Q7/&GB94/9UZ?,X>VPN(ITZF&QE#GC*"Q&%K5J+G&<
M%4YHR2_8/_A]A^U3_P!"!^S]_P"$K\1O_GK4?\/L/VJ?^A _9^_\)7XC?_/6
MK\?*[#X?_#_QG\5/&?A[X>_#WP[J'BKQEXJU!-,T+0M,2,W-Y<F.2>:22:>2
M&TL-/L+2&XU'5M6U&XM-*T;2K2]U;5KVRTVRNKJ'VZ_@WX1X6A6Q.)X-X?P^
M&P]*I7Q&(KJ=*A0H4H.I5K5JM3$1ITJ5*G&4ZE2<HPA"+E)I)L\>CXL>*.)K
M4L/A^+<]KXBO5IT:%"BX5:U:M5DH4J5*E"A*=2K4G*,*=.$7*<FHQ3;2/U3_
M .'V'[5/_0@?L_?^$K\1O_GK4?\ #[#]JG_H0/V?O_"5^(W_ ,]:O8?AG_P0
M]\57/V2\^,GQQ\/Z-Y'B"#[?X>^&?AW4O$O]J^%8OL$MU]D\9>*7\)_\(_X@
MOMVJ6,'G>!?$NG:5Y5AJLG]L^?<:/;?<7@7_ ()!?L:>$?[5_P"$@T3X@_%'
M^T/L/V3_ (3KQY?Z?_8?V3[9Y_\ 97_"L[7X=>=_:?VF'[=_;?\ ;'E_V?9_
MV;_9^^_^W?@^=\5_15R=U(4.&\+GU6G92IY)D^,J)R<XQ<:>)S+$Y9@ZMHR=
M5SI8F=-PA*,9NKRTY?M63\,_27S50G7X@Q.24JEW&IG&;82#4>24E*>'R_#Y
MCBZ=Y15-1J8>-13E%R@J?-4C^H5%%%?PZ?V2%?C9^WA_P5*TKX):KXG^"OP'
MMM/\5?%.RT^^TGQ'\09+JVN_#'PL\3FYM[=M,LM)DL;VT\;>,-'M!J9U.RN;
MFT\/>$?$(TFQUN/Q5?67BSP;I?'_ /!2;_@I-_PK_P#M_P#9X_9XU_\ XN!_
MI.C_ !,^)FCW/_)/_O07_@WP;?P-_P E!_UEMXA\0VTG_%O_ -[I6E2_\+ ^
MUW?P_P#YNJ_L;P+^C]3S:EAN,N/L#*66U8T\1D7#N(4Z;Q\7RU*69YK34H3^
MH25I83+YV681:K8N#R]PHX[^4/&?QSJ995Q'"?!&,2S"G*=#.<^H<E18&2O"
MKEV63:E#Z]'6.*QL+O R3HX62QRG5P70>*?%OBKQSKU_XI\;>)O$'C'Q/JGV
M7^T_$?BG6=2\0:]J/V*SM].LOM^KZM<W>H7?V33[2TL+7[1<2?9[.UM[6+9!
M#&B\_178?#_X?^,_BIXS\/?#WX>^'=0\5>,O%6H)IFA:%IB1FYO+DQR3S223
M3R0VEAI]A:0W&HZMJVHW%II6C:5:7NK:M>V6FV5U=0_W%*6$R_"2G.6'P.!P
M.'<I2DZ>&PF#PF&I7E*4GR4</A\/1@VVW"E2I0N^6,=/XVC'%8[%1A".(QF-
MQF(48QBJF(Q6*Q6(J6C&,5SU:^(KU9I))2J5:DK+FE+4^'_P_P#&?Q4\9^'O
MA[\/?#NH>*O&7BK4$TS0M"TQ(S<WER8Y)YI))IY(;2PT^PM(;C4=6U;4;BTT
MK1M*M+W5M6O;+3;*ZNH?Z5?V0/\ @DO\-_A!]B\;?M!CP_\ &#XCQ?V];IX3
M^SQ:Y\&='L[[RK'3KK^QO$?A^RU#QCX@AT^.^N/M_B&TM=!TZ?7/*L?"TNM>
M&M(\8S_2/[#/[#/@S]D#P8]U=/I_BKXT^*M/AB\>^/8H9#;6EL9(;O\ X0GP
M3]KAAN[#P?87<,$UW=S06FJ^,]5M+?7==M[*VLO#7AKPK]Y5_ 'C)](?,^(L
M5B^'>!L;7RSAJESX;$YMA^?#YCGK:E"LZ51\M; Y7-/EHTH*EB\533J8J<*=
M;ZG2_N+PF\!\NR'#87/N,\'1S'B&IR8C#Y77Y*^ R5)QG252FN:EC,R@US5:
MDW4PV'FU3PT)SI?6ZI1117\K']+!1110 4444 9^K:3I6OZ5J>A:[IFGZUH>
MM:?>Z3K.C:M96VI:5JVE:E;26>HZ9J>G7D<UI?Z??VDTUK>V5U#+;75M+)!/
M')$[*?P;_;P_X)1Z4=*\3_&;]EC2-037(]0OO$7BKX(6$=M+I5UI4MM;R7LG
MP@TZTLH;NPU"PNX;_5W^'\EQJ5MJUMJ4^E> $T671?#W@C7_ -]**^VX&\0.
M)O#[-Z6:\/XZI2C[2#QV6U93GEN9T%*+GA\;AN91ESQ3A#$4^3%8>[GAZU*6
MI\?QGP-P]QUE=3+,]P4*DN2?U/,*48PS#+JS3Y:^$Q'*Y1Y9-2G0GSX:O91K
MT:D=#_/WHK]D_P#@K;^QYI7P?\9V?[1/@,:@/"?QD\8:W'X]TN]N[:YMO#OQ
M1U:.Z\2F]TFXN]1;7+C3_'\4'BC6I-,&GW6G^%]5T/4XXM6M=*U_PUX;T?\
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M1S>'P&&YWIB<;[*JE55.K#"TH3K5(2E[&E6Y_P#8\_X)_?"+]DO2AJ*QZ?\
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MX3;P3]KFFN[_ ,'W]W-!#=VDT]WJO@S5;NWT+7;B]MKWPUXE\5?QTUV'P_\
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MCF@DFM+_ $^_M)K?4=)U;3KB[TK6=*N[+5M)O;W3;VUNIO\ 03PO\6^'/%#
M5:F71GEN<X*%.69Y#BZM.IB</&:@GBL)6@H+'Y=[:3H1Q<:-"I&HH+%87"RK
MT(U?X8\1_"[/_#C&TH8]PS#*,9.<<NSK"TJE/#UY1<FL/BJ4G-X+'^RBJSPL
MJM:G*#D\-B<2J->5/CZ_6/\ 9/\ ^"L'QF^#%Y%X<^-MUX@^.OPXF^R6T=QJ
M^KP2?$CPCYVO2WVK:SIWBG4[:XU#QSNT_4=21/#/C35U\R6R\.:=HGBWP=HN
MGWMKJ'Y.45]?Q3P?PWQKELLJXFRG"YIA'=TG6@XXG"5'RWKX'&4W#%8*N^6,
M95,-5I2J4^:C5YZ,YTY?*\-<5\0<(9A',^'<TQ.6XI6554I<V'Q5-<UJ.-PE
M12PV,HKF;C3Q%*I&G.U6GR580G'^]CX?_$#P9\5/!GA[XA?#WQ#I_BKP;XJT
M]-3T+7=,>0VUY;&22":.2&>.&[L-0L+N&XT[5M)U&WM-5T;5;2]TG5K*RU*R
MNK6'L*_B8_9/_:P^)'[)'Q(B\;>"9?[5\/ZK]DL?B!\/[^[EMM!\<Z#;2RO'
M;W$B17/]E>(-*^TW=QX6\4V]I<WF@WES=12VNJ^']5\0^'M;_L&^!/QV^&_[
M1OPWT7XH_"[6O[5\/ZKNM;VRNEBMM>\+Z];102:GX6\4Z9'/<_V5X@TK[3 U
MQ;K/<V=[9W-AK6BWVJ^']5TG5K__ #>\7O!C./##&PQ5*K5S?A;'57# 9Q['
MDJ8:L^:4<MS6%-RIT<9&";HXB/)A\PIPG6H0H5(5\)AO] ?"OQ<RKQ&PD\/5
MIT\KXEP5-3QV5>U<Z>(I+EC+,,MG-1G5PLIM*K0ESU\#.<*5:=:G*ABL1[#1
M117XJ?KP4444 %?%O_!0OX7:5\5OV//CAI>HG3[:[\(>#]0^*.A:K>Z);:U<
MZ5JOPT@D\7S+I(GGM9=*U#Q%H>EZSX+DUJSN4N=/TKQ-J9:#4;22ZTJ^^TJ^
M?OVL_P#DU;]IC_LW[XR_^JY\25]'P=B\1@.+>&,9A*LJ.)PO$&3UJ%6*BW"I
M3S##RB^6:E"<;JTH3C*$XMPG&4)-/P.*\+0QO"_$>$Q5)5L/B,CS6C6IRYDI
MTYX&NI+FBXSC+K&<)1G"24X2C))K^'BBBBO]C3_)X*_9/_@BG\/[G7?VA_B%
M\0KCP[I^IZ)\/_A=<Z9#KMZFE3W/AGQGXWU_28-"DTF&ZD.JVNH:MX3T#XA:
M=)JVDV_EV^E-J>DZC>V\6N06NH_C97] G_!"O_FZ3_NB/_O7:_'_ !]QU?+_
M  BXTKX?E]I4P>7X&7-SV]AF>=9;EN)^"<'S?5L75Y;MPYK>TA4I\U.7ZMX(
M8.CCO%/A&A7YN2&+QV,CR\M_;9=E&89AA_CC-6^L86ES62ERWY)0GRSC_0)1
M117^5Y_I4%%%% !1110 4444 %?F;_P5B^#FE?$O]DGQ3XN70=0U7QE\'-0T
MCQMX7NM$TNVOM5MM*NM7TS0O'EO?3C2[_58?!\/A._O/%OB6+3KG2[:.Y\&Z
M%KVLW;:;X=EA?],J\N^.'@G5?B7\%OB_\.-"N-/M-<^('PN\?^"=&NM6EN8-
M*MM5\5>$]6T+3KC4Y[.TO[N'3X;N_ADO9;6QO;F.V61X+2XE"PO]3P1G=3AO
MC#AG/:=;V']F9WEV*K5'.5.#PD<53CC:56<;R5"OA)5Z%>R;=&I45G<^;XQR
M>GQ!PKQ%DM2E[;^T<GQ^'I04(SDL3+#U)82I3C*T76HXJ-&M0NTE6IP?0_A(
MHHKZ!_9,_P"3J?V9_P#LX'X-?^K&\-U_KUF>,_L[+<PS#V?MOJ."Q>,]CS^S
M]K]5H5*_L_:<L^3GY.7GY)\M^;EE:S_ROR["?7\PP.!]I[+Z[C,-A/:\GM/9
M?6:T*/M.3FAS\G/S<G/#FM;FC>Z_M'^%/PS\*_!KX;^"_A9X)M/LGACP-X?T
M_P /Z9OM].M[R^^R1#[;K>K_ -DV&EZ?=>(/$&H/=Z[XCU*WT^T_M;7M1U'4
MY85GNY,^@445_C'B<3B,9B<1B\55GB,5BJ]7$XFO5DY5*U>O4E5K5:DGK*=2
MI*4YR>KE)L_UNP^'H83#T,+AJ4*&&PU&EA\/1IQY:=&A1A&G2I4XK2,*=.,8
M12VBD@HHHK V"OYV_P#@L!^Q[H/A;^SOVI/AGX:_LR#Q#X@ETGXVV6D17CZ<
M->UK9)X=^(ATRSTF73]#_MS4(K_1/'&M7>L:?9ZQXJU3P9/!I5UXG\2>(]6U
M+^B2OF[]L;2=*UK]D[]I.SUG3-/U:TA^!WQ/U:&UU.RMK^VBU70/!VKZ[H6I
MQP74<L2:AHNN:;IVLZ3>JHN=-U6PLM1LY(;NU@FC_2?";B_,>#..\@S+ U*O
ML,5C\+EF:82%24*>/RW'UZ>'KT:L+J%25+GCBL-[1.-/%T*%7[)^?^)_"N X
MNX*SS+\93I^VPV"Q&8Y;BITXSJ8+'X*C/$4:M*33G!5>26&Q'LVI5,+6K4_M
M'\1%%%%?ZSG^7X5T'A+Q3KW@;Q5X9\;>%K[^R_$_@[Q!HWBGPYJ?V6SO?[.U
M[P_J-MJVD7_V+4;>[T^[^R:A:6]Q]EO[2ZL[CR_*NK>:!WC;GZ*BK2IUJ=2C
M6IPK4:T)TJM*K"-2G5IU(N$Z=2$TXSA.+<9PDG&46TTTVBZ=2I1J4ZM*<Z56
ME.-2E5IRE"I3J0DI0J4YQ:E"<))2C*+4HR2:::/[1_V)OVL-!_:V^#.E^,_-
M\/Z;\1]#VZ1\4_!.B7=Y+_PC&O">]BT_48;34XH]0A\/^,=/LO[?\/OYVL6=
MIYNI>%_^$CUS6O"VNW$?V#7\/'[,'[0_BK]EWXS>%_B[X6MO[7_LC[9IOB/P
MM-JNI:1IWC#PKJ\!M=7\/ZE<:=)_U[ZQHDU]9ZOIVD^*M(\/Z_=:)J_]D)83
M?V;?!;XO^#/CW\+O!_Q=^'\^H3>$_&FGSWNG+JUA)IFJV5S8:A>:-K.DZG9L
M\L2:AHNN:;J6D7LEC=7^E7-S8R76CZGJFE36>HW/^9OCMX1U?#K//[4RFC5G
MP?G>(J2R^JUS0RG'577KSR*K4YYU)1I4:<JV75JRC/$8.,Z3GB*^"Q5>7^B'
M@MXI4N/<F_L[,ZM.'%63T(1QU.]IYI@J:HT89U3AR0A&56M4C2Q]*BY0H8J4
M*BC0HXS#48^HT445^"'[:%%%% !1110 4444 ?QD_P#!0CX.:5\#_P!K;XL>
M$?#6@ZAX?\&ZIJ&F>-O!]K<Z7;:5I3:5XSTBRUW4K?PC!I^EZ3I1\'Z!XLNO
M$GA+0(M+MI+;2K;PZV@W%W=:EI%_,WQ;7[9_\%O?!.JV'QI^#7Q'FN-/;0_%
M7PNO_!.G6L<MR=5AU7X?^+-3UW6;B]@:T2TCT^YM/B7H4>F2P7UQ<S7-IJR7
M5I9106<U_P#B97^MOA-G=3B+PVX-S6O6^L8BKDF&PN*KN<JDZV+RQSRS%5:L
MY:RKU,1@ZLJ_15G42;23/\N_$_)Z>0^(/%F64:7L*%+.,1B,-04(PC1PV8*&
M8X:G3C'1484,73C0Z^Q4&[.Z/VS_ .")7PNTKQ%\7?BW\6=1.GW-W\,O!^A>
M&]"TZ]T2VOKFUU7XEWVKM-XHTG69Y_-T/4-,T/P1K/AN06=D]SJFE>,]3MFU
M"SM([JSU7^E6OQL_X(EZ3I4/[-GQ+UV'3-/BUS4OCCJ^DZCK,=E;)JM_I6B^
M OA_>:-IE[J*QB[NM/TF[U_7;K3+*>:2VL+G6M6GM8XI=2O&F_9.O\^_I!YO
M6S;Q9XH]I*;HY;/ Y1A*<^3]S1P6 PZJQ@XI7A5QU3&8J/.Y37UAQ;M%17]S
M^!65TLK\,.&_9QA[7,(8S-,54AS?O:V,QM=TI24F[3I8.&%PTN51B_8*25VV
MRBBBOQ8_70HHHH _EZ_X*K_L3>%?@!KV@?&SX3:7_8?PX^)/B"_T3Q)X2M5T
MZVT'P-X\ELY=9T^'PM;"]CU"'P_XQT^R\1:A;^'[32I=&\'7GAZ_M+/4K'1=
M<\+^&=&_'RO[1_V__ O_  L7]C3]H;P__:G]C_V?\/[SQU]K^P_VAYW_  JZ
M^L/B9_97D?;+'R_[<_X1'^Q/MWG/_9G]H?VE]CU#[)]@N?XN*_TP^CAQOF'&
M/ +H9QB9XS->',QJ91/%5I5*F)Q>7O#T,5EV(Q5:4%&I7A&M7P#ESU*]2G@*
M>(Q4I5J\JE3_ #Q\?^#\#PIQNJV4X:&$RWB# 0S6&&HQIT\/A<<J];#8^AAJ
M49.5.C*5*CC5'DA1A/&SH8:,:-!4Z91117] 'X:>@_"GXF^*O@U\2/!?Q3\$
MW?V3Q/X&\0:?X@TS?/J5O9WWV24?;=$U?^R;_2]0NO#_ (@T][O0O$>FV^H6
MG]K:#J.HZ9+,L%W)G^S;]E/]IKP9^UC\(M-^*?@^QU#194U"X\->+_#&IB26
MY\*^,]-L=-O]5T2/5!;6MIK^GBTU;3=2TG7;"**._P!*U*R;4+'1=<35= TK
M^(BOK']CC]JSQG^R=\7='\8:-J6H/X#UK4-'TSXL>$+>WCU*V\5>#(K[-[):
M:5<ZEI-H?&&@6EUJ-_X)U9M2TV2PU666PO+U_#6M>)-*U7\)\<_"2CXD9$L=
MEL(4N+<DHU)976E*<89AA$Y5:^3U^527[Z7-4P-64&Z.,M!SI8?$XF9^T^#/
MBC6X SIX+,)SJ<+YQ6A',J48QE+ XEJ-*CFM'FY9?NDHT\93C-*MA+S4*E?#
MX>)_:O17'_#_ .('@SXJ>#/#WQ"^'OB'3_%7@WQ5IZ:GH6NZ8\AMKRV,DD$T
M<D,\<-W8:A87<-QIVK:3J-O::KHVJVE[I.K65EJ5E=6L/85_F57H5\+7K8;$
MT:N'Q.'JU*&(P]>G.E7H5Z4W3JT:U*HHU*56E4C*%2G.,9PG%QDDTT?Z)T:U
M'$T:6(P]6G7P]>G3K4*]&<:M&M1JQ4Z56E5@Y0J4ZD)1G3J0DXSBU*+::844
M45D:!1110 4444 9^K:3I6OZ5J>A:[IFGZUH>M:?>Z3K.C:M96VI:5JVE:E;
M26>HZ9J>G7D<UI?Z??VDTUK>V5U#+;75M+)!/')$[*?XF/VO_A!;? ;]IGXR
M?"S3H-/M-#\.^,+F]\+6&F7^JZI;:9X,\56EIXP\%:3)J&MH-5NM0TGPGK^C
M:;JTEY+>R?VK:WJKJ>JQ!-2N_P"W>OY6O^"R_A;0?#_[76FZMI%A]DU#QS\'
MO!GBGQ3<?:KRX_M37K37/&'@FWOO*NKB:"R\OPQX.\.:9]ETZ.TLW_L[[:]N
MVH7=]=W7]2_1/SS$8/CK-,C=6N\%G.0XFM]7@VZ/]H9=B<+6P^(JP=2,8\F#
MJ9A152,*E1SK4X65-SE'^;/I.9-0Q?!>6YRJ5%8S*,[P]+V\E:M]0S##XFE7
MH4Y*$I2YL7# U7"4X4U&E4E=S4(O\G*_H4_X(A?""V32OC+\?;Z#3YKNZU"P
M^$'A>YCO]5&JZ;;6%MIGC3QY!>Z6$BT1]/UJ74OAQ)IE^[W^JQ7.@:M;QII-
MI-*=:_GKK^L;_@D%X%_X1']C31/$']J?VA_PM'X@^//'7V3[#]D_L/\ L^^M
M?AG_ &5Y_P!LN?[3\[_A77]M_;O)T_R_[8_LW[&_]G_;[[^B?I-9O4ROPKQ^
M'IUY8>>=YME64>XJG/6@ZE7,JV'4Z?\ #C4H9;5]JZCC3JT%5P\N9UE"7X-]
M';*H9EXEX*O4H*O#)\LS+-?><.6C-0IY?1KN$_XDJ=;,*?LE!2J4ZSIUX\OL
M7./ZA4445_FB?Z&!7Y^_\%%/VO\ _AE#X,C_ (1:]^S?&7XE?;]&^%OG:#_;
M6G:9_94^C?\ "7^+=2^U2P:1%_PC6D:S;_V);7_]J_;?%6I^'_M7AG7/#=MX
MF^Q?>6K:OI6@:5J>NZ[J>GZ+H>BZ?>ZMK.LZM>VVFZ5I.E:;;27FHZGJ>HWD
MD-I8:?86D,UU>WMU-%;6MM%)//(D2,P_B8_:U_:"U7]ISX]^._BQ>/J$6AZE
MJ!TGP'HVH-<I)X>\ :*7L_"^F'3I=:U^TTG4+JT#:_XGLM&U%]%G\9ZUXDU7
M3HXHM2*U^]?1_P##2GQ_Q;]<S6C[3AOAKV&/S*E.E&=+,L7*;>7Y34]HI4W0
MQ$Z53$8V+A453!8:KA6J4L73KT_Q/QR\0ZG _"ZPN6U?9\0<0^WP67U85)0J
MX##1A'Z_F<.1J:K4(5:=#!R4X.GB\13Q*=2.%J4:GS]JVKZKK^JZGKNNZGJ&
MM:YK6H7NK:SK.K7MSJ6JZMJNI7,EYJ.IZGJ-Y)-=W^H7]W--=7M[=32W-U<R
MR3SR/*[,<^BBO]-(QC",80C&$(1480C%1C&,5:,8Q5E&,4DDDDDE9:'^=LI2
MG*4YRE*<I.4I2;E*4I.\I2D[MR;;;;=V]6%?TJ_\$C/V.;;P/X,A_:@^(6CZ
M?<>,OB!IX'PGL]3T?58-:\!^#&DU;3M1\21MJOV:T34/B7:26\^DZAIVESR1
M> %LKG2?%%QIOQ U_1K;\&_V:?A!<_'SX]_"GX10P:A-:>-/&&F67B%M)O\
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M*O\ U8WPIK\N\:_^35<<?]B2K_Z>HGZ1X0?\G,X-_P"QQ3_]-5C^H6BBBO\
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M2GA_K&18K&8G+Z^(HJ4I9?BZ%54X1QL.7]W1Q7-%8;$)NE*M?#U'3JRH*O\
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M^ZG?^KC^(5?Q\U_8-_P2T_Y,1^!?_=3O_5Q_$*OZ=^EK_P FXR7_ ++;+?\
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M17^V!_C^%?L'_P $3_\ DZGQ_P#]F_>*O_5C?"FOQ\K]@_\ @B?_ ,G4^/\
M_LW[Q5_ZL;X4U^7>-?\ R:KCC_L25?\ T]1/TCP@_P"3F<&_]CBG_P"FJQ_4
M+1117^4!_IP%%%% !1110!_/W_P74_YM;_[K=_[R*OY^Z_H$_P""ZG_-K?\
MW6[_ -Y%7\_=?ZB?1U_Y,WP=_P!W!_ZU.>'^;_CW_P G9XK_ .Z%_P"LUDX4
M445^V'X^?Z!%%%%?XGG^P 4444 <_P"+?%.@^!O"OB;QMXIOO[+\,>#O#^L^
M*?$>I_9;R]_L[0?#^G7.K:O?_8M.M[O4+O[)I]I<7'V6QM+J\N/+\JUMYIW2
M-OX)]6U?5=?U74]=UW4]0UK7-:U"]U;6=9U:]N=2U75M5U*YDO-1U/4]1O))
MKN_U"_NYIKJ]O;J:6YNKF62>>1Y79C_0I_P6._:PL]/T&W_9*\(R^?J^O?\
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M"VACTSPQH_A[Q1X+T'3+JSO_ .E3X-_M ?!G]H+09O$?P<^(?A_QSI]IY?\
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M5A4IRD\+"MRPJ4YPG*T)0DFT_P"K6BBBO\@#_50**** "BBB@ HHHH ****
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MU7*L1B<%%74O[0R^/U_ *+BU*/-B\-2IRM?FISG"49PE*$OXF****_UP/\N
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MM7[!U^/G_!;#_DU;P!_V<#X5_P#5<_%:OU'P4_Y.KP/_ -CNE_Z9K'YOXO\
M_)L^,O\ L3U/_3M$_EZK^P;_ ():?\F(_ O_ +J=_P"KC^(5?Q\U_8-_P2T_
MY,1^!?\ W4[_ -7'\0J_KWZ6O_)N,E_[+;+?_5%Q(?RO]%[_ )+_ #?_ +(_
M,/\ U=</GZ!4445_GB?W@%%%% !1110 4444 %%%% !1110 5_#Q^UG_ ,G4
M_M,?]G _&7_U8WB2O[AZ_AX_:S_Y.I_:8_[.!^,O_JQO$E?U[]$/_DH^,/\
ML28'_P!3V?RO]*?_ )$'"O\ V.,;_P"H2/GZBBBO[S/XG/V#_P"")_\ R=3X
M_P#^S?O%7_JQOA37]0M?R]?\$3_^3J?'_P#V;]XJ_P#5C?"FOZA:_P UOI0?
M\G5Q?_8DR;_TS4/]"/HX_P#)L\+_ -CC-O\ T[3"BBBOYX/W@**** "BBB@
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MO^2CX?\ ^QWE7_J?0/'XA_Y$&>?]B?,__4*N?P\4445_LJ?Y+A7] G_!"O\
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M.I\?_P#9OWBK_P!6-\*:_'ROV#_X(G_\G4^/_P#LW[Q5_P"K&^%-?ZO^-?\
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M]\9?_5<^)*_AXK^\_HA_\DYQA_V.\#_Z@,_B?Z4__(_X5_[$^-_]34?T"?\
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MX(^V/G[]K/\ Y-6_:8_[-^^,O_JN?$E?P\5_</\ M9_\FK?M,?\ 9OWQE_\
M5<^)*_AXK^\_HA_\DYQA_P!CO _^H#/XG^E/_P C_A7_ +$^-_\ 4U'[!_\
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M0^-M*\/030W=AJ%A=PV]AX\M-.TT>&--U75_#^H:3<:=;>*K7PKX>_S]\??
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ML+'$>'-*M*<HO <1Y9BH))-5)3P^88%PE?9*&,E.ZUYH16S9^/E%%%?Z.G\
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M !+_ ,F5X@_[-=FO_K)US_,?A[_D[V1_]G(RS_UIZ!_8-1117^4!_IP%%%%
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M75O- [QM_7M^PS^W-X,_:_\ !CVMTFG^%?C3X5T^&7Q[X"BFD%M=VPDAM/\
MA-O!/VN::[O_  ??W<T$-W:33W>J^#-5N[?0M=N+VVO?#7B7Q5_GM](#P2_U
M1Q-3C#A/ S_U6Q<W+-,#0CST^'L95J)1G2@O?I91C)S2HJTJ6 Q-\-STJ%;
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M#=%%%?Z9G^=P5^XG_!#WQW_9_P 5/CE\,_[*\[_A+OA_X=\=?VW]N\O^S_\
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MV#K\?/\ @MA_R:MX _[.!\*_^JY^*U?">"G_ "=7@?\ ['=+_P!,UC[3Q?\
M^39\9?\ 8GJ?^G:)_+U7]@W_  2T_P"3$?@7_P!U._\ 5Q_$*OX^:_L&_P""
M6G_)B/P+_P"ZG?\ JX_B%7]>_2U_Y-QDO_9;9;_ZHN)#^5_HO?\ )?YO_P!D
M?F'_ *NN'S] J***_P \3^\ HHHH **** "BBB@ HHHH **** "OX>/VL_\
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MI--:WME=0RVUU;2R03QR1.RG[_PY\0\\\..(*.<Y36E+"U94J.<99-MX7-,
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MK5G"E2I0E4JU:DE"G3IPBY3J5)R:C"$(IRE*348Q3;:2/XF/VL_^3J?VF/\
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MP_-]7P.%P^#H<W+S>QPM&%"ES<D80YN2$;\D(1O\,8JR11117&=1\_?M9_\
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M+_ZL;Q)7]P]?P\?M9_\ )U/[3'_9P/QE_P#5C>)*_KWZ(?\ R4?&'_8DP/\
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M%%<_XM\4Z#X&\*^)O&WBF^_LOPQX.\/ZSXI\1ZG]EO+W^SM!\/Z=<ZMJ]_\
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M445_ Y_;@4444 %%%% !1110!^)G_!;WP3I5_P#!;X-?$>:XU!=<\*_%&_\
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M-7Y_KF:1>!HRIV3]^C[>6(3?NI46Y72:?\_=?OI_P0Y^']M+JOQ^^*=]X=U
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M/V=?#9;CL11J<L9<E:CA:M2G/EG&4)<LXQ?+.,HNUI1:NC^'BOV#_P"")_\
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M[=E_1)_P1Q_:PL]0T&X_9*\72^1J^@_\))XQ^%&IW%WH-G9ZAH-U>0:MXG\
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MG^6KWHX[+76A.I*C3E4I4XYCA$IU<NKRG#V=252A4G]5Q6*IU?SWQ*\/\O\
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M3F&88FA@L#@J%3$XO%XFI&CA\/0I1<ZE6M5FU"$(13<I2:1_+6#P>+S#%X?
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MO&W@R6^NX/#GC;28;>_U:T&GZ_:6IEDM+;5M2DT/58M3\-:I<)KFBZI:V_\
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MFL?V=_:FHHVH7=U(_P!Q?\%'/V^?^&JM>M/AM\.H/LGP*\#>(#K&DZC?Z?\
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M\N&?-4Y*4;U:E.$O9R;P[XZX@=/^R>%,[Q-*M;V>*G@:N$P$KSA#_D88U8?
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M2U75M5U*YDO-1U/4]1O))KN_U"_NYIKJ]O;J:6YNKF62>>1Y79CGU] _!/\
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MZM/+\-4H0J-MTE]8Q,H:0E*5N=_K'1117\U']"!1110 4444 %%%% '\]?\
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M (1_6_B#\4?[0^W?:_\ A!? =_I_]A_9/L?D?VK_ ,+,NOAUYW]I_:9OL/\
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M?A_I_P#8_P!N^R?\(+9W_P +O._M#['Y_P#:O_"L[_PC_;GE_88?L/\ ;?\
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M)2HX6G*C3PN48##TZ4GE.'J.5.%+#PC3DZDG4;BDW-N7Q-L^#O\ @FW^Q/\
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M\-2I0:ASSY%:T>>?+;F=RBBBO,/0"BBB@ HHHH **** "BBB@ HHHH ****
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MY)/5)MI/4T****X#M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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B5H1K<OM(T:E2C2J5*2DH3G2ISE%RA%KU&BBBOX@/[&/_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
